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ABSTRACT 
 
 
 
The prevalence of musculoskeletal disorders is a major burden for modern societies. Due to the 
increasing aging population and the lifestyle changes, a significant number of people are severely 
affected worldwide. The important issue with these diseases is the fact that they cause pain and 
disability on a person's physical functioning for long time, thus diminishing the quality of life of the 
individual. Moreover, they are accompanied by a high financial cost for the society and the 
healthcare system. Current ways of treatment do not provide optimum therapy. They employ high 
concentration of growth factors and they are expensive, inefficient and many times exhibit various 
side effects. For this reason, an alternative solution is needed.  
Tissue engineering (TE) strategies offer a novel approach to the problem. The combination of the 
appropriate cell source with the essential scaffold leads to the formation of three-dimensional (3D) 
constructs, which can be subsequently, cultured within a bioreactor, with the employment of proper 
osteoinductive factors. This process leads to the generation of high number of efficiently 
differentiated cells, which are needed for cellular therapies.  
In this project, the generation of 3D mineralised cellular constructs was performed using mouse 
Embryonic Stem Cells (mESCs) encapsulated in alginate hydrogels. The novelty of this project lied 
on two components; the employment of a custom-made rotating wall vessel (RWV) perfusion 
bioreactor, which had been shown previously to exhibit advantageous properties regarding the 
efficient differentiation of high cell numbers needed for potential therapeutic applications and the 
use of simvastatin (Sim) in the culture media, acting as an osteoinductive substance in very low 
concentration of the nanomolar scale. Sim had been previously employed to induce osteoblast 
differentiation. The novelty lied on the total combined configuration with the low concentration of 
Sim and the perfusion bioreactor used for cell culture and differentiation.  
Evaluation of cell proliferation and osteogenic differentiation was performed through several 
analyses. Extended gene expression was tested and obtained results were also compared with those 
acquired previously by the currently used protocol with dexamethasone (Dex). Acquired results 
indicated that the favorable environment of the perfusion bioreactor culture could support higher cell 
number sand more efficient osteogenic differentiation in comparison to static configuration. Sim 
was more efficient when supplied in the culture at the appropriate time point, after two weeks of 
initiation of the experiment. Sim and Dex indicated similar outcome in biochemical analysis. 
Osteogenic gene expression was strongly induced after Dex treatment while Sim supported the 
generation of higher cell numbers. These findings suggested the generation of a more progenitor cell 
type after Sim treatment and a more mature phenotype after Dex treatment.  
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b-GP              b-glycerophosphate  HAC Hydroxyapatite ceramic 
BMCs bone marrow cells  HARV High Aspect Ratio Vessel 
BMD bone mineral density  hBMSCs Human bone marrow stromal 
cells 
BMP Bone morphogenetic protein  HepG2 Human hepatocarcinoma cell   
line 
BMPR BMP receptor  HepG2-CM   HepG2 conditioned media 
BSP Bone sialoprotein  HESC Human embryonic stem cells 
BTE   Bone Tissue Engineering  hiPSCs Human induced pluripotent   
stem cells 
Ca Calcium  HMG-CoA    3-hydroxy-3-methylglutaryl- 
CoA 
Cbfa-1  Core-binding factor subunit alpha-1  HSC Hematopoietic stem cell 
cDNA complementary DNA  ICM Inner cell mass 
CNS Central nervous system  IGF-1           Insulin-like growth factor-1 
COL 1 Collagen I   IPSC Induced Pluripotent Stem Cell 
COL 10 Collagen 10   LDL   Low-density lipoprotein 
DAPI 4', 6’ diamidino-2- phenylindole  LIF Leukemia inhibitory factor 
Dex Dexamethasone  MESCS Mouse embryonic stem cells 
Dlx5 distal-less homeobox 5  miRNAs        microRNAs 
dsDNA Double-stranded DNA  miPSCs mouse induced pluripotent                            
stem cells 
EB Embryoid body  mPCL medical-grade poly-e-
caprolactone 
ECM          Extracellular matrix  MSC Mesenchymal stem cell  
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Msx2   Msh homeobox 2  Runx2 Runt-related transcription 
factor2 
n-HA           nano-hydroxyapatite  RWV Rotating Wall Vessel 
OBL Osteoblast  SCID Severe combined 
Immunodeficient 
OCN Osteocalcin  SD     standard deviation 
Oct-4           Octamer binding protein-4  SDS-PAGE    
sodium dodecyl sulphate-
polyacrylamide gel 
electrophoresis 
OI Osteogenesis Imperfecta  SEM Scanning electron microscopy 
ON Osteonectin  SIBLING Small Integrin Binding Ligand 
N- linked Glycoprotein 
OPN Osteopontin  Sim Simvastatin 
OSX Osterix  Sox2   SRY - box2 
P    Phosphate  Sox5 SRY - box5 
Pax6 Paired box protein  Sox6 SRY - box6 
PBS phosphate buffered saline  Sox 9 SRY - box9 
PCR polymerase chain reaction  Sox17 SRY - box17 
PDFG platelet-derived  growth factor                 SPARC Secreted protein, acidic, rich in 
Cysteine 
PLAGA poly (lactic acid  glycolic acid)          SRY sex determining region Y 
PLLA  Poly L lactic acid  SSCs  Somatic stem cells 
PTH Parathyroid Hormone  SSEA-1          Stage-specific embryonic  
 antigen-1 
PTHrP parathyroid hormone - related 
 protein                     
 SSEA-3         Stage-specific embryonic  
 antigen-3 
PTH1R Parathyroid hormone 1 receptor  SSEA-4         Stage-specific embryonic  
 antigen-4 
qRT–PCR     Quantitative real-time PCR     STLV    Slow Turning Lateral Vessel 
rhBMP-2     recombinant human bone     
morphogenetic protein-2 
 TE Tissue Engineering 
rhBMP-7       recombinant human bone   
 morphogenetic protein-7 
 TE buffer  Tris-EDTA buffer 
rhOP-1          recombinant human  
 osteogenic protein-1 
 TGF-β           Transforming growth factor-β 
RM     Regenerative `medicine  VEGF Vascular endothelial growth   
factor 
RNA    Ribonucleic acid  vitD3   1,25-dihydroxyvitamin D3 
rNPP   r-nitrophenol phosphate  2D Two-dimensional 
Rpl27 
RT-PCR 
ribosomal protein L27 
Real-time polymerase chain reaction 
 
 
3D 
3DP 
Three-dimensional 
 
Three-dimensional printing 
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1ST CHAPTER  
 
 
1. LITERATURE REVIEW 
 
 
1.1  Bone Biology        
 
 
Bone is one of the most important dynamic tissues in the human body. It receives blood supply 
and it has the unique capacity to regenerate and the ability to self-repair and to heal small-scale 
defects after an injury. It has major role in several significant functions in human body.  
Due to the increasing aging population, musculoskeletal diseases affect significantly the quality 
of life of millions of people around the world. Very common are metabolic bone diseases, which 
are disorders of bone remodeling, exhibiting an imbalance between bone formation and 
resorption and resulting in an increased risk of fracture. The high clinical need for bone repair is 
the motivation of the project. 
The literature review follows a specific organization pattern starting with important information 
regarding the biology of bone tissue. Description of the main structure, the important functions 
of this tissue, the cell types it contains and the essential role of the extracellular matrix, are 
presented. Bone development and the role of gene markers contributing to the differentiation 
process and the timeline of their expression are also described.  
Following this introductory fundamental information, the current problem and the clinical need 
for bone formation and regeneration are highlighted through presentation of several major 
clinical diseases affecting significantly the life of many people. Data are presented specifically 
for the UK population using information obtained from charities and organizations dedicated to 
help and support people with these diseases.   
It also includes the description of currently employed therapeutic strategies and presents the 
appeared and observed limitations of their application. It mainly refers to grafting procedures 
followed and the use of growth factors to enhance bone formation.  
In addition, the literature review focuses on new approaches and alternative ways to treat these 
problems in the near future. The focus is TE and analysis of each of its main components. 
Examples of current applications are also presented.  
The literature review is finishing by highlighting the novelty and the importance of this project. 
The next chapter will state the aim and objectives of this research project.  
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1.1.1 Structure/Function     
 
Bone tissue in the adult skeleton consists of two major types with different architectural forms: 
the cortical or compact bone and the cancellous or trabecular bone (Figure 1.1).  
Cortical bone is a dense tissue, which is organized in cylindrical structures known as osteons or 
Haversian systems. These contain blood vessels, lymphatics, nerves and connective tissue. 
Cortical bone forms the outer shell of long bones and the outer surface of the small and flat 
bones. It consists 80% of the skeleton, but it is characterized by low porosity. It provides 
mechanical and protective function (Sikavitsas et al., 2001).  
Cancellous bone is a highly porous structure composed of many interconnecting spaces, which 
contain the bone marrow (Brydone et al., 2010). It is organized in trabecules. This type of bone 
is found at the ends of the long bones and inside flat bones (Athanasiou et al., 2000; Yaszemski 
et al., 1996). It represents approximately 20% of the skeleton. Cancellous bone is a very active 
metabolically tissue (Buckwalter et al., 1996a; Buckwalter et al., 1996b) and constitutes the 
major site of bone remodeling (Feng and McDonald, 2011). 
 
 
 
Figure 1.1: Cortical and trabecular bone morphology. Adapted from (DiGirolamo et al., 2012) 
 
 
 
Bone is a unique tissue, which contributes to a number of significant functions and can affect 
either in a positive or a negative way the quality of life of an individual. The main role of bone is 
to provide structural support to the skeleton. It also protects vital internal organs, such as the 
heart, the brain, the lungs and the spinal cord. Bone constitutes a mineral storage for the body 
containing calcium (Ca) and phosphate (P), which are released in the blood stream when 
necessary. Moreover, it has attachment points for skeletal muscles and supports locomotion 
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(Salgado et al., 2004). Bone also provides the environment for hematopoiesis (the production of 
all blood cells) within the marrow spaces (Bowman and Zon, 2009; Rafii et al., 1997). It also 
contains the yellow bone marrow, which is composed mainly of adipose cells and constitutes 
storage of chemical energy for the body (Gurevitch et al., 2009).  
 
1.1.2 Cells and Extracellular matrix  
 
Bone is composed of a cellular component and an extracellular matrix (ECM). The cellular part 
consists of three cell types: the bone-forming osteoblasts, the bone-resorbing osteoclasts, and the 
osteocytes, which are inactive osteoblasts trapped in the ECM. Osteoblasts and osteocytes 
originate from mesenchymal precursors named osteoprogenitors, whereas osteoclasts are derived 
from hematopoietic stem cells (HSCs) that give rise to monocytes and macrophages (Boyle et 
al., 2003). Osteoclasts are multinucleated cells formed by the fusion of mononuclear precursors 
(Udagawa et al., 1990).  
The principal function of the osteoblasts is to synthesize the proteins of the bone ECM. They are 
also responsible for the expression of genes necessary for calcification and secrete important 
molecules that regulate the generation and the function of osteoclasts (Cohen, 2006; Rucci, 
2008). Osteoblasts have an essential role in mineralisation. They promote hydroxyapatite (HA) 
formation by regulating the release of matrix vesicles containing Ca and P (Clarke, 2008). They 
also express high level of alkaline phosphatase (ALP), which is anchored to the external surface 
of the plasma membrane and has been indicated to play an important role in bone mineralisation 
(Manolagas, 2000). Their membrane has been also shown to possess receptors for parathyroid 
hormone (PTH). When bone formation is completed, a high percentage of osteoblasts undergo 
apoptosis and the remaining become osteocytes or bone-lining cells. When preosteoblasts stop 
proliferating, osteoblast precursors change shape from spindle-shaped osteoprogenitors to large 
cuboidal differentiated osteoblasts. It is characteristic the fact that osteoblasts never appear or 
function individually but they always appear in as clusters of cuboidal cells along the bone 
surface (~100-400 cells per bone forming site) (Hadjidakis and Androulakis, 2006). Moreover, 
mature osteoblasts have large nuclei, enlarged Golgi structures and extensive endoplasmic 
reticulum, which support them in synthesizing bone matrix and secrete mainly collagen type I 
(Col I) (Clarke, 2008).  
Osteocytes act mainly as mechanosensors by recognizing mechanical stress signals received by 
the cell and turn them into biologic activity. They also contribute to homeostasis by maintaining 
the right oxygen and mineral levels. Osteocytes are considered an important regulator of bone 
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mass and a key endocrine regulator of phosphate metabolism (Dallas and Bonewald, 2010). 
Osteocytes are the most abundant cell type in bone, being 10 times more than osteoblasts. They 
are usually located throughout the mineralised matrix and communication with each other and 
with cells on the bone surface is performed via multiple extensions of their plasma membrane 
(Manolagas, 2000). Osteoclasts are the cells responsible for resorption of bone matrix through 
the process of bone remodeling. Their function is regulated from signals received from 
osteoblasts (Boyle et al., 2003). 
It has been indicated that growth factors and cytokines produced in the bone marrow 
microenvironment control the development and differentiation of both osteoblasts and 
osteoclasts. Moreover, it has been shown that various hormones and mechanical stimulus also 
exert significant effects and participate in this process. Finally, there are several adhesion 
molecules that mediate cell-cell and cell-matrix interactions (Manolagas, 2000).  
Osteoblasts and osteoclasts play a significant role in coordinating the bone remodeling. Bone 
remodeling is a complex process, which occurs throughout life and by which old bone is 
continuously replaced by new tissue in order to maintain bone strength, mineral homeostasis and 
adapt to changing biomechanical forces (Clarke, 2008), following many cycles of bone 
resorption and subsequent new bone formation (Hadjidakis and Androulakis, 2006). 
ECM constitutes the second element, which is the cornerstone of bone tissue. The matrix, which 
is responsible for the mechanical strength of the bone tissue, is formed by an organic and a 
mineral phase. The organic phase is mainly composed of collagen fibers and few non-
collagenous proteins whereas the mineral phase consists of HA crystals (Frohlich et al., 2008). 
ECM offers several significant functions to the cells. One of its major roles is that it acts as a 3D 
scaffold for the cells allowing them to attach and grow on it by offering them the required 
environment for the development of the specific tissue (Huang and Ingber, 1999). It also 
provides structural support and regulates intercellular communication and the dynamic behavior 
and nature of the cells. Moreover, it separates tissues from each other acting as a borderline 
(Baptista et al., 2009). Finally, ECM contains important bioactive molecules such as water, 
nutrients, cytokines and growth factors, which regulate cell behavior.  
ECM is considered as a dynamic network of cell-secreted molecules that regulate cell behavior 
by modulating the proliferation and differentiation. To summarize, bone development and 
regeneration are complex processes regulated by a number of different growth and transcription 
factors, which have been indicate to coordinate the interaction of cells and matrix in response to 
external or internal stimuli (Kneser et al., 2006). 
 
 1.1.3 Bone development 
Bone development takes place through two
stem cell (MSC) proliferation and condensation 
2002). The first mechanism is called endochondral ossification
process, MSCs differentiate initially into proliferating chondrocytes and form a cartilage 
template. In the next step, they further differentiate into hypertrophic chondrocytes which are 
subsequently invaded by blood vessels and finally, they are replaced by bone. This process takes 
place in the development of long bones and the majority of bones of the skeleton 
Jacobs, 2010). The second mechanism is called intramembranous ossification 
is the direct differentiation of the condensed MSCs into osteoblasts 
process mainly occurs in the head region to 
Jacobs, 2010). 
 
 
Figure 1.2: Intramembranous 
Several important gene markers are expressed during different stages of bone development and 
can be used in order to identify the status of the cell at a specific time point. A 
essential bone markers are usually tested
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cartilage and hypertrophic chondrocytes can also be tested in order to identify the ossification 
process followed. Finally, gene markers of the three germ layers can also be evaluated in order to 
follow the process of differentiation. 
 
 
1.1.4 Gene expression markers of bone development, ossification pathway and three 
germ layer formation 
 
ESCs have the capacity to differentiate to all cell types consisting the embryo apart from the 
placenta. In order to follow the differentiation pathway towards a specific cell type, ESCs go 
through the stage of the three germ layer formation and they first need to commit to a specific 
germ layer before proceeding to the differentiation towards the desired cell type. Gene 
expression markers are presented in the following section according to the stage of 
differentiation. Initially, the expression of markers from each of the three germ layers was 
evaluated in order to get more insight information regarding the differentiation process and the 
efficiency of the employed protocol. Starting with ectoderm, the expression of the transcription 
factor Pax6 and of Nestin protein was evaluated.  
 
• It has been previously indicated that expression of homeobox transcription factor Pax6 in 
uncommitted ESCs favored their differentiation towards neuroectodermal lineage. In particular, 
it has been proposed that in mouse cells Pax6 expression was implicated in the progression of 
neuroectoderm toward radial glia-derived early neurons (Suter et al., 2009). It is well known 
that Pax6 is highly conserved among vertebrate and invertebrate species and is crucial for the 
development of the eye, pancreatic islet cells and the central nervous system (CNS). The same 
group indicated that there is enhanced Pax6 expression during induction of neural progenitor 
cells from ESCs (Gao et al., 2011). 
 
• Nestin is a well-known neuroectoderm marker (Mansergh et al., 2009) identified on neural 
progenitor cells and specifically a marker of the central nervous system (Jin et al., 2009).  
Earlier research suggested that nestin may be a common marker of multi-lineage progenitor 
cells as it has been demonstrated that it is abundant in early embryonic stem-derived progenitor 
cells that proliferate and differentiate into the neuroectodermal, mesodermal and endodermal 
lineages. It has been also proposed that nestin-expressing cells may be directly implicated in 
tissue regeneration (Wiese et al., 2004). 
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The next germ layer to be evaluated was the endoderm. The expression of the transcription 
factors Gata4 and Sex Determining Region Y- Box17 (Sox17) was tested. 
 
• During early mouse development, Gata4 is expressed in the primitive endoderm, the first germ 
layer to be formed from the pluripotent inner cell mass (ICM) of the early blastocyst (Arceci et 
al., 1993; Morrisey et al., 1996). Its expression is restricted to the primitive endoderm and the 
derived visceral and parietal endoderm of the extraembryonic tissues (Arceci et al., 1993; 
Koutsourakis et al., 1999; Morrisey et al., 1998). Apart from endoderm formation, Gata4 is 
considered a key regulator of cardiogenesis (Pikkarainen et al., 2004) and heart development 
(Afouda et al., 2008) and essential for cardiomyocyte gene expression and differentiation 
(Grepin et al., 1995). Gata4 has been shown to function in both mesoderm and endoderm, 
consistent with a role in regulating the emerging lineages derived from a common precursor 
germ-layer, referred to as the mesendoderm (Loose and Patient, 2004). 
 
• Sox17 is expressed in mouse visceral endoderm and parietal endoderm as well as in definitive 
endoderm. It has been suggested to have a crucial role in the differentiation of the definitive 
endoderm in the mouse, thus indicating the conservation of the mechanism of endoderm 
development between vertebrates (Kanai-Azuma et al., 2002). 
 
Finally, the expression of markers from the germ layer of interest, mesoderm in that case, was 
evaluated. The protein Desmin and the transcription factors BMP4 and Hand1 were tested.  
 
• Desmin has indicated strong expression from mesodermal precursors (Torres et al, 2012). It 
has been shown to regulate the expression of transcription factor genes important for 
mesodermal and early myocardial differentiation. Moreover, it promotes proliferation of 
differentiating cardiomyocytes and also has a well-known function in the maintenance of the 
muscle cell phenotype. These data suggest its supportive role during commitment and early 
differentiation of cardiomyocytes (Hofner et al., 2007).  
 
• BMP4 has been indicated to play a significant role in fate decision in ESCs as it has been 
demonstrated to reduce neuroectoderm differentiation and to induce mesoderm formation 
(Johansson and Wiles, 1995; Lindsley et al., 2006; Ying et al., 2003). In particular, during ESC 
differentiation, BMP4 has been shown to enhance the expression of posterior and 
extraembryonic mesoderm genes at the expense of anterior primitive streak patterning 
(Willems and Leyns, 2008). BMP4 has been indicated to participate in the differentiation of ES 
cells toward cardiac or hematopoietic fates (Kennedy et al., 2007; Laflamme et al., 2007). 
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• The transcription factor Hand1 has been indicated to possess an important role in 
extraembryonic mesodermal and heart development (Firulli et al., 1998). It is expressed in 
neural crest derivatives and lateral mesoderm (Cserjesi et al., 1995; Thomas et al., 1998). 
Recently, it has been suggested as one of the key cardiac transcription factors (Mendjan et al., 
2014).  
 
 
Following germ layer formation, the expression of a hypertrophic chondrocyte marker and a 
couple of cartilage markers was also examined in order to evaluate if endochondral or 
intramembranous ossification was followed. 
 
• Collagen 10 (COL10) is the only known hypertrophic chondrocyte–specific marker. It has 
been shown that Runx2 can directly transactivate COL10 promoter both in vitro and in vivo via 
Runx2 binding sites found in the promoter region (Zheng et al., 2003). 
 
• The first transcription factor to be tested was Sex Determining Region Y-Box9 (Sox9). Sox9 
expression has been indicated in all chondroprogenitor cells in mouse embryos and at higher 
levels in chondrocytes but its expression is completely shut off in hypertrophic chondrocytes. 
Research has also indicated that Sox9 together with Sox5 and Sox6, are responsible for 
activating the chondrocyte-specific genetic program that produces the characteristic cartilage 
ECM (de Crombrugghe et al., 2000). Sox9 is particularly needed for formation of 
mesenchymal condensations (de Crombrugghe et al., 2001).  
 
• Aggrecan is a large chondroitin sulfate proteoglycan and constitutes the major structural 
component of the articular cartilage ECM (Kiani et al., 2002). It has been demonstrated that 
Sox9 activates and enhances the transcriptional activity of the aggrecan promoter (Sekiya et al., 
2000).  
 
Finally, the expression of a number of important bone genes was examined in order to evaluate 
in vitro bone formation. These osteogenic markers are only expressed in particular stages during 
bone formation. 
 
 
• Alkaline phosphatase (ALP) is known to be an early marker of the osteoblast phenotype. It is 
upregulated at the onset of differentiation and subsequently decreased as mineralisation occurs 
(Jia et al., 2014; Rawadi et al., 2003). 
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• Collagen 1 (COL 1) is the most abundant protein in mineralised tissues (Young, 2003a; 
Young, 2003b) and is widely distributed in almost all connective tissues with the exception of 
hyaline cartilage. It is the major protein in bone, skin, tendon, ligament, sclera, cornea, and 
blood vessels (Viguet-Carrin et al., 2006). COL 1 comprises approximately 95% of the entire 
collagen content of bone and about 80% of the total proteins present in bone (Niyibizi and 
Eyre, 1994). 
 
• Bone Morphogenetic proteins (BMPs) are considered the most potent inducers of osteoblast 
differentiation. They stimulate osteoprogenitors to differentiate into mature osteoblasts but also 
induce nonosteogenic cells to differentiate into osteoblast lineage cells (Gersbach et al., 2007; 
Nakamura et al., 2005; Wang et al., 1993). BMPs are members of the Transforming Growth 
Factor-β (TGF-β) superfamily and play critical roles as soluble mediators of tissue 
morphogenesis. They have a significant role in embryonic development and the induction of 
bone formation in postnatal life. It has been indicated that these molecules activate the cascade 
of bone differentiation and induce bone formation when implanted in heterotopic extraskeletal 
sites (Reddi, 1998; Reddi, 2005; Ripamonti, 2006; Ripamonti et al., 2006). BMP-2 in particular 
has been shown to stimulate the expression of ALP through activation of the BMP receptor 
(BMPR) (Nohe et al., 2002). It is also involved in the expression of the nuclear transcription 
factors Cbfa-1/Runx2 (Jadlowiec et al., 2003) and Dlx5 (Kim et al., 2004). BMP-2 has been 
indicated to participate in the commitment of multipotent stromal cells (MSCs) towards the 
osteogenic lineage and to induce new bone formation (Riley et al., 1996). 
 
• Runt-related transcription factor2 (Runx2), also known as Core-binding factor subunit 
alpha-1 (Cbfa-1), is a transcription factor essential for osteogenic cell differentiation (Ziros et 
al., 2008). It is required for osteoblast commitment and for both intramembranous and 
endochondral bone development (Toth et al., 2010). At the early stage of embryogenesis, 
Runx2 determines the osteoblast lineage from multipotent mesenchymal stem cells, whereas 
inhibits it at the late stage (Ducy et al., 1999). Runx2 is initially detected on day 9.5 in the 
notochord and on day 10.5 is strongly expressed in all developing skeletal elements (Otto et al., 
1997). Ectopic expression of Runx2 in mesenchymal cell lines leads to up-regulation of 
osteoblast-specific genes like OCN, ALP, BSP and COL1a1 (Ducy et al., 1997). 
 
• The zinc-finger-containing transcription factor Osterix (OSX) acts downstream of Runx2 and 
has been indicated to be essential for osteoblast differentiation and bone formation during 
embryonic development (Nakashima et al., 2002). OSX is specifically expressed in osteoblast 
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lineage cells and, at lower levels, in prehypertrophic chondrocytes (Zhou et al., 2010). It has 
been shown to be essential for activation of bone-specific genes that support bone formation in 
embryos and adults (Sinha and Zhou, 2013).  
 
• Osteonectin (ON), also known as secreted protein acidic and rich in cysteine (SPARC), is 
the major non-collagenous bone matrix protein. It is highly expressed early in osteogenic 
differentiation and decreases when cells acquire more mature phenotype (Delany and 
Hankenson, 2009; Kusafuka et al., 1999). 
 
• Osteopontin (OPN) is considered a mid-stage marker (Frank et al., 2002). It is a protein 
secreted by osteoblasts throughout the differentiation process, but is up regulated at the onset of 
matrix mineralisation (Hughes and Aubin, 1998). 
 
• Osteocalcin (OCN) is a protein secreted by osteoblasts and signals terminal osteoblast 
differentiation (Paredes et al., 2004). 
 
• Bone sialoprotein (BSP) is a noncollagenous small integrin-binding ligand N-linked 
glycoprotein (SIBLING) in mineralised tissues such as bone, dentin, cementum, and calcified 
cartilage (Fisher et al., 1990). During bone morphogenesis, BSP is produced by osteoblasts, 
osteoclasts, osteocytes and hypertrophic chondrocytes. Through binding specific integrins, BSP 
mediates cell attachment and signaling, HA nucleation with subsequent mineral deposition and 
binding of Col I with high affinity (Fisher and Fedarko, 2003; Ganss et al., 1999; Kruger et al., 
2013; Masi et al., 1995; Tye et al., 2005).  
 
• A recently discovered bone marker is Activating Transcription Factor 4 (ATF4), which has 
been shown to regulate terminal differentiation and function of osteoblasts. It also determines 
the synthesis of Col I, the most abundant bone ECM protein by favoring amino acid import 
(Yang et al., 2004). The same group discovered that ATF4 osteoblast-specific accumulation is 
controlled by a post-translational mechanism. Moreover, they indicated that ATF4 could induce 
osteoblast-specific gene expression in non-osteoblastic cells (Yang and Karsenty, 2004). It has 
been also shown that there is a functional relationship between ATF4 and Runx2. They form a 
complex (Dobreva et al., 2006) and cooperatively regulate OCN mRNA expression by binding 
to specific sites on its promoter (Xiao et al., 2005). 
 
In Figure 1.3, there is a graphical representation indicating the process starting from three germ 
layer formation, following endochondral ossification and subsequent osteogenic differentiation. 
 Gene markers associated with each stage are presented in orde
based on gene expression. 
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Figure 1.3: Gene expression markers characterizing 
endochondral ossification and osteogenic differentiation
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Apart from the above-mentioned and widely used bone markers to evaluate gene expression and 
osteogenic differentiation, there are also some recently discovered transcription factors. In 
particular, members of the Msx and Dlx family have been indicated to play an important role in 
patterning and formation of skeletal structures during embryogenesis and are acting as upstream 
regulators of Runx2, a key activator of osteogenesis (Hassan et al., 2006; Samee et al., 2007). 
 
 
 
 
• Specifically, Dlx5 and Msx2 proteins have been shown to antagonize each other during 
osteoblast differentiation by competing for binding to common response elements in bone-
specific marker genes such as OCN (Hassan et al., 2004; Newberry et al., 1998; Ryoo et al., 
1997) and ALP (Kim et al., 2004). It has been suggested that this regulation takes place at the 
transcription level with Msx2 inhibiting Dlx5 expression and vice versa. Results regarding the 
exact role of these proteins are controversial within research groups but in general, the majority 
suggest that Dlx5 functions at later stages (Ryoo et al., 1997) and stimulates osteoblast 
differentiation by activating the promoter of bone marker genes (Bendall and Abate-Shen, 
2000; Kim et al., 2004; Newberry et al., 1998) whereas Msx2 has an opposite role and 
stimulates cell proliferation while inhibits osteogenic differentiation (Dodig et al., 1999; Hu et 
al., 2001) and in particular osteoblast terminal differentiation since it is expressed before OCN 
(Hoffmann et al., 1994). More recent studies indicated once more the significant role of Dlx5 in 
controlling the expression of bone-related genes (Samee et al., 2007; Samee et al., 2008). 
 
 
• Type 1 PTH receptor (PTHR1) has being recognized as an important regulator of bone 
remodeling (Datta and Abou-Samra, 2009). It is expressed at later stage of differentiation by 
committed preosteoblasts (Moseley et al., 1991; Suda et al., 1996).  
 
Deciphering the transcriptional mechanisms underlying osteogenic differentiation of ESCs is 
crucial in order to get deeper understanding of the followed process and try to ameliorate it.  
Finally, another widely used indicator of bone formation is matrix mineralisation. Matrix 
mineralisation is considered a late-stage marker of the osteoblastic phenotype. It is measured by 
the amount of calcium deposition onto the scaffolds over the culture period (Sikavitsas et al., 
2003).  
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 1.1.5 Common bone disorders and data from the UK population 
 
Osteoporosis is one of the most commonly occurred metabolic bone diseases. It affects mostly 
women and is characterized by increased bone resorption, meaning excessive loss of calcified 
matrix, bone mineral and collagenous fibers, which gradually results in reduction in total bone 
mass. It is often referred to as the ‘fragile bone disease’. Based on current data obtained from 
National Osteoporosis Society, each year in UK, there are about 300.000 fractures incidents due 
to osteoporosis. These incidents have a substantial financial cost for the National Health Service, 
which estimates the total cost for hospital and social care for patients with a hip fracture to more 
than £2.3billion per year. Nowadays, it is estimated that around 3 million people in the UK 
have osteoporosis and this leads to bones becoming fragile and breaking easily, resulting in pain 
and disability (http://www.nos.org.uk).  
Another common metabolic disease is Paget's disease characterized by increased activity of 
osteoclasts, which break down bone more rapidly. Osteoblasts respond with depositing bone at 
an increased rate. This unbalanced remodeling causes bones to become thickened and enlarged 
but also brittle due to abnormal structural development. Based on current data from the Paget’s 
Association charity, the disease in UK is happening to approximately 8% of men and 5% of 
women, by the age of 80 years (http://www.paget.org.uk). 
Osteogenesis imperfecta (OI) or brittle bone disease is another common bone disorder. It is 
caused by a genetic mutation that affects the body’s production of collagen, the main protein that 
forms the bone structure. Collagen produced is usually of poor quality or not enough to support 
its role, resulting in fragile bones, which is the hallmark of OI. This also causes increased 
fracture incidents. OI is difficult to diagnose. However, based on current data from The Brittle 
Bone Society, it is estimated that approximately 1 in every 15,000 people in the UK have OI 
(http://www.brittlebone.org).   
Osteoarthritis is a very common disease affecting the joints. A joint is located between two or 
more bones and allows them to move in a freely but controlled way. The knees have also layers 
of cartilage between the bones acting as shock absorbers to spread the load more evenly across 
the joint. In osteoarthritis, there is incident of wear and tear of the surface within the joints 
resulting in difficulty to move smoothly. Cartilage covering the end of the bones becomes rough 
and thin while bone underneath gets thick. Osteoarthritis is causing pain and stiffness in the 
joints. Recent data from Arthritis Research UK suggest that the disease affects approximately 8 
million people in the UK (http://www.arthritisresearchuk.org).  
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Another type of prevalent bone disease that affects many people is bone cancer and its various 
types. Resection of musculoskeletal tumors, like malignant bone and soft tissue sarcoma, results 
in large bone defects where bone regeneration is compromised or the quantity needed is far 
beyond the normal potential of self-healing. Reconstruction of these defects is still one of the 
most demanding procedures in orthopaedic surgery associated with high socioeconomic costs 
and highly influences patients’ quality of life. The constraints of common treatment strategies 
have triggered a need for new therapeutic concepts to design and engineer functional bone grafts. 
The use of TE strategies together with a more biological approach can help satisfy the need for 
long-term repair and good clinical outcome (Holzapfel et al., 2013). Based on recent data from 
Cancer Research UK, around 560 people were diagnosed with bone sarcoma in 2011 in the UK, 
that’s more than one person every day. Moreover, there were 246 deaths from bone sarcoma in 
2012 (http://www.cancerresearchuk.org).  
 
 
The above-presented information is summarized in Table 1.1. 
 
Table 1.1: Common bone disorders affecting UK population 
 
COMMON BONE DISORDERS DATA FROM UK POPULATION 
 
Osteoporosis 
 
3 million people suffer from the disease 
 
Paget’s disease 
 
Affects 8% of men and 5% of women  
 
Osrteogenesis imperfecta 
 
1 in 15.000 people have the disease 
 
Osteoarthritis 
 
8 million people are affected 
 
Bone cancer 
 
Deaths from prevalence of bone sarcoma  
 
 
1.2 Current clinical treatment and observed limitations  
 
Bone is a unique tissue with the ability to regenerate and self-repair small injuries. However, the 
case is different when dealing with large bone fractures, where injury exceeds a critical size and 
cannot heal by itself within the lifetime of the individual or in the event of unhealthy patients 
with pre-existent problems affecting bone formation. These incidents and their effective 
treatment are still considered a challenge for orthopaedic surgeons.  
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Different types of grafting procedures are usually followed to treat these defects (Brydone et al., 
2010). The ideal graft in order to successfully regenerate bone should possess four specific 
features. The first one is osteoconductivity, meaning the ability to provide a platform, which 
facilitates the migration of osteoblasts and allows them to grow. The second one is 
osteoinductivity, indicating the capacity to induce osteogenic differentiation of undifferentiated 
or progenitor cells. The third characteristic is osteogenicity, which refers to the ability to form 
new bone using the cells seeded on the construct. Finally, a new requirement, which was recently 
added to the definition, is osteointegrativity, meaning the ability to incorporate with the 
surrounding native tissue (Greenwald et al., 2001). 
Currently, gold standard treatment for osteogenic bone replacement in osseous defects is 
autologous bone grafting or autograft. This is performed by using bone obtained from another 
part of the patient, usually from the iliac crest. Autograft is considered ideal for grafting 
procedures, providing osteoinductive growth factors, osteogenic cells, an osteoconductive 
scaffold and the ability to integrate very well with the surrounding host tissue. Moreover, 
autologous transplantation has the advantage of not posing a risk for immune rejection as it 
comes from the patient’ own body but has the drawbacks of donor site morbidity, limited 
material supply and the fact that is an invasive procedure (Amini et al., 2012). An alternative 
solution is allograft transplantation using cadavers or demineralised bone matrices, which both 
do not contain living cells and the material comes from another human donor. This approach has 
inherent risk of disease transmission and immune rejection. A third possible solution is 
xenograft where the material comes from a non-human donor posing a number of risks, such as 
immune rejection or cross species contamination (Oryan et al., 2014). 
Apart from the grafting solutions, another way of treatment incorporates the use of Bone-Graft 
Substitutes, which consist of scaffolds made of natural or synthetic biomaterials with or without 
the combination of osteoinductive agents (Nandi et al., 2010).  
Synthetic bone grafts are widely used because of their high availability but compared to an ideal 
bone graft; they possess only osteoconductive and osteointegrative properties while lacking 
osteoinductivity and osteogenesis (Giannoudis et al., 2005; Miron and Zhang, 2012). For 
example, Poly L lactic acid (PLLA) is a biocompatible polymer which is Food and Drug 
Administration (FDA) approved to be used for bone reconstruction due to the fact that is highly 
biodegradable (Schofer et al., 2011a; Schofer et al., 2011b). There are also composite graft 
substitutes combining two different biomaterials. Usually composites include an osteoconductive 
matrix with bioactive agents that provide osteoinductive and osteogenic properties (Malhotra et 
al., 2013). 
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It is of outstanding importance to mention that an ideal graft should be easy to use and readily 
available at low cost. Moreover, it is essential to be biocompatible, to provide biomechanical 
support and eventually to degrade in non-toxic byproducts (Giannoudis et al., 2005; Janicki and 
Schmidmaier, 2011). The above-mentioned information on the current grafting options and the 
existing limitations are summarized in Table 1.2.  
 
Table 1.2: Current grafting options and the existing limitations 
 
GRAFTING TREATMENT LIMITATIONS REFERENCES 
 
Autograft 
 
 
Donor site morbidity 
Limited material supply 
Invasive procedure 
 
 
(Amini et al., 2012) 
 
 
Allograft 
 
Disease transmission 
Immune rejection 
 
 
(Oryan et al., 2014) 
 
 
Xenograft 
 
 
Immune rejection 
Cross-species contamination 
 
 
(Oryan et al., 2014) 
 
 
Bone-Graft substitutes 
 
Lack osteoinductivity 
Lack osteogenesis 
 
 
(Nandi et al., 2010) 
 
 
The majority of bone fractures heal well after treatment by bone grafting, distraction 
osteogenesis or the use of bone replacement materials. However, large bone defects, which 
cannot heal by themselves within the lifetime of the individual, are a challenge for orthopaedic 
surgeons. Millions of people around the world suffer from large bone fractures caused by 
trauma, infection and diseases such as osteoporosis or cancer like osteosarcoma (Calori et al., 
2011). Currently applied treatments are neither effective nor sufficient to completely treat these 
defects and they usually lead to poor quality of life of the patient after few years. This fact makes 
urgent the need for the discovery of a novel and effective treatment strategy aiming to improve 
patient’s life due to the increasing aging population and the lack of donor tissue. 
 
1.2.1 Use of Osteoinductive molecules/Growth factors 
 
One interesting strategy to improve the osteoinductive properties of the scaffolds used for bone 
regeneration is to incorporate the application of biologically active molecules, such as the growth 
factors (Jabbarzadeh et al., 2008; Janicki and Schmidmaier, 2011). The most important and 
widely used osteoinductive growth factors are analyzed in the following section. 
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1.2.2 Bone Morphogenetic Proteins (BMPs) 
 
 
In 1965, Marshall Urist demonstrated that demineralised, lyophilized segments of bone were 
capable of inducing new bone formation when implanted into ectopic sites (Urist, 1965).  
Responsible for the ectopic bone formation was proven to be some low molecular weight bone 
glycoproteins named BMPs. BMPs are pleiotropic and multifunctional growth factors, which 
belong to the transforming growth factor b (TGF-b) superfamily. Several cell types, such as 
osteoprogenitor cells, osteoblasts, chondrocytes and platelets have been observed to synthesize 
these proteins. BMPs participate in several different functions, most of which are related with 
bone tissue. They are considered potent regulators of bone and cartilage formation and repair 
(Garrett, 2007; Reddi, 2001a; Reddi, 2001b).  
During embryonic development, they support cell proliferation while in the adult life, they 
contribute to maintenance of bone homeostasis (Chen et al., 2004). They have been proved to be, 
through various in vitro and in vivo studies, the strongest osteoinductive molecules able to 
regulate mesenchymal cell proliferation and differentiation to osteoblasts. They actively regulate 
both endochondral and intramembranous ossification and support bone formation and skeletal 
integrity (Carreira et al., 2014a; Carreira et al., 2014b). They also support the development of 
many cell types in various tissues and participate in a cascade of events starting from 
chemotaxis, continue with regulation of growth and differentiation, to finish with angiogenesis 
and apoptosis (Lissenberg-Thunnissen et al., 2011).  
Nowadays, there are about 20 different human BMPs that have been discovered and grouped in 
subfamilies (Miyazono et al., 2005; Wu et al., 2007). Treatment with these proteins is used all 
over the world for spinal fusions, non-union fractures, bone defects, osteoporosis and 
maxillofacial reconstruction. In 2002, the U.S. FDA approved the use of two recombinant human 
BMPs for specific clinical applications. The first one was recombinant human BMP-2 with the 
commercial name INFUSE Bone Graft (McKay et al., 2007) which received approval for fusion 
of the lumbar spine in skeletally mature patients with degenerative disc disease and for certain 
oral and maxillofacial uses. The other was recombinant human osteogenic protein-1 (rhOP-1) or 
recombinant human BMP-7 with the commercial name OP-1 implant or Osigraft which received 
approval for an alternative to autograft in recalcitrant long bone nonunions (White et al., 2007).  
BMPs are promising molecules for TE and bone therapy. However, there are several significant 
drawbacks regarding their clinical application to humans. The first issue is their high cost. 
Recombinant technology products like the BMPs require a high financial cost for their 
production. Another disadvantage of these molecules is their short half-life. They also need 
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appropriate carriers for efficient delivery. BMPs, in order to be effective for in vitro applications, 
are used in very high superphysiological concentrations in the experimental procedures. 
Furthermore, these cytokines and their receptors are regularly found within tumors. The last two 
observations, regarding the location and the application of these molecules, raise suspicions for 
carcinogenicity of these compounds and there is literature evidence supporting this idea and 
observing such outcome (Laitinen et al., 1997; Poynton and Lane, 2002; Soda et al., 1998; 
Yoshikawa et al., 1994). 
 
1.2.3 Parathyroid Hormone (PTH)   
 
Another FDA approved anabolic agent for treatment of Osteoporosis is PTH. Human PTH is an 
84-amino acid, single-chain polypeptide with a molecular weight of 9,425 Da. The section of 
human PTH between the N terminus and amino acid 34 (PTH1–34) retains the biological activity 
of full-length PTH (Morley et al., 2001) and is marketed as a drug. PTH is secreted from the 
parathyroid gland and has an important role in regulating calcium levels in the blood. When 
calcium in the blood decreases, PTH is secreted and stimulates bone metabolism, which in turn 
releases calcium from bone in the circulation to restore the appropriate level (Rizzoli and 
Reginster, 2011).  
PTH has been shown to have different effects on bone remodeling depending on the way it is 
administered. For example, it has been indicated that intermittent administration of PTH causes 
bone anabolic effects while continuous use favors bone resorption (www.fda.gov). To further 
support this idea, preclinical and clinical studies have shown that intermittent treatment with 
PTH stimulated the creation of new bone and improved bone density and bone quality generating 
strong new bone that was resistant to fracture (Esbrit and Alcaraz, 2013). PTH stimulated also 
bone formation by increasing the number of osteoblasts (Jilka, 2007). 
Nevertheless, serious side effects have been observed after PTH treatment suggesting that 
careful consideration and further research should be conducted to solve current problems and 
observed limitations. The way of administration had a significant impact on the resulting 
outcome. For example, some recent data from animal testing indicated that prolonged PTH 
administration led to development of osteosarcoma (Subbiah et al., 2010). 
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1.2.4 Other important growth factors 
 
BMPs and PTH are the most widely used growth factors for bone regeneration. Moreover, 
platelet-rich plasma isolated from platelets is a source of various growth factors (Marx et al., 
1998). It has been shown that many growth factors are released from platelets after activation 
(Franchini et al., 2005; Frechette et al., 2005) and can support bone formation. Some of these 
factors are the platelet-derived growth factor (PDFG), the transforming growth factor-β (TGF- 
β), the insulin-like growth factor-1 (IGF-1), the vascular endothelial growth factor (VEGF) and 
the fibroblast growth factor (FGF) (Lieberman et al., 2002).  
 
 
 
1.2.5 Problems resulting from the employment of growth factors  
 
The only currently approved osteoinductive molecules for bone anabolic treatment are the 
recombinant proteins BMP2, BMP7 and PTH. One major drawback for all of these proteins is 
their high cost due to the recombinant technology used for their production and purification. 
Moreover, a problem for the patients is the fact that current recombinant protein therapies must 
be administered through either repeated injections or surgical implantation leading to painful and 
invasive procedures (Bessa et al., 2008; Deal and Gideon, 2003). There is also the issue of 
immunogenicity of these molecules, which have been reported to cause undesirable immune 
reactions in patients (Dingermann, 2008; Hwang et al., 2009a; Schellekens, 2010). 
 One major issue with the therapeutic use of drugs is that they are administered in very high, 
super physiological concentrations of milligrams in assays, which are a million times higher as 
compared to the nanogram range in vivo (Bessa et al., 2008; Gamradt and Lieberman, 2004) and 
can often exhibit serious side effects and complications (Mroz et al., 2010).  
The last years, problems of increased swelling and significant ectopic bone formation leading to 
significant pain and limit limb function as well as a high risk of adverse side effects (Lo et al., 
2012b) have been observed and associated with the use of recombinant BMP2 (Smoljanovic et 
al., 2009; Smucker et al., 2006).   
Research has indicated that effective doses of BMP in humans are very high compared to smaller 
animals and a possible reason for this could be related to a less responsive BMP signaling 
pathway in humans (Bishop and Einhorn, 2007). Finally, one major concern is the widely off-
label use of BMPs for various applications leading to undesirable side effects (Woo, 2011). 
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As mentioned previously, PTH is widely applied for treatment of bone defects. However, apart 
from the above-mentioned general problems of all growth factors, this hormone exhibits some 
additional important aspects. To be more specific, parathyroid hormone-related protein (PTHrP) 
has been shown to regulate tumor-relevant genes and to play a role in tumorigenesis, modulation 
of tumor progression and response to treatment in breast cancer and bone metastases (Liao and 
McCauley, 2006; Luparello et al., 2001). In particular, PTHrP has been indicated to interfere 
with multiple cell survival and apoptosis signaling pathways by inhibiting both death receptor 
and cell cycle–mediated apoptosis signaling (Mak et al., 2012).  
 
 
 
 
 
1.3 Necessity for novel approaches and alternative solutions for clinical treatment  
 
The discovery of recombinant human BMPs for clinical treatment of bone defects in 
combination with the methods of TE created a new era in scientific research and opened up the 
field for more effective therapies. FDA approval of the use of growth factors led to several 
successful therapeutic applications and decreased the need for postoperative surgical 
interventions after complications. 
 Results of various in vitro and in vivo applications were really encouraging on the beginning. 
There appeared, however, significant issues and side effects related with the use of the growth 
factors. The major problem was the high cost of recombinant technology and the high 
concentrations of these molecules needed for effective treatment of bone diseases. There 
appeared also incidents of carcinogenesis and immunogenicity related with the employment of 
increased levels of growth factors. 
All the above-mentioned findings plus protein instability created concerns among scientists and 
made urgent the need towards the pursuit of an alternative and more effective way of treatment 
of bone disorders. The idea was to identify a molecule that could induce the secretion of these 
osteoinductive factors and activate the required signaling pathways without the need to be 
provided in high concentrations.  
Regenerative medicine (RM) applications and tissue engineering (TE) strategies emerged the last 
years as a new promising solution to try and effectively treat and heal all the potential bone 
related problems that could appear.  
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1.3.1 Regenerative medicine (RM) 
 
RM is considered an interdisciplinary field of research aiming at repairing, replacing or 
regenerating compromised tissues and impaired functions resulting from injuries, diseases, 
congenital defects or aging. It employs different approaches including the use of soluble 
molecules, gene therapy, stem and progenitor cell therapy, TE and the reprogramming of cell 
and tissue types. These methods often stimulate and support the body’s own self-healing 
capacity going beyond traditional transplantation therapies (Daar and Greenwood, 2007). 
 
 
 
 
1.3.2 Tissue Engineering (TE) 
 
TE is one of the major components of RM. Nowadays, TE and RM are considered as the same 
field of research and the same definition applies often to both of them. TE employs principles 
from engineering and life sciences and tries to better understand tissue formation and 
regeneration in order to create biological substitutes to improve tissue function (Kneser et al., 
2006; Langer and Vacanti, 1993; Lyons et al., 2008). 
In 2002, in a paper by Godbey and Atala, they distinguished in vitro and in vivo TE indicating 
the cellular and acellular approach of TE. In vivo TE was referring to the use of scaffolds with no 
cells and was relying solely on the body’s regenerative capacity to heal the defect (Godbey and 
Atala, 2002). Acellular approaches employing different scaffolds are still used but for treatment 
of small-scale defects. Nowadays, the important contribution and the significant role cells play 
for tissue repair has been recognized and the majority of TE applications employ the cellular 
pathway.  
To be more specific, TE is utilizing three main components to deliver its target, known as “the 
tissue engineering triad” (Figure 1.4) (Murphy et al., 2013). 
The triad consists of an appropriate cell source, a suitable scaffold and the necessary regulatory 
signals (Murphy et al., 2013). TE aims at replacing damaged and non-functioning tissues with 
3D cellular constructs obtained from the seeding of cells within a natural or synthetic scaffold 
(Baptista et al., 2009). These constructs should be functionally, structurally and mechanically 
equal to, if not better than, that which they have been designed to replace (Logeart-Avramoglou 
et al., 2005; Stock and Vacanti, 2001). 
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For successful outcome of TE applications, it is crucial not only to really understand the role of 
each component of the TE triad individually but also to realize the interplay between the cells, 
the scaffolds and the regulatory signals (Murphy et al., 2013).  
 
 
Figure 1.4: The concept of TE and the essential components of the TE triad. Adapted from 
(Murphy et al., 2013) 
 
 
 
 
The choice of the cells is crucial in order to facilitate the formation of the desired tissue. Scaffold 
has an essential role in providing structure and substrate for the growth and development of the 
tissue. The scaffold is responsible for supporting 3D tissue formation within the construct and 
for mimicking the function of the natural ECM until the cells start producing their own matrix 
(Baptista et al., 2009; Stock and Vacanti, 2001). Finally, the use of appropriate growth factors or 
biophysical stimuli is essential in order to create the environment needed for properly directing 
the growth and differentiation of cells within the construct (Murphy et al., 2013).  
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1.3.3 3D bioprinting 
 
 
Recent years, the use of microscale technologies has emerged as a novel approach for 
manipulating biological materials in the context of TE. The reason for this change is related with 
the advantages offered by this technology, which allows the reduction of the platform scale 
guiding to the need for low sample and reagent volumes as well as short experimentation times 
and cost reduction. The small experimental scale allows a better control over cell manipulation 
and permits testing of several different experimental parameters. Cell encapsulation and 
bioprinting strategies are some of the widely used microfabrication techniques to create 3D cell-
containing materials (Selimovic et al., 2012).  
Three-dimensional printing (3DP) otherwise known as additive manufacturing is a rapid 
prototyping technique that enables the creation of biocompatible materials, cells and supporting 
components into complex 3D functional living tissues (Murphy and Atala, 2014; Oryan et al., 
2014). The main limitation of that method is the restricted options of materials to be used 
(Castilho et al., 2013).  
3D bioprinting has already been applied for the production of tissues like skin, heart, bone and 
for research purposes like drug discovery and toxicology (Murphy and Atala, 2014). Moreover, 
it has been used to generate 2D and 3D structures for various purposes, including fabrication of 
scaffolds and tissue constructs for tissue regeneration. One major problem of the constructs 
created using printing technology is the lack of mechanical strength and integrity due to the 
innate properties of hydrogels (Seol et al., 2014). An alternative and recently discovered method 
for fabricating scaffolds with microscale and nanoscale resolution constituted the layer-by-layer 
microfluidic patterning, where cells and matrix materials flew through specific channels with 
controlled flow rates. 3D structures were generated by the sequential deposition of cells and 
matrix within the microchannels (Khademhosseini et al., 2006).  
 
 
 
 
1.3.4 Gene therapy 
 
 
A novel approach used for growth-factor delivery in the field of BTE is gene therapy (Caplan, 
2000; Chen, 2001). This method includes the transfer of genetic material into the genome of the 
cell of interest, thus allowing the cell to express important bioactive factors inducing different 
functions for long time.  
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Gene transfer can be performed using a viral (transfection) or a non-viral (transduction) vector. 
Gene therapy poses issues related with high cost, efficacy and biological safety, which need 
further research before the method is applied to humans. There are, however, promising results, 
especially with the use of BMPs, from various performed animal experiments (Calori et al., 
2009; Dimitriou et al., 2011; Tang et al., 2008b).  
 
 
 
 
1.3.5 MicroRNAs 
 
The recent discovery of microRNAs (miRNAs) and their ability to control global gene 
expression patterns gives new potential to the more effective treatment of bone defects and the 
more efficient stem cell differentiation.  
MiRNAs are short, non-coding RNA molecules involved in transcriptional regulation that 
function to inhibit the expression of target mRNAs and regulate significant developmental 
processes (Erson and Petty, 2008; Lee et al., 2006). These small RNAs shorten the half-life of 
the mRNAs by binding to their 3’ untranslated region and prevent their translation into 
functional proteins (Mariner et al., 2012).                      
MiRNAs have been associated with the control of bone formation and the regulation of 
osteoblast differentiation. Reports suggested that miRNAs were implicated in various levels of 
gene regulation during bone development and in several functions, such as the initial response of 
progenitor cells and the structural and metabolic activity of the mature tissue (Lian et al., 2012). 
Future application of miRNAs as gene therapy targets for the clinical treatment of metabolic 
bone diseases and bone injuries has been proposed (Dong et al., 2012) 
 
 
 
 
 
1.4 Stem cell bioprocessing and TE for bone regeneration 
 
 
The significant role of TE strategies and the contribution of stem cell bioprocessing protocols for 
the efficient cell differentiation have been recognized. One of the widely applied field of 
research and application of these methods is bone regeneration.  
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Bone tissue engineering (BTE) strategies, by combining cells with the right biomaterial and the 
use of necessary osteogenic factors, can generate a 3D construct that mimics natural bone tissue 
and can be used for bone formation offering an alternative solution to current existing 
limitations. Necessary component is the employment of the appropriate bioreactor in order to 
automate and scale up cell production (Figure 1.5) (Seong et al., 2010). 
 
 
 
 
 
Figure 1.5: Components of BTE. Modified from (Seong et al., 2010) 
 
 
 
The aim of BTE is try to eliminate many of the pitfalls of current treatments and create a more 
effective healing process. To further support this function, bioprocess engineering can contribute 
to alleviate possible limitations and support the efficient transition to 3D culture, which is closer 
to the original environment. The development of bioprocess technology can enhance the 
successful transfer of laboratory-based practice of stem cell and tissue culture to the clinic as 
therapeutics through the application of engineering principles (Placzek et al., 2009). 
Each of the main three components of BTE will be examined and analyzed separately in the 
following sections where appropriate examples will also be provided and thoroughly described. 
It is important to mention that later, the initial trial idea has been reconsidered and the 
importance of the mechanical environment as the fourth necessary element for proper support 
and completion of bone regeneration and fracture healing has been introduced (Guilak et al., 
2001; Virk and Lieberman, 2012). 
 
 
 1.4.1 Cell types 
 
The first component of BTE is considered the appropriate cell 
cell groups are widely employed: primary cells and stem cells. Primary cells mainly used include 
osteoblasts and chondrocytes whereas stem cells are divided in two main groups based on their 
origin, the somatic stem cells (SSCs) 
to adult stem cells (ASCs) and foetal stem cells 
derived from (Figure 1.6).  
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Figure 1.6: Cell types available for regenerative medicine applications
(O'Connor and Crystal, 2006
 
1.4.2 Primary cells 
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tissue (Hutmacher and Sittinger, 2003; Mailhot and Borke, 1998; Zuk et al., 2001). Previous 
studies have indicated the existence of considerable variation (Bouet et al., 2014) and differences 
in cell yield, proliferation and osteogenic potential between these sources (Jaquiery et al., 2005; 
Sakaguchi et al., 2005). Primary cells are also sensitive to the batch of serum used (Gong et al., 
2009; Zheng et al., 2006).  
Widely used candidates in various applications are osteoblasts. There are also several examples 
with the use of patient’s own bone marrow cells and committed stromal cells of osteoblastic 
lineage. Chondrocytes have also been employed as a primary source for subsequent bone 
formation. The main advantageous characteristic of using primary cells directly isolated from the 
bone of the patient is the fact that these bone-forming cells lack immunogenicity and can be 
directly implanted on the defect site and start producing bone matrix immediately without risk of 
rejection (Meijer et al., 2007). However, these cells exhibit restricted proliferation capacity in 
vitro and for this reason, their application is limited (Jayakumar and Di Silvio, 2010; Liu et al., 
2007; Meyer et al., 2004).  
There are few studies reporting the direct use of primary cells and most of them employed 
osteoblasts. In one of these studies, researchers used periosteal derived osteoblasts and indicated 
ECM production and mineralisation (Wiesmann et al., 2003). In another study, researchers 
seeded osteoblasts on titanium and analyzed the observed interactions (Muller et al., 2006). 
Siggelkow ang his collegues studied the expression pattern of bone-related genes during 
osteoblast differentiation in primary human osteoblasts (Siggelkow et al., 1999) and compared it 
with the already established and known panel of rat calvarial osteoblasts (Owen et al., 1990; 
Stein et al., 1990). Neonatal calvarial osteoblasts were also employed in a recent study and 
compared the quality of the generated final product with that of ESCs and MSCs (Gentleman et 
al., 2009).  
Primary bone cells can be obtained from various anatomical locations within the humanbody 
(Marolt et al., 2014). One recently discovered source includes primary humanalveolar bone cells 
that could be potentially used for periodontal and maxillofacial TE-based bone repair. Constructs 
made of these cells have been shown to enhance de novo bone formation in critical-size skull 
defects in immunodeficient mice (Pradel et al., 2008; Xiao et al., 2004; Xiao et al., 2003) and 
were used to treat jaw bone defects in several clinical case studies (Pradel et al., 2006; Pradel 
and Lauer, 2012; Springer et al., 2006). Prior work indicated that osteogenic cells originating 
from the jaw bone exhibit distinct differentiation properties both in vitro and in vivo (Akintoye et 
al., 2006) and also diverse drug responses compared to osteogenic cells originating from the 
long/iliac bones (Marolt et al., 2012a; Marolt et al., 2012b; Stefanik et al., 2008).  
 1.4.3 Stem Cells 
 
Stem cells can be defined as clonal precursors, which have two significant characteristics: the 
ability to self-renew producing identical daughter cells or to differentiate into various specialized 
cell types (Placzek et al., 2009
stem cell types (Figure 1.7). Based on that, there are totipotent stem cells
a whole organism. Zygote, produced from the fusion of an egg and sperm cell, is the only 
totipotent cell. Next group are the pluripotent stem cells
derived from any of the three germ layers (endoderm, mesoderm and ectoderm) of the embryo or 
germ cells but not cells of the placenta. Finally, there are multipotent stem cells
generate all the cells only of their ti
types of blood cells, but cannot develop into brain cells or other types of cells 
Boheler, 2005). 
 
Figure 1.7: The hierarchy of stem cells
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1.4.4 Somatic stem cells (SSCs) 
 
 
1.4.5 Adult stem cells (ASCs) 
 
SSCs have been isolated from various foetal, neonatal and adult tissues such as bone marrow, 
skin, liver, eyes, gastrointestinal tract and heart (Brittan and Wright, 2002; Fausto, 2004; Lavker 
et al., 2004; Leri et al., 2005; Modlin et al., 2003; Tumbar et al., 2004). Bone marrow contains 
the best characterised populations of stem cells including two types of stem cells, with notably 
different properties: MSCs and HSCs. MSCs can differentiate into mesodermal tissues such as 
bone, fat and cartilage, while HSCs can differentiate into cells present in the hematopoietic 
system (Friedenstein et al., 1974). The frequency of SSCs declines with age, with only 1 in 
100.000 cells being a stem cell in teens and 1 in 400.000 cells at the age of 50 (Caplan, 2007).  
SSCs are believed to reside in specific regions called niches within a tissue (Walker et al., 2009). 
Stem cell niche is the microenvironment composed of cells, which supports the development and 
nourishes the SSCs. It also contributes to the maintenance of tissue homeostasis (Moore and 
Lemischka, 2006). Stem cell niche has a pivotal role in regulating the balance between the 
quiescent and the activating state of SSCs. This is achieved through a complex network of 
interactions between somatic and supporting stem cells and also through the activation of various 
signaling pathways (Mimeault et al., 2007).  
Niche cells provide the appropriate environment to protect stem cells from differentiation and 
apoptotic stimuli that would change their state (Moore and Lemischka, 2006). Because of the 
significant role of stem cell niche, SSCs have limited ability to expand in vitro. Nevertheless, 
they have the advantage of not forming tumors when transplanted in vivo and they are not 
rejected because they originate from the same tissue and they have similar immunological 
features. Another advantage is that ASC populations are more accessible than ESCs and for this 
reason they have already been used in cell replacement therapies within the tissue of their origin 
under pathological conditions. For example, they stimulate endogenous regenerative process 
after tissue injury (Brittan and Wright, 2002; Bryder et al., 2006; Mimeault and Batra, 2006). 
Adult MSCs are multipotent and they can produce all cells of a particular germ layer or more 
restrictedly of a specific tissue. There is also strong evidence that ASCs may stimulate to self-
renew or differentiate, for example into gastrointestinal cell lineages (Brittan and Wright, 2002; 
Moore and Lemischka, 2006) after activation by exogenous application of specific growth 
factors or cytokines in vivo (Mimeault et al., 2007). MSCs are the first cells that have been 
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widely used for BTE applications and bone replacement therapies. MSCs can differentiate 
relatively easy in vitro into osteoblasts by treatment with Dex that stimulates proliferation and 
promotes osteogenic differentiation. Other supplements such as ascorbic acid (AA) phosphate 
and 1,25-dihydroxyvitamin D3 (vitD3) and members of the BMP family of growth factors are 
also commonly used for osteogenic induction of MSCs (Muller et al., 2008). 
MSCs have been widely tested in vivo in various animal models to evaluate their capacity in 
repairing large segmental bone defects. Initial experiments were conducted in mice or rat models 
(Bruder et al., 1998a; Bruder et al., 1998b; Bruder et al., 1998c; Pereira et al., 1998) and 
performed using allogeneic MSCs in order to assess their ability to facilitate bone healing. 
Results indicated the ability of allogeneic MSCs to efficient repair bone defects in the same 
degree as autologous MSCs. These positive results are related with the most advantageous 
property of MSCs, which is their immunosuppressive ability and regenerative capacity (Tsuchida 
et al., 2003). The absence of immunogenicity of allogeneic MSCs is the critical feature that 
renders these cells suitable for clinical applications in orthopaedics. For this reason, there are 
many experiments and applications using these cells, which can be guided towards osteoblast 
differentiation relatively easy (Guo et al., 2009).  
The rat/mice model was an important demonstration of the principle of MSC-mediated therapy 
and results were successful but these animal models do not really represent human conditions. 
Prior to transferring this technology to the clinic, it should be first translated to a larger animal 
model such as the canine, which is biomechanically relevant to humans. Following previously 
applied protocols, experiments with large animal models were initiated and obtained results were 
considered more accurate and representative to be tested in humans. One of the first large 
animals to be tested was canine. Researchers isolated MSCs from canine bone marrow, they 
seeded them on a porous ceramic scaffold and demonstrated that they can form both bone and 
cartilage upon implantation in subcutaneous and intramuscular sites of canine animal model 
(Kadiyala et al., 1997). Further experiments demonstrated that new-bone formation could be 
elicited in critical-sized segmental defects in dogs by the implantation of autologous MSCs 
(Bruder et al., 1998b). 
 To take it one step further, a few years later the same group used allogeneic MSCs loaded on a 
ceramic scaffold and implanted in a critical-sized segmental defect in the canine femur. Results 
indicated repair of the defect and although there was no use of any immunosuppressive therapy, 
there was no observation of any immune reaction (Arinzeh et al., 2003). 
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The next animal model to be evaluated was sheep. In one study, researchers used bone marrow 
stromal cells seeded on coral scaffolds and they implanted the construct in a bone defect of 
clinically relevant volume in a sheep model. It has been shown that bone remodeling in these 
animals is comparable to that in humans and coral material has been previously employed in 
several clinical applications (Yukna, 1994; Yukna and Yukna, 1998). Obtained results indicated 
acceleration of the repair process and successful reconstruction of the large bone defects (Petite 
et al., 2000). A few years later, people from the same group repeated this experiment by 
implanting bone constructs made of MSCs and coral granules of a standard size in a sheep model 
and they observed repair of the large segmental defects. They also noticed that the osteogenic 
ability of the employed bone constructs approached significantly that of bone autografts (Viateau 
et al., 2007).  
Kon and his collegues used a sheep model to evaluate the osteogenic ability of marrow-derived 
osteoprogenitor cells. Autologous cells were seeded on hydroxyapatite ceramic (HAC) scaffolds 
and implanted in critical-size tibial gaps. HAC scaffolds without cells were also implanted. 
Obtained results indicated a faster bone repair and regeneration of the defect in the cell-seeded 
scaffolds compared to the scaffolds alone (Kon et al., 2000). 
MSCs were also tested in children with Osteogenesis Imperfecta, a congenital disease 
characterized by defective bone formation. Report showed that three months after infusion of 
cells into children, there was a general and significant improvement of mineralisation together 
with new bone formation and reduction of fractures (Horwitz et al., 1999).   
Nowadays, MSCs are usually combined with different porous biomaterials and the generated 
constructs are then implanted in the defect site. This approach has better outcome and seems to 
enhance bone regeneration more efficiently (Bruder et al., 1998a; Bruder et al., 1998b; Bruder et 
al., 1998c; Cancedda et al., 2003; Richards et al., 1999; Rose and Oreffo, 2002; Vats et al., 
2003). It is generally accepted that local implantation of porous biomaterials covered with 
autologous bone marrow MSCs represents the most effective approach for repairing bone defects 
(Quarto et al., 2001).  
 
 
 
1.4.6 Foetal stem cells (FSCs) 
 
FSCs may be harvested from most tissues and organs of the fetus (Gerrard et al., 2005) and 
mainly from bone marrow, blood, liver, kidney or from cord blood and placenta and tend to be 
more primitive the earlier in gestation they are derived. FSC collection causes ethical issues 
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because they are mainly isolated from abortal tissue after first or second trimester termination of 
pregnancy (Guillot et al., 2006). These cells do not pose the risks of ESCs such as the immune 
rejection and at the same time they are in a more progenitor stage in comparison to ASCs. 
Amniotic fluid-derived stem cells (AFS) have shown the capacity to differentiate into various 
cell types of the three germs layers such as osteoblasts, adipocytes, chondrocytes, muscles, 
endothelial cells, neurons and hepatic cells (De Coppi et al., 2007; Delo et al., 2006; Kolambkar 
et al., 2007). Specifically, human AFS are the first foetal cells to be tested for their ability for 
osteogenic differentiation. These cells express a combination of ESC and ASC markers and 
exhibit some of the features of both. They have unlimited expansion potential but unlike ESCs 
they do not seem to be tumorigenic. They can be expanded for more than 250 population 
doublings retaining long telomeres and a normal chromosomal karyotype unlike ASCs (De 
Coppi et al., 2007).  
Human amniotic fluid mesenchymal stem cells (hAMSCs) were seeded on microcarriers and 
cultured in a perfusion culture system to proliferate and achieve high cell numbers before 
induced to undergo osteogenic differentiation. Osteogenic differentiation was performed with the 
classic DAG protocol described previously for ESCs and MSCs. Mineral deposition and calcium 
content were confirmed with increased ARS. There was also increased gene expression of bone 
markers ALP, COL 1 and BGLAP (Chen et al., 2011). 
In another study, aMSCs were seeded on scaffolds and the generated constructs were implanted 
in animals for sternal repair. Two months later, obtained results indicated defect closure in all 
animals and also increase in ALP activity. This finding demonstrated the promising role of these 
cells as candidates for alternative and potentially more efficient treatment of bone defects 
(Steigman et al., 2009). Researchers from another group seeded AFS on porous medical-grade 
poly-e-caprolactone (mPCL) scaffolds and they observed significant production of mineralised 
matrix. Bone formation was also confirmed in vivo in a rat subcutaneous model. This outcome 
suggested that AFS could be a potentially effective cell source for the production of large, 
mineralised constructs to be used for functional repair of large bone defects in various clinical 
cases (Peister et al., 2009). 
Apart from the amniotic fluid, cells isolated from the placenta have been indicated to stimulate 
bone formation (Li et al., 2011). A relatively recent and novel cell source for bone regeneration 
is tooth-derived stem cells isolated from very young donors so they belong to the group of FSCs 
(Bluteau et al., 2008; Gronthos et al., 2002; Gronthos et al., 2000; Park, 2013; Yen and Sharpe, 
2008). 
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1.4.7 Embryonic Stem Cells (ESCs) 
 
ESCs are isolated from the ICM of the blastocyst of the developing embryo. Human ESCs 
(hESCs) were isolated for the first time by Thomson and his group at the University of 
Wisconsin (Thomson et al., 1998). ESCs have also been isolated from rodents (Graves and 
Moreadith, 1993; Martin, 1981) and primates (Thomson et al., 1995). In particular, the first 
pluripotent mESC line from mouse embryo was derived in 1981 (Evans and Kaufman, 1981). 
Since their discovery, mESCs initially and hESCs the last years are widely used by many 
scientists all over the world because they possess two significant characteristics, which make 
them an ideal experimental tool. Firstly, ESCs can be propagated indefinitely in vitro as a stable 
self-renewing cell population without losing their undifferentiated status and secondly, they are 
pluripotent cells meaning that they can differentiate into any cell type in the embryo apart from 
the placenta (Handschel et al., 2010; Wobus et al., 2001). 
Several authors have reported the differentiation of ESCs into cardiomyocytes (Kehat et al., 
2002; Xu et al., 2002; Yang et al., 2008), hematopoietic cells (Kaufman et al., 2001; Wiles and 
Keller, 1991), neurons (Bain et al., 1995; Carpenter et al., 2001; Lee et al., 2007a; Schuldiner et 
al., 2001), chondrocytes (Hwang et al., 2008; Kramer et al., 2000; Oldershaw et al., 2010), 
adipocytes (Dani et al., 1997), muscle cells (Rohwedel et al., 1994), osteoblasts (Ahn et al., 
2006; Kuznetsov et al., 2011; Mateizel et al., 2008), pancreatic islets (Assady et al., 2001) and 
endothelial cells (James et al., 2010).  
There are also many studies demonstrating the capacity of hESC to differentiate into 
mesenchymal cells as a first step and subsequently used to regenerate a specific defected area 
(Barberi et al., 2005; de Peppo et al., 2010; Lian et al., 2007; Olivier et al., 2006).  
ESCs are also characterized by long telomeres and high telomerase activity. Telomerase is an 
enzyme, which protects the ends of chromosomes, the so-called telomeres and expands them 
after each cell division in order to maintain their length. Telomere shortening is associated with 
replicative senescence (Mimeault and Batra, 2006; Thomson et al., 1998).  
These properties make ESCs an ideal cell source for cell therapies and TE applications. One 
major demand in various therapies is the need for high cell numbers. ESCs with their unlimited 
self-renewal capacity and maintenance of undifferentiated status can provide the high number of 
cells needed for cell replacement therapies and other clinical applications. They can also be 
differentiated to all cell types of human body and applied for treatment of various diseases 
(Howard et al., 2008; Jukes et al., 2008). 
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In their undifferentiated state, ESCs express various markers that have been associated with 
pluripotency, the most important of which are the transcription factor octamer binding protein-4 
(Oct-4) of the POU family, which prevents stem cells from differentiating and helps them 
maintain self-renewal and pluripotency (Scholer et al., 1990a; Scholer et al., 1990b), the 
homeodomain protein Nanog, which directs pluripotency and differentiation of undifferentiated 
ESCs and works together with the transcription factor SOX2, which regulates transcriptionally 
active genes involved in pluripotency maintenance (Chambers et al., 2003). Pluripotent ESCs in 
humans also express stage specific embryonic antigens SSEA-3 and SSEA-4, the keratan sulfate-
associated antigens Tra-1-60 and Tra-1-81 and the zinc-finger containing gene Rex-1 at high 
levels (Chen and Daley, 2008; Guillot et al., 2007). Moreover, ESCs are characterized by high 
ALP activity (Wobus et al., 2001). 
ESCs seem a very promising candidate for cell therapies and TE applications based on their 
advantageous performance in vitro. There are, however, a couple of important considerations 
regarding their transfer to in vivo applications in human beings.   
It is not very easy to efficient direct ESCs to fully differentiate towards a specific lineage. 
Because of that, it has been shown that when injected in vivo into severe combined 
immunodeficient (SCID) mice, undifferentiated ESC form teratomas (Mimeault and Batra, 2006; 
Thomson et al., 1998). Tumor formation is a very serious risk and it indicates the importance to 
create more efficient differentiation protocols and reassure all cells are fully/terminally 
differentiated before in vivo implantation.   
Another important hurdle for in vivo therapy is the immunological incompatibility and the 
challenge to identify a strategic solution to circumvent immune rejection (Grinnemo et al., 
2008). Experiments using both human and mouse ESCs revealed that these cells were rejected 
after transplantation into immunocompetent mice in contrast to immunodeficient mice. Prior 
sensitization of the host by repeated transplantation resulted in accelerated ESC death. These 
results suggested that transplanted ESCs triggered cellular and humoral immune responses. The 
use of immunosuppressive drug regimens may be a solution (Swijnenburg et al., 2008).  
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1.4.8 Induced pluripotent stem cells (iPSCs) 
 
 
In 2006, Takahashi and Yamanaka generated a new cell line that aimed to combine the 
advantages of embryonic and adult stem cells and eliminate their drawbacks. iPSCs were created 
from adult fibroblasts with the addition of four defined factors that resulted to their 
reprogramming back to their pluripotent state (Takahashi and Yamanaka, 2006). iPSCs have 
similar properties to ESCs without the ethical consideration of destroying embryos and the risk 
of immune rejection due to the fact that they come from the patient himself and not from a donor 
(Jiang et al., 2014).     
There are already examples of successful derivation of osteoblasts from iPSCs. One of the first 
in vitro experiments directed the differentiation of mouse iPSCs (miPSCs) to mesenchymal cells 
as a first step and subsequently to osteoblasts. Cells were then seeded on scaffolds and were 
implanted in vivo in mice. Both in vitro and in vivo, cells demonstrated the capacity to generate a 
stable bone phenotype and an osteogenic matrix (Bilousova et al., 2011).  
In another study, miPSCs were employed and exposed to osteogenic growth factor TGF-beta 1 
or 3 in order to differentiate to osteoblastic cells. The cells were then seeded on ceramic 
scaffolds and implanted in SCID mice. Results showed the generation of progenitors from 
miPSCs that have the potential to make bone and they also demonstrated bone deposition on the 
scaffolds. These findings however should be tested in human iPSCs (hiPSCs) to evaluate if they 
are transferable (Li and Niyibizi, 2012).  
A very recent study utilizes a new strategy trying to establish a stepwise differentiation protocol 
of miPSCs and hiPSCs into osteoblasts using four small molecules under serum-free and feeder-
free conditions. The steps include an initial mesoderm induction, followed by osteoblast 
induction and finishing with ostoblast maturation. They noticed increased expression of 
osteoblast-related genes and proteins in both miPSCs and hiPSCs (Kanke et al., 2014).  
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In Table 1.3, the main advantages and disadvantages of various cell types employed in TE 
applications are presented.  
 
Table 1.3: Characteristics of cell types employed in TE applications: 
 Advantages and Disadvantages   
 
 
CELL 
TYPES 
 
ADVANTAGES 
 
DISADVANTAGES 
 
REFERENCES 
 
 
 
Primary 
cells  
 
 
 
 
- Lack immunogenicity 
 
- No risk of rejection 
 
- Restricted proliferation 
capacity in vitro 
 
- Sensitive to serum 
batch  
 
- Different sources 
exhibit variations in: 
 
+ Cell yield 
+ Proliferation capacity 
+ Osteogenic potential 
 
 
(Bouet et al., 2014) 
 
(Jaquiery et al., 2005) 
 
(Sakaguchi et al., 2005) 
 
(Gong et al., 2009) 
 
(Zheng et al., 2006) 
 
 
    
 
 
ASCs 
 
- No tumor formation 
 
- Not immune rejection 
 
- Accessible 
 
 
- Limited ability for in 
vitro expansion  
 
 
(Brittan and Wright, 2002) 
 
(Bryder et al., 2006) 
 
(Mimeault and Batra, 2006) 
 
(Moore and Lemischka, 2006) 
 
    
 
FSCs 
 
- Not risk for immune 
rejection 
 
- More primitive stage 
in comparison to adult 
 
- Ethical issues, use of 
abortal tissue 
 
(Gerrard et al., 2005) 
 
(Guillot et al., 2006) 
 
(De Coppi et al., 2007) 
    
 
 
ESCs 
 
- Unlimited self-renewal 
capacity without losing 
undifferentiated status 
 
- Differentiation to any 
cell type from the three 
germ layers 
 
- Long telomeres and 
high telomerase activity 
 
- Difficult to fully and 
efficiently differentiate 
 
 
- Tumor formation 
 
- Risk for immune 
rejection 
 
 
(Handschel et al., 2010) 
 
(Wobus et al., 2001) 
 
(Mimeault and Batra, 2006) 
 
(Thomson et al., 1998) 
 
(Howard et al., 2008) 
 
(Jukes et al., 2008) 
 
    
 
iPSCs 
 
- No ethical 
considerations 
 
- No risk of immune 
rejection 
 
- Similar advantageous 
properties of ESCs 
 
 
- Not efficient 
reprogramming protocol 
 
- Gene therapy strategies 
using virus are 
employed 
 
 
(Jiang et al., 2014) 
 
(Warren et al., 2010) 
 
(Mikkers et al., 2012) 
 
(Maherali and Hochedlinger, 2008) 
 
(Soldner et al., 2009) 
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1.5 Culture systems: 2D versus 3D   
  
Traditionally, stem cell culture and expansion is performed in 2D flat surfaces such as well 
plates and tissue culture flasks. The extended use of these conventional monolayer platforms is 
due to their simple structure, which makes them easy to handle and convenient for cell culturing 
purposes. An important advantage is also their low cost (Figure 1.8).  
 
 
Figure 1.8: Major characteristics and comparison between 2D and 3D static culture. 
Adapted from (Ferrarini et al., 2013) 
 
 
However, 2D culture presents with a number of drawbacks, which render it not an optimal cell 
culture configuration.  The main disadvantage of 2D plastic substrates is the limited capacity to 
reproduce the complex in vivo environment.  It cannot support high cell numbers needed for 
cellular therapies due to the limited surface area. It cannot also mimic and recreate the in vivo 
environment where cells normally reside and cannot provide the appropriate signaling for cell 
differentiation. Consequently, it is not possible to support complex structures. Transport of 
important molecules is different between 2D and 3D cultures. Diffusion of molecules is the 
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mechanism employed in 2D cultures whereas convection is the advantageous mechanism in 3D. 
Another important issue is oxygen consumption. Cells in 3D consume more in comparison to 
2D. This is due to the fact that cells in 2D are more space restricted and they reach confluence 
faster and stop proliferating due to contact inhibition whereas 3D cultures provide a larger 
surface area for cells to grow and increase their numbers. Sufficient oxygen supply is critical in 
the early stages of proliferation where cells need and consume more oxygen compared to late 
stages (Malda et al., 2004; Radisic et al., 2006).  
 
Table 1.4:  Advantages and Disadvantages between 2D and 3D culture configuration 
 
Culture 
configuration 
 
Advantages 
 
Disadvantages 
 
References 
 
 
 
 
 
2D Cultures 
 
 
 
 
- Easier environmental 
control, cell observation, 
measurement and 
manipulation than 3D 
 
- A rich body of literature 
exists, easier to perform 
comparisons with 
obtained results 
 
 
-Altered gene expression 
- Different growth characteristics 
- Deficiency in cell-cell and cell-
matrix interactions 
- Less compatibility with in vivo 
systems and different cell 
behavior  
- Elongated, unnatural cell shape  
- Unable to depict traits exhibited 
by in vivo systems. 
- Unnatural interactions between 
cells. 
- Cell monolayer. 
- Poorer stem cell expansion. 
 
 
 
 
 
 
(Ferrarini et al., 2013) 
 
(Malda et al., 2004) 
 
(Radisic et al., 2006) 
 
(Abbott, 2003) 
 
(Cukierman et al., 
2001) 
 
(Zhang, 2004) 
 
(Serra et al., 2012) 
 
 
 
 
 
 
3D Cultures 
 
 
- Cells contact with other 
cells  
- Cells behave more like 
those in vivo 
- More natural cell shape 
- More natural 
interactions between cells 
- Cell multilayer 
- Improved stem cell 
expansion. 
 
 
- Diffusional transport limitations 
 
 - Accumulation of toxic waste 
products  
 
- Culture-dependent alterations in 
gene expression, cell proliferation, 
viability, productivity and product 
quality due to nutrient deprivation 
 
Cells cultured on 2D culture flasks are forced to adapt to a flat and rigid surface, which is 
completely different from the normal in vivo microenvironment within humanbody and this 
results in significantly altered metabolism and declined functionality. Moreover, these cells 
exhibit major differences regarding morphology, proliferation and differentiation compared to 
3D cultures. Gene expression patterns also indicate differences between 2D and 3D culture 
configurations (Abbott, 2003; Cukierman et al., 2001; Zhang, 2004).   
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Important drawbacks of 2D culture platforms are also the lack of proper control, cell 
heterogeneity and generation of low production yield making them unsuitable to be used for 
clinical applications. On the other hand, 3D culture strategies mimic more what actually occurs 
in the native microenvironment and by this way they can significantly improve cell viability and 
function and offer better results regarding efficiency, robustness, consistency and predictability 
of the cultured product. This fact indicated the promising role of 3D configuration in preclinical 
research (Serra et al., 2012).           
      
1.5.1 3D culture 
 
Scaffolds are considered the second essential component of TE, which provides the 3D 
configuration. There are various types of scaffolds for different tissues and applications. 
 
 
1.5.2 Scaffolds 
 
Scaffolds are considered the second essential component of TE. A scaffold is mainly designed to 
provide the appropriate stimulatory 3D environment needed for tissue formation (Frohlich et al., 
2010). It should also be able to mimic the function of the natural ECM (Baptista et al., 2009). 
Their choice is important and they need to possess several features in order to support their role. 
A scaffold must be biocompatible, which means to be able to integrate in the host’s tissue 
without eliciting an immune response. It should also have the appropriate structural and 
mechanical properties and thus, to be highly porous and permeable for cell seeding, infiltration, 
nutrient transport, tissue ingrowth and vascularisation. Porosity and interconnectivity are 
particularly significant for the accurate diffusion of nutrients and the removal of metabolic waste 
products resulting from the activity of the cells. Pore size is another important feature that needs 
to be taken into consideration. Small pores will be occluded by cells and this in turn will cause 
problems in matrix production, vascularisation and cellular penetration (Salgado et al., 2004). 
In the case of bone engineering, scaffolds with pore sizes in the range of 200 – 900 μm 
(Abukawa et al., 2004; Ishaug-Riley et al., 1998; Logeart-Avramoglou et al., 2005) that mimic 
the structure of bone, have been shown to enable cellular penetration, ECM production and 
eventual blood vessel ingrowth (Frohlich et al., 2010). A scaffold is also vital to have mechanical 
strength in order to withstand hydrostatic pressure and maintain the spaces required for cell 
growth and matrix production. Ideally, it should have properties matching those of the native 
bone (Leong et al., 2003). Furthermore, it should gradually be degraded in non-toxic derivatives 
and replaced by engineered tissue deposited by the cells. Finally, a scaffold should be 
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osteoconductive, osteoinductive and osteointegrative (Frohlich et al., 2008). 
 Osteoconduction refers to the ability of the scaffold to allow bone growth on its surface 
(Albrektsson and Johansson, 2001). It also characterizes the recruitment of osteoblasts to the 
defect area by the surrounding tissues (Yuan et al., 2010).  
Osteoinduction refers to the process where undifferentiated progenitor cells are stimulated to 
differentiate towards the osteogenic lineage resulting in de novo bone formation (Yuan et al., 
2010). In particular, it has been suggested that a material is considered osteoinductive if it has 
the capacity to induce bone formation heterotopically (Barradas et al., 2011).  
Osseointegration is referring to the area of bone/implant interface (Dohan Ehrenfest et al., 2010) 
and characterizes the bone anchorage to the implant material (Albrektsson and Johansson, 2001) 
and the stability of the implant itself (Albrektsson and Zarb, 1993). Initial definition was 
targeting only metal implants but nowadays the term is also applied on non-metal surfaces 
(Wenz et al., 2008), although the followed biochemical mechanism underlining the two 
processes is different. The choice of the appropriate material for the production of a scaffold is 
important for BTE. Various materials, from both natural and synthetic sources, have been 
utilized up to now. 
 Natural biomaterials usually come from an in vivo source and this means they are constantly 
available in large quantities and reasonable prices. Their biggest advantage is their 
biocompatibility due to the fact that they contain binding sites for cells and adhesion molecules. 
However, they have some disadvantages like their limited mechanical properties. There is also 
the risk for impurities, which may cause unwanted immune reactions. Lot-to-lot variability is 
another concern of in vivo sources. Some widely use natural biomaterials for bone applications 
are collagen, silk, alginate and chitosan (Table 1.5) (Bartis and Pongrácz, 2011).  
In TE applications nowadays, a number of synthetic biomaterials are widely employed. Their 
main advantage is the high reproducibility. It is also very useful that their properties can be 
tailored and adjusted to current needs. Mechanical properties, degradation rate, shape and 
composition are some of the features that can be easily controlled. Synthetic materials however 
often lack sites for cell adhesion and many times they do not possess biocompatibility and they 
are not able to support stem cell differentiation. Some widely applied synthetic biomaterials are 
ceramics and metals (Table 1.5) (Bartis and Pongrácz, 2011). Metals and most of the ceramics 
are not biodegradable. Some materials like bioceramics have been shown to induce bone 
formation without prior cell implantation. This strategy could be used for small defects where 
low amount of cells is needed but it would not be effective for critical size bone defects due to 
the large number of cells required to repair the damage (Perka et al., 2000).  
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From the synthetic biomaterials, calcium phosphate ceramics are widely used as bone graft 
substitutes due to their similar properties with the mineral part of natural bone tissue. These 
ceramics have indicated great biocompatibility and osteoconductive capacity without exhibiting 
any adverse immune reactions (Gosain et al., 2002). However, at the same time, ceramics, such 
as HA or HA-tricalcium phosphate do not provide good mechanical properties and they are 
fragile (Grundel et al., 1991; Moore et al., 1987).  
Nowadays, scientists examine and focus on the use of biodegradable materials, such as 
hydrogels, which seem to be better candidates for BTE. These can be either natural or synthetic 
(Hutmacher, 2000; Yang et al., 2001).  
 
 
Table 1.5: Materials used to form scaffolds for the regeneration of orthopaedic tissues. 
Adapted from (Evans, 2013) 
 
Class Examples 
 
 
 
Natural polymers 
Collagen  
Gelatin 
 Silk 
 Fibrin 
 Alginate 
 Chitosan 
 Hyaluronan 
 Coral (hydroxyapatite) 
 
 
 
Ceramics 
Hydroxyapatite  
β-Tricalcium phosphate (TCP)  
Biphasic calcium phosphate (BCP) 
Calcium sulfate (plaster of Paris) 
Octacalcium phosphate 
 Bioglass 
 
 
 
Synthetic, biodegradable polymers 
Polylactic acid 
Polyglycolic acid (vicryl) 
Poly (lactic-co-glycolic acid) 
Polycaprolactone 
Polyhydroxyalkanoate 
Polyurethane 
 
 
 
Tissue extracellular matrix 
Demineralised bone matrix (DBM) 
Small intestine sub-mucosa (SIS) 
Skin 
Dermis 
Fascia 
Pericardium 
 
 
 
 Other 
Self-assembling peptides 
Hybrid scaffolds  
      Collagen-glycosaminoglycan  
             Collagen-hydroxyapatite 
             Gelatin - hyaluronan 
           Hyaluronan – polycaprolactone  
           Polycaprolactone - polyurethane 
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1.5.3 Hydrogels 
 
Hydrogels are considered an attractive option and have been extensively examined for their 
capacity to be employed as scaffolds for various TE applications due to their advantageous 
features, which resemble natural tissues (Peppas et al., 2000a; Peppas et al., 2000b; Slaughter et 
al., 2009). Hydrogels are highly hydrated polymer materials, which possess a number of 
beneficial characteristics for BTE, for example biocompatibility and controllable 
biodegradability. Moreover, due to their soft and pliable nature, they exercise minimized 
mechanical or frictional irritation to the surrounding tissue and it is convenient to change their 
physical and chemical properties in order to be applied in any surgery. Furthermore, they allow 
rapid diffusion of nutrients and metabolites (Vinatier et al., 2006) and provide homogenous cell 
distribution in a 3D structure (Bienaime et al., 2003; Chia et al., 2000; Uludag et al., 2000).  
Nowadays, cell-laden hydrogels are considered ideal candidates for minimally invasive 
applications. It is suggested that gel immobilization increases transplantation efficiency and 
protects the cells during implantation. Furthermore, hydrogels mimic the physiologic 
microenvironment of osteoblastic cells until they start to synthesize their own supportive ECM 
(Kneser et al., 2006). They also provide a temporal mechanical support for the cells (Gomez-
Barrena et al., 2011).  
As mentioned previously, the problem with the development of robust 3D structures is the 
limited mass transport through diffusion. Perfusion culture configuration holds the promise of 
eradicating these limitations and promoting the development of complex and clinically relevant 
tissues. The use of hydrogel scaffolds allows diffusive permeability to oxygen and mass 
transport of nutrients to encapsulated cells (Li et al., 2012). 
 
 
1.5.4 Alginate  
 
The alginate gel is considered as one of the most applied biomaterials for the differentiation of 
stem cells in a 3D system (Bosnakovski et al., 2006; Diduch et al., 2000; Ma et al., 2003; 
Mehlhorn et al., 2006). Extracted from seaweed, alginate is a polysaccharide that is composed of 
D-mannuronic acid residues, which contribute to its elasticity and L-guluronic acid residues, 
which contribute to mechanical strength, stability, and porosity (Figure 1.9). 
 Cells are suspended in the liquid alginate and in the presence of calcium ions; the semisolid gel 
can be formed by way of the crosslinking of alginate chains under mild conditions. When the 
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cells are encapsulated in alginate gel, interconnected pores can promote cell attachment, 
proliferation and differentiation and thereby provide pathways for nutrient and protein diffusion 
(Fragonas et al., 2000; Murtas et al., 2005).  
One of the main advantages alginate gel has is that it is injectable and can be used in a minimally 
invasive manner to transplant cells and fill lesions with irregular shapes (Stevens et al., 2004). 
High porosity has also been reported, along with an ideal porous structure, biocompatibility, and 
high affinity to water (El-Sherbiny and Yacoub, 2013), which is necessary for engineering 
scaffolds. 
 
 
 
 
   
 
Figure 1.9: Chemical structure of alginate polysaccharide composed of β-D-mannuronic acid 
(M) and α-L-guluronic acid (G) with a variation in composition and sequential arrangements. 
Adapted from (Paredes Juarez et al., 2014; Wilson and McDevitt, 2013).    
 
Cai and his group suggested that the application of hydrophilic and porous materials, such as 
alginate, might enhance the communication of seeded cells and the refreshing of nutrition. The 
plasticity of alginate/cell constructs makes them fit easily in the adjacent tissues surrounding the 
defects (Cai et al., 2007). Alginate hydrogels have been widely used for engineering various 
tissues in human body. There are examples of encapsulation and delivery of Langerhans islets 
(Johnson et al., 2011), ovarian follicles (Tagler et al., 2012) and stem cells for neural (Banerjee 
et al., 2009) and skeletal muscle (Liu et al., 2013) regeneration. Alginate has also been tested for 
engineering cartilage (Wan et al., 2011) and intervertebral discs (Renani et al., 2012).  
There are several examples of alginate hydrogels applied for BTE applications and regeneration.  
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Zhou and his colleagues encapsulated human umbilical cord mesenchymal stem cells 
(hUCMSCs) in alginate-fibrin microbeads and they noticed excellent proliferation, 
osteodifferentiation and bone mineral synthesis indicating a good delivery system to promote 
bone regeneration (Zhou and Xu, 2011).  
In another study, researchers used rabbit-derived bone marrow cells (BMCs) and encapsulated 
them in alginate microbeads. They concluded that this system could support the proliferation of 
BMCs and also their osteogenic differentiation (Abbah et al., 2008). The same group also 
experimented with murine-derived adipose-tissue stromal cells (ATSCs) encapsulated in alginate 
microcapsules and cultured in the presence of osteoinductive factors. Their results indicated 
enhanced proliferation and osteogenic differentiation. Osteogenic activity was also confirmed 
from high expression of ALP and OCN mRNA. The alginate microenvironment supported cell 
viability and allowed cell differentiation towards osteoblastic lineage (Abbah et al., 2006).  
In a more recent study, adipose-derived stem cells (ADSCs) were encapsulated in alginate 
microbeads and they were also combined with platelet-rich plasma (PRP), which has been shown 
to contain a number of growth factors. In vitro results showed increased osteogenic 
differentiation of the encapsulated cells while in vivo experiment in nude mice indicated 
vascularization and mineralisation in heterotopic site (Man et al., 2012).  
Hydrogels possess a hydrophilic nature, which does not allow protein adsorption and for this 
reason, mammalian cells cannot interact with them. Cell anchorage is crucial for cell viability. It 
has been observed that ionically crosslinked alginates lose mechanical properties over time in 
vitro, presumably due to an outward flux of crosslinking ions into the surrounding medium 
(Shoichet et al., 1996). For these reasons, many groups use covalently modified alginate by 
incorporating cell adhesion ligands, usually the RGD peptide (Rowley et al., 1999).  
For example, alginate modification with RGD-containing peptide showed to promote osteoblast 
adhesion and spreading. Researchers used a murine pre-osteoblast cell line (MC3T3-E1) for in 
vitro encapsulation and experimental analysis. They observed upregulation of important bone 
differentiation markers indicating increased osteoblast differentiation of the murine osteoblastic 
cells. To get one step further, they performed animal experiments where they transplanted 
primary rat calvarial osteoblasts encapsulated in RGD-modified alginate hydrogels and observed 
statistically significant in vivo bone formation (Alsberg et al., 2001).  
Another study used the preosteoblastic cell line MC3T3-E1 and encapsulated them in RGD 
modified alginate gels. Researchers suggested that RGD peptides promoted adhesion and 
differentiation of MC3T3-E1 preosteoblasts while there was increased collagen production and 
secretion to the ECM (Evangelista et al., 2007).  
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More recently, mESCs were encapsulated in alginate and cultured in a RWV bioreactor. The 
generated 3D mineralised constructs displayed morphological, phenotypical and molecular 
features of osteogenic lineage while presenting with the characteristic mineralised 
calcium/phosphate deposition (Hwang et al., 2009b). 
 
 
1.6 Culture systems: 3D Static versus Dynamic 
 
In the previous chapter, the limitations of conventional 2D culture configurations were reported 
and the necessity to change for 3D culture protocols which better mimic the in vivo environment 
where cells normally grow. In this chapter, comparison between 3D static and 3D dynamic 
configurations takes place (Figure 1.10). 3D static culture seems to possess important 
limitations, which do not accurately represent the in vivo microenvironment. The most 
significant limiting factor is oxygen. Oxygen has low diffusion capacity and solubility 
coefficient in aqueous solutions leading to the creation of significant oxygen gradients in static 
culture. Oxygen concentration with its turn, affects cell viability/ survival. 
 
 
 
Figure 1.10: Major characteristics and comparison of 3D static versus dynamic culture in a 
bioreactor Adapted from (Ferrarini et al., 2013) 
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 Static culture also indicates uneven levels of nutrient supply and waste removal. These gradients 
in the level of oxygen and nutrient configuration have a direct effect on tissue quality (Arkudas 
et al., 2007; Malda et al., 2007). Cells in 3D culture exhibit high proliferative capacity, which is 
severely disrupted by the oxygen gradients in static culture, which may possible cause cell death 
(Volkmer et al., 2008). Dynamic culture systems were developed to overcome many of the 
previously mentioned limitations. Flow perfusion bioreactors can improve nutrient and oxygen 
delivery and waste removal from 3D tissue cultures (Abousleiman and Sikavitsas, 2006; Martin 
and Vermette, 2005). 
The use of bioreactors is considered nowadays an essential and integral part of any TE 
applications. Bioreactors provide the essential environment required to support 3D culture 
configuration and sustain the culture of clinically relevant high cell numbers needed for therapy 
of bone disorders. They were also introduced to improve the quality of different types of 
engineered tissues, including bone and to overcome diffusional limitations of static culture. They 
provide a better recapitulation of in vivo environment. The third essential compound of TE is the 
use of the appropriate culture platform, a bioreactor that would control the culture conditions and 
create an environment ideal for the cells to proliferate and reach high numbers and subsequently 
differentiate to the desired cell type.  
 
 
 
 
 
 
 
1.6.1 Bioreactors 
 
 
Bioreactors are devices in which biological and biochemical processes develop under controlled 
and regulated environmental (temperature, pH and oxygen) and operating conditions. Recent 
years, there is increasing interest on the use of bioreactors for various bioprocessing applications. 
The automatisation, the product quality and the reproducibility they offer in the expansion and 
differentiation of cells is one of their major advantages (Martin et al., 2004). Traditional in vitro 
static culture methods of 3D scaffolds cannot maintain 3D tissue-engineered constructs due to 
the inherent limitation in chemo transportation of nutrients (Sailon et al., 2009). Diffusion is not 
sufficient to supply nutrients in the centre of large scaffolds and this leads to different cell 
densities either because cells die creating a necrotic center in the core of the scaffold or cells 
move from the core and grow at the periphery (Goldstein et al., 2001). Bioreactor systems are 
used to reduce these limitations by continuously mixing media, thus supplying nutrients to cells 
and removing metabolites throughout cultivation (Suck et al., 2007).  
 
 In the case of BTE, there are three main 
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media (Chen and Hu, 2006). However, they face problems with random collisions between 
scaffolds and the culture vessel wall, which result in non-homogenous cell growth and matrix 
development (David et al., 2011; Zhang et al., 2010b). 
Spinner flasks and rotating wall bioreactors use convection to provide a well-mixed environment 
and increase homogeneity of nutrients in the media around the scaffold but they don’t perfuse 
media effectively into the scaffold. They don’t also show a significant increase in nutrient 
transfer in comparison with static culture (Yeatts and Fisher, 2011).  
Widely applied and well-know bioreactors are the NASA-designed RWVs available in two 
different geometries; the High Aspect Ratio Vessel (HARV) and the Slow Turning Lateral 
Vessel (STLV). The advantageous characteristic of both configurations is the creation of a low 
shear stress environment (Begley and Kleis, 2000), which has been shown to support various cell 
culture applications (Goodwin et al., 1993). The simulated microgravity environment created by 
these bioreactors has been used to study bone and cartilage differentiation in space (Freed and 
Vunjak-Novakovic, 1997; Freed and Vunjak-Novakovic, 2002). 
A RWV bioreactor consists of a cylindrical chamber in which the outer wall, inner wall, or both 
are capable of rotating at a constant angular speed. Cell constructs cultured within a RWV 
bioreactor remain suspended in the culture media due to three main forces exerted on the 
particles. The vessel walls are rotated at a speed that enables a balance between the downward 
gravitational force (Fg) and the upward hydrodynamic drag force (Fd) resulting in a state of free-
fall of the particles induced by the action of the centrifugal force (Fc) (Figure 1.12)(Martin et al., 
2004; Partap et al., 2010b). 
 
 
 
Figure 1.12: Vector Velocity Diagram showing the forces acting on a particle rotating in a fluid. 
The wall of the vessel rotates, providing an upward hydrodynamic drag force (Fd) that 
balances with the downward gravitational force (Fg), resulting in the scaffold or cells 
remaining suspended in the media. Fc indicates the centrifugal force exerted on a particle. 
Adapted from (Bartis and Pongrácz, 2011). 
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RWVs keep microcarriers/cells suspended and provide an environment that alleviates large shear 
stress while ensuring adequate mass transfer. Rotation replenishes the media around the cells. 
This low turbulence culture environment promotes the formation of large, 3D cell clusters, 
which more closely resemble the original tissue found in the body due to their high level of 
cellular organization and specialization (Schwarz et al., 1992). 
Cell constructs grown in a rotating bioreactor on Earth eventually become too large to stay 
suspended in the nutrient media. However, in the microgravity environment of the RWV, cell-
seeded scaffolds are placed inside the vessel and are kept in a state of constant free-fall by 
adjusting the speed of rotation so that the centrifugal force balances the force of gravity and the 
fluid drag on the objects inside (Jessup et al., 1993; Unsworth and Lelkes, 1998). 
The size of the particles, however, changes during culture due to cell growth and proliferation 
causing an increase in sedimentation velocity, which is proportional to the square of a particle’s 
radius. In order to prevent the particles from hitting the vessel wall, it is important to increase the 
speed of rotation. Sedimentation of the particles offers also benefits in matters of mass transfer. 
The constant movement of the particles in the media is advantageous because nutrient, oxygen 
and waste are not limited by diffusion, as it is the case in static cultures (Hammond and 
Hammond, 2001; Klaus, 2001). 
Because of these properties, the RWV bioreactors are used to simulate some aspects of a 
microgravity environment in the laboratory. They are usually combined with the employment of 
encapsulation technology of cells to hydrogels, such as alginate, which has been shown that it 
does not interfere with cell function. The system employing the above-mentioned two 
components can minimize significantly shear stress experienced by surface seeded cells (Bucaro 
et al., 2004). 
 
The main advantages and disadvantages between the various types of bioreactors, described 
above, are summarized in Table 1.6. 
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Table 1.6: Advantages and disadvantages between various types of bioreactors. Adapted from 
(Panoskaltsis et al., 2005; Serra et al., 2010) 
 
BIOREACTORS 
TYPES ADVANTAGES DISADVANTAGES 
STATIC 
 
 
 
- Simplicity 
 
- Ease of handling 
 
- Low cost 
 
 
- Mass transport only with 
diffusion 
- Inhomogeneous environment/ 
Concentration gradients 
 
- Support low cell densities 
 
- Low total cell output 
 
- Difficult to scale up 
 
- Increased handling time 
 
- Increased risk of contamination 
 
- Increased cost 
  
 
 
 
SPINNER FLASK 
/STIRRED TANK  
- Enhanced mass transport 
 
- Increased cell density 
 
- Eliminate the concentration 
gradients of nutrients 
 
- Create a homogeneous 
physicochemical environment 
 
- Damage cells/tissues 
 
- High Shear stress generation 
from the impeller 
   
 
 
ROTATING WALL 
VESSEL:  
HARV & STLV 
 
- Low shear stress environment 
 
- High mass transport 
 
- Efficient mixing 
 
- Efficient gas transfer 
 
 
- Collision/damage of scaffolds 
with the bioreactor wall 
 
- Mineralisation effects and 
culturing benefits are limited to 
the outside of the scaffolds 
 
- Internal nutrient transport 
diffusional limitations 
   
 
 
 
FLOW PERFUSION 
- Enhanced mass transport 
 
- Less metabolic stress-removal 
of metabolites 
 
- Higher cell expansion 
 
- Maintain high cell density 
 
- Homogeneous cell distribution 
throughout scaffolds 
 
- High Flow rate, 
 Washing out of cells, Excessive 
shear stress 
 
- More compex system 
 
 
 
The HARV bioreactor has been widely used for BTE applications because of the features of low 
shear and high mass transfer that provides. In one study, Yu and his collegues used rat primary 
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calvarial cells and they created 3D microsphere polymeric scaffolds made from mixed poly 
(lactic acid glycolic acid) (PLAGA). The microspheres were cultured in the HARV bioreactor 
for 7 days and the dynamic flow environment affected bone cell distribution within the 3D 
constructs. The created environment improved significantly transport of nutrients and 
metabolites resulting in increased cell viability within the scaffolds. Dynamic flow also 
promoted osteoblast differentiation and mineralisation of the constructs. High expression of the 
bone markers OCN and OPN confirmed the positive effects on bone formation (Yu et al., 2004).  
Lv and his collegues developed novel 3D PLAGA/ nano-hydroxyapatite (n-HA) mixed scaffolds 
composed of lighter-than-water (LTW) and heavier-than-water (HTW) composite microspheres 
in order to improve mechanical properties and bioactivity. For in vitro evaluation, they used 
human MSCs seeded on the composite scaffolds and cultured in the HARV bioreactor for 21 
days. HMSCs exhibited increased proliferation, differentiation and mineralisation when 
compared with pure PLAGA scaffolds probably due to surface roughness and ability of n-HA to 
absorb multiple proteins and initiate mineralisation (Lv et al., 2009). 
STLV bioreactor has been also employed in various experiments from different groups and 
results indicated successful osteogenic differentiation. Inanc and his collegues seeded human 
periodontal ligament fibroblasts on poly (lactide-co-glycolide) (PLGA) scaffolds and the 
generated constructs were cultured in an STLV microgravity bioreactor. Results indicated that 
the employed culture system was able to support osteogenic differentiation and contributed to 
the regeneration of the defected area (Inanc et al., 2006). The following year, the same group 
repeated the experiment using the same cell population but seeded on a different scaffold, on 
Chitosan-HA Microspheres. Osteogenic differentiation was successful (Inanc et al., 2007).  
Marolt and his collegues used bone marrow stromal cells seeded on porous silk scaffolds and the 
constructs cultured within an STLV microgravity bioreactor. Calcium deposition and 
mineralisation were observed in the end of the experiment. The positive outcome was partially 
attributed to the improved mass transfer and better oxygen supply provided by the rotating 
bioreactor to the cultured cells (Marolt et al., 2006). The important observation from the 
previous experiments, apart from the desired osteogenic differentiation, was the fact that culture 
within the RWV bioreactors improved the initial seeding density and provided more uniform cell 
distribution within the scaffolds. It also supported better media supply to the cells and reduced 
nutrient and metabolite transport limitations (Sikavitsas et al., 2002).  
Flow perfusion bioreactors will be described extensively and separately on a following chapter. 
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1.6.2 Bioreactor feed operation: Batch, Fed-batch and Perfusion  
 
 
Cell culture nowadays can be performed via three possible operational modes: batch, fed-batch 
or continuous perfusion mode.  
In a batch culture, all necessary fresh media components and the employed cell population are 
added in the bioreactor on the beginning of the experiment and the obtained products are only 
collected in the end of the culture. As cells grow, they consume media and waste products are 
accumulated. Medium components concentration is not controlled and varies throughout the 
experimental procedure while pH, temperature and dissolved oxygen are held constant (Lim and 
Shin, 2013).  
In a fed-batch process, the characteristic is the replacement of media and gradual provision of 
fresh nutrients at certain times during the growth process by manipulating feed rates in order not 
only to sustain but also to improve productivity and prevent nutrient depletion although temporal 
variation in nutrient supply has been observed, characterized as “feast and famine” periods 
(Patterson, 1975). Culture volume increases until reaching maximum amount. Here as well, the 
obtained products are only collected in the end of the run (Lim et al., 1977; Lu et al., 2013; Shin 
and Lim, 2006). 
Finally, widely used mode nowadays, which is the employed mode in this research project, is 
perfusion culture. In perfusion operation mode, there is continuous media exchange and feeding 
supply with fresh nutrients and at the same time, constant removal of waste byproducts and 
dilution of metabolites. In this way, the culture system achieves and maintains a steady-state 
condition. Cellular metabolism is properly regulated and allows the support and generation of 
higher cell concentrations. Bioreactors with perfusion feeding minimize the accumulation of 
toxic metabolic by-products and are suitable candidates for the efficient support of long-term 
cultures with high cell densities. Such cultures pose reduced contamination risks and require less 
labor and fewer material costs (Liu et al., 2014; Sart et al., 2014). Another important feature of 
perfusion configuration is the exposure of cells to controlled fluid mechanical forces, which has 
been indicated to enhance cell differentiation in many cases (Li et al., 2009).  
To summarize, different feeding operation modes exert different effects on stem cell cultures. 
The unregulated culture environments experienced in fed-batch cultures do not seem to be 
optimal for culture of the sensitive population of pluripotent stem cells. On the other hand, 
perfusion system has been indicated to properly and efficiently regulate significant metabolic 
and signaling factors influencing pluripotent stem cell fate.  
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The main advantages and disadvantages of the three-operation bioreactor modes described above 
are summarized in Table 1.7: 
 
Table 1.7: Advantages and Disadvantages of Batch, Fed-batch and Perfusion culture 
 
BIOREACTORS 
MODES OF 
OPERATION 
ADVANTAGES DISADVANTAGES REFERENCES 
 
BATCH 
 
- Relative simple to 
terminate and start a 
new experiment 
 
 
- Constantly changing conditions 
 
- Batch-to-batch variability 
 
 
 
 
 
 
 
 
 
(Lim and Shin, 
2013) 
 
    
 
 
 
 
 
FED-BATCH 
 
 
 
- Operational 
simplicity and 
flexibility 
 
- Increased production 
 
- Robustness 
 
- Unregulated cellular metabolism 
 
- Generation of complex data 
patterns difficult to interpret 
 
- Arbitrarily determined feeding 
schedules 
 
- Accumulation of toxic levels of 
endogenous secretions 
 
- Detrimental consequences to the 
cells 
 
- High start-up costs 
 
 
(Patterson, 1975) 
 
(Lim et al., 1977) 
 
(Lu et al., 2013) 
 
(Shin and Lim, 
2006) 
    
 
 
 
 
PERFUSION/ 
CONTINUOUS 
- Greater degree of 
homeostasis 
 
- Sustain longer 
culture periods, higher 
productivity 
 
- Reduced risk of 
contamination 
 
- Improved product 
quality 
 
- Achieve steady-state 
condition 
- More difficult to operate 
 
 
- Need for greater process control 
 
 
- Flow disturbances of the soluble 
 
cellular microenvironment  
 
- Convective mass transport 
eliminate local concentration 
gradients 
 
- Limit diffusive transport of 
solutes to and from cells 
 
- Large volumes of medium 
required 
 
(Liu et al., 2014) 
 
(Sart et al., 2014) 
 
(Li et al., 2009) 
 
(Gomez, 2008) 
 
(Paguirigan and 
Beebe, 2008) 
 
(King et al., 2008) 
 
 
The bioreactor operation mode in this project was perfusion configuration and it will be analyzed 
in more details in the following section where appropriate examples will also be presented.  
 
1.6.3 Perfusion 
 
Flow Perfusion bioreactors use a pump to perfuse media through the interconnected pores of a 
scaffold in order to improve mass transport inside the 3D cellular constructs by utilizing 
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interstitial flow (Bancroft et al., 2003; Goldstein et al., 2001; Yeatts and Fisher, 2011). Perfusion 
bioreactors are broadly classified into indirect or direct systems, depending on whether the culture 
medium is perfused around or throughout/within the tissue-engineered constructs (Cartmell et al., 
2003; Meinel et al., 2004; Sladkova and de Peppo, 2014). It is important to reassure that flow goes 
through the scaffolds, minimizing the nonperfusing flow which is the path of least resistance that 
goes around the scaffold (Yan et al., 2011). 
Nowadays, perfusion bioreactors are widely used for TE of different organs and their use is 
combined with specific scaffolds on which cells are seeded at different concentrations thus, 
creating a 3D environment that mimics the in vivo conditions. The most important features for 
creating a 3D environment is the existence of a balance between the mass transfer of nutrients and 
waste products, the maintenance of matrix components within the construct and the control of 
fluid shear stress within the scaffold (Martin et al., 2004). Perfusion enhances culture performance 
by replacing exhausted nutrients and removing inhibitory metabolic by-products (King and Miller, 
2007). Perfusion systems, which expose cells to shear stress, have been shown to enhance more 
efficiently nutrient transfer by effectively perfusing media throughout the scaffold. It has been also 
indicated that they enhance mineralised matrix deposition, they increase calcium deposition and 
they upregulate osteoblastic markers in response to culture (Yeatts and Fisher, 2011).  
Perfusion system offers several advantages in comparison to static culture system including 
enhanced transfer of materials by fluid flow, the ability to provide mechanical forces influencing 
tissue development and better control of the culture conditions (Martin et al., 2004). It is well 
known that in vivo bone remodels in response to mechanical forces and it has been shown that in 
vitro, mechanical stimulation through fluid shear stress influences bone differentiation and 
mineralisation (Bancroft et al., 2003; Bilodeau and Mantovani, 2006). 
In static culture, there are mass transport limitations to the interior of the scaffolds such that only 
cells around the perimeter of the scaffold have access to nutrients in the medium whereas in the 
bioreactor, cells can receive a constant supply of food and oxygen, while harmful metabolic 
products can be excluded from the inside of the 3D scaffold, which is now able to support greater 
cell growth, as evidenced by higher cell numbers achieved (Holtorf et al., 2005).  
Evidence shows that the bioreactor enhances matrix formation by bone cells and it induces cell 
viability. It is significant the fact that perfusion reduces problems of mass transfer limitations, 
which exist in all kinds of cultures within a bioreactor. Moreover, it enhances cell survival and 
achieves higher seeding efficiencies by supplying sufficient transport of nutrients, especially 
oxygen, for cells within constructs, facilitating uniform distribution of the cells and enhancing 
bone tissue formation (Grayson et al., 2008). 
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To summarize, experiments in perfusion bioreactors demonstrated that culture medium flows 
through the interstitial pores of the construct rather than around its periphery (Grayson et al., 
2008), which enables local supply of oxygen and nutrients and removal of metabolites, thus 
providing better control of the cell microenvironment. The drawback of using this system is its 
complex and difficult mechanism to assemble and operate it (Goldstein et al., 2001). Perfusion 
systems also provide biophysical stimulation of the cells in large constructs (Grayson et al., 2010) 
and are commonly used for various BTE applications. 
 It is strongly believed that these conditions better mimic the native bone environment and it has 
been shown that mechanical conditioning alone in the absence of Dex, the standard osteogenic 
supplement, can induce osteogenic differentiation of BMSC in perfusion culture (Frohlich et al., 
2008). Holtorf and his collegues suggested that flow perfusion culture induces osteogenic 
differentiation of rat MSCs and that there is a synergistic effect of enhanced osteogenic 
differentiation when both flow perfusion culture and Dex are used, resulting in very high mineral 
content. It is believed that initial exposure to Dex may offer these cells a boost down the 
osteogenic pathway, which flow perfusion culture helps to maintain (Holtorf et al., 2005).  
Nowadays, the importance of perfusion culture to properly control nutrient transport has been 
recognized and is widely applied for BTE applications. Many examples show perfusion’s positive 
effect on osteogenic differentiation and bone formation. Datta and his collegues used a different 
approach to indicate the important role of perfusion cultures in bone generation. They employed 
titanium (Ti) fiber mesh discs with incorporated pre-generated bone-like ECM. They seeded them 
with MSCs and cultured them in a flow perfusion bioreactor with or without the osteogenic 
culture supplement Dex. They observed that the bone-like ECM together with the fluid shear 
stress from the bioreactor synergistically enhanced the osteodifferentiation of MSCs. There was 
also increased mineralisation even in the absence of Dex (Datta et al., 2006).  
In a following study, Gomes and his collegues used highly porous starch-based fiber mesh 
scaffolds seeded with marrow stromal cells and cultured under flow perfusion conditions. They 
identified that the combination of these scaffolds with the fluid flow bioreactor improved nutrient 
transport and provided mechanical stimulation to the seeded cells, which demonstrated increased 
osteogenic differentiation and mineralisation (Gomes et al., 2006). This finding confirmed 
previous results, which suggested the important role of fluid flow not only in mitigating nutrient 
transport limitations in 3D perfusion cultures of MSCs but also in providing mechanical 
stimulation to seeded cells in the form of fluid shear stress, resulting in increased deposition of 
mineralised matrix (Bancroft et al., 2002; Sikavitsas et al., 2003). 
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The same year, Hosseinkhani and his collegues performed similar experiments to identify the 
important role of perfusion cultures. They seeded MSCs in a custom made hybrid scaffold made 
of a hydrogel formed through self-assembly of peptide–amphiphile (PA) with cell suspensions in 
media and a collagen sponge reinforced with poly (glycolic acid) (PGA) fiber incorporation and 
the whole system cultured in a flow perfusion bioreactor. Researchers confirmed in vitro results of 
osteogenic differentiation indicated from previous groups. They took it however one-step further 
and implanted the constructs in vivo in rats where they observed ectopic bone formation 
(Hosseinkhani et al., 2006a).  
Most of the initial experiments with perfusion bioreactors tested the use of MSCs. More recently, 
a number of research groups started to experiment with the promising but controversial cell source 
of ESCs. It has been shown previously that the hESC-derived mesenchymal progenitors behave 
similarly to the adult bone marrow-derived MSCs (de Peppo et al., 2010). Based on these findings, 
Marolt and her collegues decided to use hESC-derived mesenchymal progenitors seeded on 
osteoconductive scaffolds and cultured in a bioreactor with interstitial flow of culture medium. In 
vitro osteogenic differentiation and formation of compact bone constructs was observed. 
Engineered bone constructs were subsequently implanted in immunodeficient mice for eight 
weeks. Maintenance and maturation of bone matrix with continuous bone development was 
observed. There were no signs of teratoma formation compared to implantation of undifferentiated 
hESCs. These results suggested the potential transfer and use of protocols developed for 
osteogenic differentiation of ASCs to ESCs (Marolt et al., 2012a). 
The same group, one year later, performed the same experiments using this time hiPSC cells. 
Based on their previous idea, they cultured hiPSC-derived mesenchymal progenitors on 
osteoconductive scaffolds in a flow perfusion bioreactor. Molecular analysis indicated repression 
of proliferation and increased expression of bone genes. Constructs were then subcutaneously 
implanted in an animal model and kept a stable bone phenotype for twelve weeks. More research 
is needed but initial indications show promising results from the use of iPSCs (de Peppo et al., 
2013a). These findings confirmed the capacity of flow perfusion cultures to augment bone 
formation and improve osteogenic differentiation. 
 
1.7 Examples and culture protocols of in vitro bone differentiation from ESCs 
 
When kept in culture, murine ESCs remain undifferentiated in the presence of leukaemia 
inhibitory factor (LIF). When LIF is removed, mESCs differentiate by spontaneously forming EBs 
when cultured in suspension in vitro (Mimeault and Batra, 2006). EBs consist of spheres 
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containing a variety of more differentiated progenitor cell types and contain cells from all three 
germ layers. The use of specific growth factors or cytokines during the outgrowth of EBs in 
culture in vitro might induce their differentiation into the specific cell lineages (D'Amour et al., 
2005; Trounson, 2006; Yao et al., 2006). 
During in vivo gastrulation, the visceral endoderm plays an important role in inducing mesoderm 
formation. Hepatic cells are known to be very similar with visceral endoderm in their biological 
function. It has been reported that culturing mESCs in human hepatocarcinoma cell line-derived 
conditioned media (HepG2-CM) enhances mesoderm formation, thus resulting in increased 
osteogenic differentiation in the presence of osteogenic supplements such as b-GP, AA and Dex 
(Hwang et al., 2006).  
EB formation has the problem of spontaneous and uncontrolled differentiation. Recent approaches 
tried to find a way to bypass the step of EB formation and it has been reported that ESCs were 
differentiated into osteogenic lineage by treatment with HepG2-CM without EB formation and by 
culturing them in the presence of b-GP, AA and Dex (Hwang et al., 2008; Karp et al., 2006).  
B-GP provides the phosphate ions needed while AA facilitates osteogenic differentiation by acting 
as a cofactor in Col I synthesis and by inducing ECM production (Both et al., 2007; Choi et al., 
2008; Langenbach and Handschel, 2013).  
In cell cultures, nowadays, ascorbic acid-2-phosphate is used as a more stable analogue of AA. 
Jaiswal and his group observed that better osteogenic differentiation of human BMSCs is achieved 
by using 50μM ascorbic acid-2-phosphate (Jaiswal et al., 1997).  
Dex is a synthetic member of the glucocorticoid class of steroid hormones, which exerts a strong 
effect on the osteodifferentiation of MSCs. In particular, it has been shown that Dex is such a 
potent induction agent that when MSCs are exposed to it immediately after harvest, they may start 
differentiating before completing proliferation. There have been observed higher cell numbers and 
slower differentiation when cell are cultured without Dex. However, cells retain a greater 
osteogenic capacity when Dex is present in the medium immediately after harvest (Holtorf et al., 
2005). 
Apart from the above-mentioned protocols used for osteogenic differentiation, the incorporation of 
various growth factors is widely employed and has been suggested as a method to enhance bone 
formation. There are several examples from different cell lines used for the experiments.  
BMPs are characterized as the strongest osteoinductive factors. For this reason, they were employed 
in various in vitro osteogenic differentiation protocols. In particular, BMP-2, -4, -6, -7 and -9 have 
been shown to promote osteogenic commitment and terminal osteogenic differentiation in MSC 
(Dorman et al., 2012; Kang et al., 2009a). BMP-2, the most commonly studied BMP ligand has been 
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shown to induce MSC osteogenic differentiation both in vitro and in vivo (Varkey et al., 2006). Its 
application is mainly through gene transfection studies (Kempen et al., 2008; Park et al., 2009; Tang 
et al., 2008b; Wegman et al., 2011). BMP4 was used for osteogenic differentiation of mESCs and 
results indicated an induction in the expression of the tested bone markers. However, mineralisation 
was only observed when both BMP4 and DAG protocol were combined indicating that BMP4 is 
insufficient to promote osteogenic differentiation when acting alone (Kawaguchi et al., 2005). To 
further support the previous study, Camargos and his collegues recently performed osteogenic 
differentiation of mESCs using BMP4 and they indicated an upregulation of Activin A, a growth 
factor released by mature osteoblasts and of the bone markers OCN and ALP (Camargos et al., 
2014). In another study, Trikkonen and his collegues tried the efficiency of BMP2, BMP7 and 
VEGF growth factors alone or in combination with the classic osteogenic media employing the 
DAG factors to perform differentiation of adipose stem cells. Obtained results indicated that 
application of classic osteogenic media alone significantly enhanced osteogenic differentiation and 
there was no extra benefit from the addition of the growth factors (Tirkkonen et al., 2013).  
 
Table 1.8: Examples of protocols for osteogenic differentiation and the resulting outcome. 
Osteogenic supplements (DAG) include b-glycerophosphate, ascorbic acid and dexamethasone. 
 
STEM CELLS DIFFERENTIATION  
PROTOCOL 
OBSERVED OUTCOME 
ESCs EB formation Osteogenic supplements (DAG) 
ESCs HepG2-CM Osteogenic supplements (DAG) 
 GROWTH FACTORS  
MSCs BMP2 Both in vitro and in vivo 
 
mESCs 
 
BMP4 
 
- Transfection 
- Insufficient when acting alone 
- BMP4 + DAG efficient combination 
 
 
Adipose stem cells 
 
BMP2, BMP7, VEGF 
 
- DAG media supported efficient 
osteogenic differentiation 
-No additional benefit from growth factors 
 
mESCs FGF7 
 
 
Enhanced calcium deposition induced by 
the DAG protocol 
Bone marrow MSCs IGF-1 
 
Enhanced osteogenic differentiation 
Human dental pulp 
stem cells 
IGF-1 
 
Enhanced osteogenic differentiation 
 
 
 
Another growth factor that was employed for osteogenic differentiation was Fibroblast growth 
factor-7 (FGF7). FGF7 was used on mESCs and it enhanced the calcium deposition supported by 
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the DAG protocol alone. It also indicated increased osteogenic gene expression of Runx2, OSX, 
BSP and OCN. The use of the growth factor was again combined with the DAG protocol (Jeon et 
al., 2013).  
IGF-1 is another candidate that has been shown to enhance osteogenic differentiation of bone 
marrow MSCs and more recently of human dental pulp stem cells (DPSCs) (Feng et al., 2014). 
IGF-1 has been indicated to have an important function in osteogenic differentiation and bone 
remodeling by stimulating the proliferation and differentiation of osteoprogenitor cells (Kostenuik 
et al., 1999) and the formation of osteoclasts (Wang et al., 2006b). 
ESCs have the potential to generate any cell type of the three germ layers. This is the challenge 
that research needs to overcome and try to properly and efficiently control the differentiation of 
these cells to the desired lineages. Differentiation of ESCs to bone cells has been achieved using 
protocols from bone marrow MSCs. Initial experiments were performed for many years in 
mESCs. It has been shown that after induction to EB formation, mESCs could be guided to 
differentiate to osteoblasts using Dex in combination with b-GP and AA. Bone nodule formation 
and collagen matrix deposition were used to confirm osteoblastic differentiation (Buttery et al., 
2001).  
In the next level, researchers started to experiment with human ESCs. Using the same protocols 
for osteogenic differentiation as they employed with mESCs, they observed mineralisation in 
two independently isolated hESC lines (Thomson et al., 1998). Molecular analysis was also 
performed and revealed up regulation in the expression level of various osteogenic markers like 
Cbfa1, COL 1, PTH receptor, OPN, BSP and OCN, which are related with osteogenic 
commitment (Aubin et al., 1995; Karsenty, 2000; Malaval et al., 1999). Another significant 
indication was also the fact that mineralised nodules were composed of HA, demonstrating the 
directed commitment of human ESCs to the osteogenic lineage (Sottile et al., 2003).  
Bielby and his collegues demonstrated the derivation of osteoblasts from hESCs using the 
previously mentioned protocol. They indicated the possibility of making functional osteoblasts 
able to make mineralised tissue both in vitro and in vivo. They implanted cells in vivo and 
noticed the formation of areas of mineralised tissue whereas there were no signs of any tumor 
formation. This group proved that the culture methodology established for differentiation of 
mESCs was entirely transferable to hESCs (Bielby et al., 2004). Several other studies followed, 
where they examined and confirmed the potential of hESCs to efficiently differentiate into 
osteoprogenitor cells and to support in vivo bone formation (Ahn et al., 2006; Kuznetsov et al., 
2011; Mateizel et al., 2008). 
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In a more recent study, de Peppo and his collegues followed a different pathway. They decided 
to first differentiate hESCs into mesenchymal progenitors and then seeded these cells on 3D 
osteoconductive scaffolds and induced their osteogenic differentiation while culturing them in a 
bioreactor with interstitial flow of culture medium. It has been shown previously that hESC-
derived mesenchymal progenitors have similar properties with adult bone marrow-derived MSCs 
(de Peppo et al., 2010). Following the observation of the previous paper, they decided to follow 
this alternative way of differentiation in order to enhance osteoblast generation and reduce the 
risk for teratoma formation. This approach resulted in augmented osteoblast differentiation and 
in vivo formation of bone tissue, which when subsequently implanted in vivo didn’t exhibit any 
signs of tumors (Marolt et al., 2012a).  
 
 
 
 
 
 
 
 
1.7.1 Drawbacks of currently used differentiation protocols 
 
 
Currently used differentiation protocols possess significant limitations. The DAG protocol 
contains compounds, which are not osteoblast specific and could lead to the generation of other 
cell types as well. Moreover, Dex as a steroid can have some uncontrolled effects over 
osteogenic differentiation. On the other hand, use of BMPs and other growth factors has been 
shown to have several problems related mainly to their high cost, their short half-lives and their 
use in very high concentrations due to their ineffectiveness (Garrison et al., 2007; Garrison et al., 
2010; Zuk et al., 2011; Zuk et al., 2001). Clinical use of growth factors has been restricted 
because of the high doses needed in humans, which may cause unexpected physiological effects 
ranging from bone resorption (Giannoudis et al., 2007) to heterotopic ossification (Axelrad et al., 
2008; Wysocki and Cohen, 2007).  
Alternative methods for effective osteoinduction are under investigation and they mainly focus 
on the use of mechanical stimulation (McCullen et al., 2010; Tirkkonen et al., 2011). These 
findings made urgent the need to discover a new and safer molecule able to induce osteogenic 
differentiation without the need for exogenous supplementation of growth factors. 
One of the first experiments to be performed towards that direction identified the small molecule 
compactin as a potential factor to induce osteogenesis in mESCs and upregulate BMP2 
expression (Phillips et al., 2001).   
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1.7.2 Small molecules 
 
 
Small molecules seem ideal candidates possessing a number of advantages over the use of 
growth factors (peptides or proteins). Small molecule is defined as a non-peptide biologically 
active organic compound with a molecular size usually less than 1000 Da. These molecules can 
be designed to have desired features such as being selective, potent, water-soluble and cell 
permeable. Their strongest point is the fact that as small molecule drugs, they are very unlikely 
to create any immune reaction and also they possess very low cost of synthesis in comparison to 
recombinant proteins (Lo et al., 2012a; Lo et al., 2014; Wieghaus et al., 2006). Apart from the 
fact that they are more affordable, small-molecule based drugs are also more stable and require 
lower dosage to achieve bone regeneration and to stimulate bone formation in comparison to 
recombinant proteins (Carbone et al., 2014). (Table 1.9) 
 
Table 1.9 Comparison of therapeutic proteins and small molecules. Adapted from (Lo et al., 2012a) 
 
 
 
 Advantages Disadvantages 
Protein Specific Unstable 
 
 Impurities 
 High cost 
 Immunogenic 
 Given by injection 
Small molecule Ease of manufacturing Non-specific 
 
Low cost Off target side-effects 
Stable  
Non-immunogenic  
Orally available  
Ease of delivery  
 
 
Small molecules have their drawbacks as well. The most significant concern is their nonspecific 
side effects (Lo et al., 2012a; Weiss et al., 2007). Due to their small size, they can enter other 
cells apart from the target ones and elicit unwanted physiological reactions (Brouwers et al., 
2011). The solution to that problem is the employment of a drug delivery method to direct the 
drug directly to the desired target. The design of appropriate materials can coordinate the release 
kinetics of the small molecule drug. More research is also needed to define the optimal dosage 
requirements (Tayalia and Mooney, 2009).   
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1.7.3 Statins  
 
 
 
Statins are widely used small molecule drugs to lower cholesterol. Their mechanism of action 
involves the inhibition of the enzyme HMG-CoA reductase, which participates actively in the 
pathway of cholesterol production.  
The mevalonate pathway is responsible for the production of cholesterol from acetyl-CoA. One 
of the key steps in this pathway is the conversion of HMG-CoA into mevalonate by the enzyme 
HMG-CoA reductase. Statins are blocking the enzyme by competitive inhibition with the normal 
substrate in the enzyme’s active site (Schachter, 2005). They alter the conformation of the 
enzyme when they bind to its active site and prevent the enzyme from attaining a functional 
structure. This action leads gradually to the reduction in the intracellular content of cholesterol. 
Cells react by increasing the number of low-density lipoprotein (LDL) receptors in the cell 
membrane and they remove higher levels of circulating LDL resulting in reduced cholesterol 
levels in the bloodstream (Corsini et al., 1999). Due to their properties, statins are also employed 
for the treatment of hyperlipidemia, arteriosclerosis and cardiovascular diseases (Davignon, 
2004; Frostegard, 2013; Gotto, 2011; Kobayashi et al., 2011). 
There are hydrophobic and hydrophilic statins. Hydrophobic/lipophilic statins are lovastatin, 
Sim, compactin, fluvastatin, cerivastatin and atorvastatin (Fong, 2014) and have the major 
advantage of being able to get in the cell with passive diffusion. Hydrophilic statins are 
pravastatin and rosuvastatin and can only get in the cell with active transport (McTaggart et al., 
2001; McTavish and Sorkin, 1991). Lovastatin, Sim and pravastatin are naturally derived from 
fungal fermentation (Henwood and Heel, 1988; Kishida et al., 1991; Todd and Goa, 1990) while 
atorvastatin, fluvastatin, cerivastatin, pravastatin, pitavastatin and rosuvastatin are fully synthetic 
compounds, which are chemically synthesized (Davidson, 2002; Lennernas and Fager, 1997). 
(Table 1.10) 
 
Table 1.10: Members of statin family are distinguished as hydrophophic or hydrophilic and as 
natural or synthetic compounds 
STATINS 
Hydrophobic/ 
Lipophilic 
Hydrophilic/ 
Lipophobic 
 Natural 
Fungal fermentation 
Synthetic 
Chemically derived 
Lovastatin Pravastatin Lovastatin Atorvastatin 
Simvastatin Rosuvastatin Simvastatin Fluvastatin 
Cerivastatin   Pravastatin Cerivastatin 
Fluvastatin   Rosuvastatin 
Atorvastatin   Pitavastatin 
Pitavastatin    
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1.7.4 Pleiotropic effects of statins and the mevalonate pathway 
 
Statins are well known drugs for lowering cholesterol and they are used for treatment of 
cardiovascular diseases, atherosclerosis and hyperlipidemia. They perform that function through 
inhibition of the enzyme HMG-CoA reductase in the mevalonate pathway, which is responsible 
for cholesterol production. Apart from their main role in lowering cholesterol levels, statins exert 
a number of cholesterol-independent functions. The mevalonate pathway leads also to the 
production of a number of important molecules called isoprenoids, which are involved, in various 
important cellular functions (Wang et al., 2008). The inhibition of isoprenoid synthesis is the 
reason behind the various actions of statins on cells and tissues within the body, which are referred 
to as pleiotropic effects (Ray and Cannon, 2005).  
Statins are involved in immunomodulation (Greenwood et al., 2006), neuroprotection (Kivipelto 
et al., 2005) and cellular senescence (Brouilette et al., 2007). More recently, there are data 
suggesting the implication of statins in improvement of endothelial dysfunction, increased nitric 
oxide bioavailability, antioxidant properties, inhibition of inflammatory responses and 
stabilization of atherosclerotic plaques (Davignon, 2004; Endres, 2005; Gazzerro et al., 2012; 
Giurgea et al., 2006; Zhou and Liao, 2010). These findings also indicate the application of statins 
in various diseases affecting vascular tissue such as arterial hypertension (Deschaseaux et al., 
2007), alzheimer’s dementia, rheumatoid arthritis, multiple sclerosis (Holmberg et al., 2006; Jung 
et al., 2004), fibroproliferative disorders (Abe et al., 2012) and atherosclerosis (Kurata et al., 
2012). 
One of the significant pleiotropic functions of statins is the anabolic effect on bone metabolism 
suggested from various in vitro and in vivo results. Statins are under investigation as a safe and 
effective drug for managing skeletal injuries by stimulating the healing of fresh fractures, non-
unions and spinal fusions (Park et al., 2009; Wang et al., 2007; Zou et al., 2012). 
 
 
 
1.7.5 Effects of statins on skeletal system  
 
In 1999, Mundy and his group looked for agents that could enhance bone formation and osteoblast 
differentiation. They were interested in small molecules that could activate the promoter region of 
BMP2 gene. After examining more that 30.000 compounds from natural products, they identified 
the statin lovastatin as the only natural product that strongly activated the promoter of BMP2 
(Mundy et al., 1999).  
After their discovery, statins started to be widely used and it has been proved that they stimulate 
bone formation both in vitro and in vivo. Initially, experiments were largely performed in vivo, by 
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injecting statins in animal models. Mundy and his group were the first who did animal 
experiments using statins which were orally provided to rats or injected to mice and they noticed 
increase on bone volumeand in bone formation. They also tested statins in vitro and they noticed 
that these molecules stimulated bone formation in cultured osteoblasts. The same group also 
observed a decrease in osteoclast cell numbers but the effect was minor compared to the anabolic 
action on bone formation (Mundy et al., 1999). 
Following this initial study, several research groups suggested that statins also inhibit bone 
resorption. In particular, another research group tested 40 different statin analogs and they 
observed that they acted as potent inhibitors of osteoclastic bone resorption in vitro (Staal et al., 
2003). To further support this idea, another group suggested that statins ability to reduce fracture 
risk is more a result of inhibition of resorption rather than a stimulation of bone anabolism 
(Grasser et al., 2003). (Figure 1.13) A very recent paper indicated that statins reduced alveolar 
bone resorption observed during periodontal disease and after tooth extraction (de Mones et al., 
2015). It has been proposed that statins may increase bone formation through inhibition of 
osteoblast apoptosis (Ruan et al., 2012). Sim in particular has been shown to inhibit osteoclast 
differentiation (Moon et al., 2011; Yamashita et al., 2010).  
 
 
Figure 1.13: Mechanism of action of statins and bone formation. Adapted from (Danesh et al., 
2003; Rogers, 2000)  
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As mentioned previously, statins are widely used drugs to lower cholesterol levels. For this 
reason, the majority of the experiments and clinical studies performed from the beginning on 
human patients and on animal models. The aim of these trials was to evaluate the effect of statins 
on bone formation. Targeting population for the experimental procedures were post-menopausal 
women or patients with hypercholesterolaemia. After treatment with statins for specific time 
duration, researchers observed anabolic effects on various parameters of bone metabolism of the 
tested patients (Chan et al., 2001; Mostaza et al., 2001; Stein et al., 2001). They also noticed a 
beneficial influence of statins in bone mineral density (BMD) (Chung et al., 2000; Edwards et 
al., 2000; Lupattelli et al., 2004; Montagnani et al., 2003; Sirola et al., 2002; Uzzan et al., 2007) 
and a decrease in the risk of fractures (Bauer et al., 2004; Meier et al., 2000; Pasco et al., 2002; 
Rejnmark et al., 2004; Schoofs et al., 2004; Wang et al., 2000). 
Similar experiments were also performed in animal models, in rats in particular and results 
confirmed previous findings indicating an increase in BMD (Oxlund et al., 2001; Serin-Kilicoglu 
and Erdemli, 2007). However, there were some controversial results published on the effect of 
statins on the skeletal system between the previously research groups and more experiments 
should be performed to confirm the above findings. 
A recent study examined the effect of statins on two skeletal dysplasias, the thanatophoric 
dysplasia (TD) and achondroplasia (ACH) which are both, caused by mutations on the fibroblast 
growth factor receptor 3 gene (FGFR3). Fibroblasts obtained from patients with one of these 
skeletal dysplasias and converted to iPSCs for in vitro testing. There was also a mouse model of 
FGFR3 skeletal dysplasia created for in vivo studies. Chondrogenic differentiation of TD iPSCs 
and ACH iPSCs resulted in the formation of degraded cartilage. Application of statins indicated 
the ability to correct the degraded cartilage in both chondrogenically differentiated TD and ACH 
iPSCs. ACH is causing disproportionate short-limb dwarfism. Treatment of ACH mice with 
statin resulted in significant recovery of bone growth and bone elongation. These results showed 
that statin treatment rescued both human iPSC disease models and mouse disease models, 
indicating the possibility to be used for treatment of patients with these diseases (Yamashita et 
al., 2014).  
On the other side, there are few studies, which did not observe any positive effects on bone 
fracture (LaCroix et al., 2003; Pedersen and Kjekshus, 2000; Reid et al., 2001; Yue et al., 2010). 
These findings indicate the need for further research in order to elucidate the statin influence on 
bone skeleton. Research is also needed in order to define the potential side effects of statin 
therapy and identify ways to avoid them. Several studies have reported that statin use is 
associated with myopathy, which rarely can progress to rhabdomyolysis (Baker and 
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Tarnopolsky, 2001; Ballantyne et al., 2003; Omar et al., 2001; Thompson et al., 2003).  
Rhabdomyolysis occurs when extensive muscle damage results in the release of cellular contents 
into systemic circulation. Statins can cause serious muscle toxicity resulting in muscle pain and 
weakness. According to a recent study, the risk is increased with enhanced system exposure to 
statins and also in people with renal disease (Hedenmalm et al., 2010). 
 To summarize, it is generally accepted and has been proved that statins exert their skeletal 
anabolic effect mainly due to increased gene expression of BMP2, the strongest osteoinductive 
factor. Statins stimulate the transcription of BMP-2 and also increase the endogenous expression 
of BMP-2 mRNA and protein in human osteoblastic cells (Ohnaka et al., 2001; Sugiyama et al., 
2000).  
 
 
1.7.6 Simvastatin 
 
 
The lipophilic statin, Sim, seems to be the most attractive candidate as it is readily available, 
inexpensive and has shown the most consistent positive effects on bone formation (Tang et al., 
2008a). Moreover, due to the better potency, it started to be commonly used in several 
experiments. A number of animal experiments using ovariectomized mice confirmed previous 
results from Mundy and his group, showing the anabolic effects of Sim on bone formation and 
an improvement in fracture healing (Skoglund et al., 2002). Similar experiments from another 
group indicated increased bone formation and decreased bone resorption in the mice after oral 
administration of Sim (Pytlik et al., 2003). 
In another study, when Sim was provided locally to the fracture area, exhibited a strong positive 
effect on biomechanical parameters and the strength of fracture healing (Skoglund and 
Aspenberg, 2007). In a study performed in 2007, Sim was injected subcutaneously into tissue in 
close proximity of the fracture in ovariectomized rats and it promoted the process of fracture 
healing. Local application had better and more controllable outcome compared to oral 
administration of the drug (Wang et al., 2007). 
Further research was conducted to evaluate the interaction of statin with implants. Titanium 
implants are widely used for the treatment of many bone defects. Sim has been shown to 
enhance osteogenesis around titanium implants in one experiment (Ayukawa et al., 2004) and to 
improve osseointegration of these implants in osteoporotic rats (Du et al., 2009). Sim induced 
bone healing and enhanced bone formation around the implants. This result may be associated 
with the way Sim acts by increasing BMP2 expression, which stimulates osteoblast 
differentiation (Mundy et al., 1999).  
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Sim has also a significant influence on osteogenic gene expression. It has been shown initially 
that Sim enhances the expression of BMP-2 and VEGF (Maeda et al., 2003). In a following 
study by the same group, Sim has been shown to stimulate the expression of the differentiation 
markers ALP, Col-1, BSP and OCN leading to increased formation of mineralised nodules 
indicating mineralisation (Maeda et al., 2004). Several in vitro studies have documented 
increased osteoblast differentiation and mineralisation induced by application of Sim on different 
cells. One of the early studies, performed by Maeda and his collegues, tested the effects of Sim 
in non-transformed osteoblastic cells (MC3T3-E1) and rat bone marrow cells and they observed 
that relatively low doses of Sim (significant at 10-8 M and maximal at 10-7 M) stimulated 
osteoblast differentiation and enhanced ALP activity and mineralisation (Maeda et al., 2001).  
Baek and his collegues used humanbone marrow stromal cells (hBMSCs) in their study and they 
observed that Sim (10-6) had anabolic effects on bone by promoting osteoblast differentiation of 
the tested cells. There was also increased expression of ALP, OCN and mineral deposition. In 
this study, however, inhibition on the proliferation of hBMSCs was noticed (Baek et al., 2005). 
Sim has been also tested on mouse bone marrow stromal cells and indicated that it could 
promote osteoblastic differentiation and inhibit adipocytic differentiation of these cells. It also 
increased significantly BMP2 expression levels (Song et al., 2003). Periodontal ligament (PDL) 
cells were also tested with Sim. Results showed that low concentrations enhanced cell 
proliferation and osteoblastic differentiation. Sim also stimulated ALP activity, OPN content and 
increased calcium deposition after three weeks of culture (Yazawa et al., 2005).  
More recently, Sim has been indicated to induce the osteogenic differentiation of mESCs in the 
absence of osteoinductive supplements. In the same study, there was also an increase in the 
expression of the significant bone markers OSX and OCN (Pagkalos et al., 2010). To 
summarize, Sim has been reported to promote osteoblastic activity and inhibit osteoclastic 
activity and thereby, increase cancellous bone volume, bone formation rate and cancellous bone 
compressive strength in vivo (Montagnani et al., 2003).  
In vivo animal research strongly supported the idea that Sim exerted beneficial effects on bone 
metabolism and indicated anabolic effects on bone formation and fracture healing (Tang et al., 
2008a). These findings showed the potential use of statins for bone regeneration and the majority 
of these studies demonstrated these effects via systemic, transdermal or local subcutaneous 
administration of the statins.  
However, in vitro results are conflicting about the effects of Sim. This is due to the fact that 
different parameters are employed in the experiments and probably influence the outcome. These 
important influential features are the method of administration, duration of exposure, 
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experimental animal model and bioavailability. Further research is needed to determine the 
optimal therapeutic threshold, mode of application and the effectiveness for humans for bone 
regeneration (Park, 2009).  
One more superior element supporting strongly the use of statins in bone industry is the fact that 
they possess a long history of clinical systemic usage with very acceptable good toxicity profiles 
(Garrett, 2007). This indicates faster approval times to be used clinically for orthopaedic 
applications once their properties are established in a large animal model (Carbone et al., 2014). 
These features render them an appealing choice to be used for the treatment of bone diseases. It 
is generally accepted and required from people all over the world the discovery of affordable, 
safer and more effective therapies for the future. In the case of bone diseases, TE can offer a 
promising solution with less invasive and more effective treatments. Further research should be 
conducted in order to achieve the desired outcome.  
 
 
 
1.8 THE NOVELTY OF THIS PROJECT 
 
 
This PhD thesis recommends and describes extensively the application of an alternative solution 
trying to solve currently existing limitations in the field of BTE, presented before in the literature 
review section.  
The novelty of this project lied on two elements. The first one was the use of a custom made 
RWV perfusion bioreactor for the culture of cellular constructs. The design of this bioreactor 
was based on NASA’s STLV bioreactor idea with incorporated improvements. The main change 
was the use of a permeable to oxygen membrane, made from Teflon and silicon, around the 
vessels. There was also an oxygenator system to provide appropriate oxygenation level to the 
media before getting into the vessel. This biorector has been designed and used for osteogenic 
differentiation and bone formation by Dr Jae Min Cha (Cha, 2010). Dr Cha performed 
osteogenic differentiation using the widely employed DAG protocol and compared the custom-
made RWV perfusion bioreactor with NASA’s designed HARV biorector. Following and 
continuing his work, the RWV perfusion bioreactor was used for my experiments and 
comparison was performed with static configuration. To take it one step further and get more 
insight information, the system was operating under 24-hour continuous perfusion mode, 
something that was different from the previous work conducted by Dr Cha. Continuous 
perfusion combined with rotating movement provided significant and novel information 
regarding osteogenic differentiation. 
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The RWV perfusion bioreactor has been also employed by other PhD students for different 
purposes. In particular, Dr David C. Yeo used this platform to support and maintain pluripotency 
of mESCS while Dr Ailing Teo employed the same configuration and indicated successful 
cardiomyogenesis of ESCs. Both researchers have published their work on the RWV perfusion 
bioreactor (Teo et al., 2014; Yeo et al., 2013). 
The second novel element was the employment of the small molecule Sim. Sim was tested in a 
very low concentration, in the range of nanomolar, as an agent for performing chemical 
induction and achieve osteogenic differentiation without the use of expensive growth factors, 
such as BMPs. It was supplied in the osteogenic differentiation media at specific and appropriate 
time point during the experiment. The aim was to get some more insight information on the 
possible role of statins in BTE applications. Sim has been tested previously by Dr Joseph 
Pagkalos (Pagkalos et al., 2010), who defined an optimal concentration and designed a 
differentiation protocol based on his experiments, which were all performed in 2D configuration. 
He ended up using a very low concentration of Sim. Based on these previous findings, I tried as 
a first step to replicate his results and test the efficacy of his protocol. Initial outcome was not 
encouraging and a short optimization was performed to define the appropriate time point for 
supplementation of Sim in the culture media. Next step involved the transition and 
experimentation in 3D culture configuration. It was the first time to employ such a low 
concentration of Sim as part of the differentiation media in order to perform osteogenic 
differentiation of mESCs in the dynamic environment of the RWV perfusion bioreactor. 
Moreover, Qiao and his collegues performed osteogenic differentiation of mESCs using Sim and 
obtained important information regarding the followed signaling pathway (Qiao et al., 2011). My 
contribution on this part was the extended gene expression analysis performed and the 
significant information provided regarding the osteogenic differentiation using this protocol.  
The use of mESCs and their encapsulation in alginate hydrogels have been already tested and 
optimized. A single step bioprocess design for the efficient expansion and osteogenic 
differentiation of the encapsulated in alginate mESCs within the custom-made RWV perfusion 
bioreactor has been previously created (Cha, 2010).  
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2ND CHAPTER  
 
 
2. AIMS AND OBJECTIVES 
 
The overall aim of the proposed PhD study is to explore an alternative paradigm in BTE that 
could be potentially employed for future orthopaedic clinical applications. The major target of 
this project is to generate 3D mineralised cellular constructs made from mESCs encapsulated in 
alginate hydrogels, chemically induced by Sim and cultured within an automatable and scalable 
custom-made RWV perfusion bioreactor. In particular, the main objective is to assess and 
evaluate the ability of Sim to induce osteogenic differentiation of mESCS in a 3D configuration. 
 
 
 
 
The specific objectives of this research project are:  
 
- To analyse and evaluate the osteoinductive capacity of Sim. 
- To determine the effects of dynamic rotary culture on cell proliferation.  
- To utilize extensive gene expression analysis in order to gain more insight information 
regarding the whole differentiation pathway of mESCs, from the initial undifferentiated 
status to the final osteogenic phenotype.  
- To compare bioprocess parameters between static and dynamic 3D culture platform 
configurations. 
- To compare the Sim employed chemical induction protocol with the previously used 
protocol with Dex; distinguish similarities and differences among them. 
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3RD CHAPTER  
 
 
3. MATERIALS & METHODS 
 
 
 
In this chapter, the employed cell culture techniques are initially described followed by the 
various methods of experimental analysis used during this project.  
 
3.1 Cell culture in 2D configuration 
 
3.1.1 mESCS expansion and maintenance media formulation 
 
All procedures associated with cell culture were carried out in a cell culture hood. The E14 
thioguanine resistance 2 mESC (E14Tg2a) line (cat. No. CRL-1821, purchased from American 
Type Culture Collection – ATCC) was routinely cultured on tissue culture flasks coated with 
0.1% gelatin (Sigma-Aldrich, Poole, UK) in a 95% humidified cell culture incubator (Nuaire, Nu 
– 5510E, Triple Red Ltd) set at 37ºC and 5% carbon dioxide (CO2) level. 
Undifferentiated mESCs (<passage 20) were subcultured every 3 days at a seeding density of (2 
– 4)×104 cells/cm2 and fed every day with fresh maintenance medium based on high glucose 
Dulbecco's Modified Eagle Medium (HG-DMEM) without sodium pyruvate (Invitrogen, 
Paisley, UK) supplemented with 10% (v/v) of foetal bovine serum (FBS) batch-tested/heat 
inactivated (Invitrogen, Paisley, UK), 100 units/mL penicillin and 100 μg/mL streptomycin  
(LGC Standards, Middlesex, UK), 2 mM of L-glutamine (LGC Standards, Middlesex, UK),  0.1 
mM of 2-mercaptoethanol (Sigma-Aldrich, Poole, UK) and 1000 Units/ml of LIF (Millipore 
(U.K.) Limited, Watford, UK). 
Prior to sub-culture, culture media was aspirated and tissue culture flasks were washed with 1× 
phosphate buffered saline (PBS), without calcium and magnesium (Gibco) before dissociation 
using 0.05% (v/v) trypsin ethylenediaminetetraacetic acid (Trypsin-EDTA; Gibco). Trypsin was 
applied for 5 minutes at 37oC, 5% CO2, resuspended using gentle pipetting for 1 minute to 
ensure complete dissociation, before fresh maintenance media was applied to inactivate trypsin 
and stop the reaction. Centrifuging at 360g/1280rpm for 5 minutes was used at all steps to 
separate the cell pellet from its supernatant before fresh maintenance medium was added for 
further subculture. 
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3.1.2 Embryoid body (EB) formation and osteogenic differentiation in 2D configuration 
 
EB formation involved careful preparation of mESCs prior to suspension culture and was well 
documented (Desbaillets et al., 2000; Hopfl et al., 2004; Martin and Evans, 1975). Nonetheless, 
empirical determination of the correct conditions before suspension was established with the 
E14Tg2a cell line. Briefly, cells in monolayer culture should be around 70% confluent on either 
day 2 or 3 of culture and morphologically undifferentiated. Cells were shortly trypsinised for 1-2 
minutes ensuring cell clumps. The clumps were then centrifuged at 300g for 3 minutes at room 
temperature and then re-suspended in EB formation medium based on Minimum Essential 
Medium Alpha (a-MEM) (Invitrogen) containing 15% (v/v) of FBS batch-tested (Invitrogen), 
1% (v/v) of penicillin and streptomycin 100 units/ml (Invitrogen) and distributed evenly into two 
90 mm diameter bacteriological grade petri dishes.  
On day 3 of EB formation the medium was exchanged with fresh one and on day 5 the EBs were 
harvested, transferred to 50 ml centrifuge tubes and then settled down for 30 minutes in a CO2 
incubator. The medium was aspirated and replaced with pre-warmed PBS to wash away traces of 
serum. The EBs were settled down again and the PBS was aspirated. After PBS washing, 2 ml of 
Trypsin-EDTA was added to the EBs for 3-5 minutes in a CO2 incubator to make them a single 
cell suspension. 8 ml of pre-warmed medium was then added to halt trypsinization. An 
Erythrosin B cell count (Sigma-Aldrich) was performed together with centrifuging the remaining 
10 ml of TE/media/cell suspension at 1280 rpm for 5 minutes. The cell pellets were re-suspended 
in medium and seeded at 3 x 104cells/cm2 density to induce osteogenic differentiation. The 
following day, the media was changed to osteogenic media based on the EB media containing 50 
μg/ml L-ascorbate-2-phosphate (Sigma-Aldrich) and 10 mM b-GP (Sigma-Aldrich) from day 8 
to 29 and 1 μM Dex (Sigma-Aldrich) from day 21 to 29. 
 
Figure 3.1: Conventional osteogenic/chondrogenic differentiation of mESCs via EB formation. 
Adapted from (Hwang et al., 2007). 
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3.1.3 Erythrosin B cell counting 
 
Cell counting was performed using Erythrosin B staining for dead cells in order to quantify the 
total cell number as well as the percentage of live cells. Cells were dissociated into single cells 
and seeded into a haemocytometer and observed using a Leica DM-IL inverted phase 
microscope (Leica). Individual cells having compromised membranes were stained red (non 
viable) whereas viable cells were unstained. 
 
3.2 3D cell culture for BTE 
 
Initial step included cell expansion in 2D cell culture flasks following the previously mentioned 
protocol in order to obtain the required cell numbers to proceed for alginate encapsulation and 
culture within the bioreactor. The next steps included collection of HepG2-CM, alginate cell 
encapsulation, set-up and operation of the bioreactor and finally, 3D cell culture and osteogenic 
differentiation within the cell culture platform. Detailed description of each step follows. 
 
 
3.2.1 HepG2-CM formulation 
 
HepG2 cells (ATCC HB-8605) were cultured in the same way with our previous work (Hwang 
et al., 2006). Briefly, cells were initially cultured in a density of 5.0 × 104 cells/cm2 with DMEM 
containing 10% (v/v) FBS and 1% (v/v) of penicillin and streptomycin. The culturing medium 
was not changed for the following 4 days and then collected to the 0.22-μm filter-unit (VWR 
International, Poole, UK) for filter-sterilization followed by supplementing 0.1 μM of 2-
mercaptoethanol and 2 mM of L-glutamine. HepG2-CM was formulated with 50% (v/v) of the 
fresh mESC growth medium and 50% (v/v) of the medium from the culture above and 
subsequently 1000 units/ml of LIF was added in the mixture (Rathjen et al., 1999). 
 
 
Figure 3.2: Enhanced mesoderm derivation from ESCs using HepG2-CM. Adapted from (Lake 
et al., 2000) 
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3.2.2 Alginate encapsulation and characterization of the generated beads 
 
 
Undifferentiated mESCs were trypsinized from T-flasks, dissociated into a single cell 
suspension, counted and resuspended at a density of 2.5 x 106 cells/ml (20.000 cells/bead) in 
0.22-μm sterile filtered solution composed of 1.1% (w/v) alginic acid (Sigma-Aldrich) and 0.1% 
(v/v) porcine gelatin (Sigma-Aldrich) (both dissolved in PBS, pH 7.4) as described in previous 
study (Randle et al., 2007).  
Before the beginning of encapsulation, tubes were autoclaved and washed initially with ethanol 
and then with sterile PBS. After that, the mESC–alginate solution was passed through a 
peristaltic pump (Model P-1, Amersham Biosciences, Buckinghamshire, UK) and dropped in the 
solution for cross-linking the alginate beads, composed of 100 mM calcium chloride (CaCl2; 
Sigma-Aldrich), 10 mM N-(s-hydroxyethyl) piperazine-N-(2-ethane sulfonic acid) (HEPES; 
Sigma-Aldrich) and 0.01% (v/v) Tween 20 at pH 7.4.  
HEPES is a buffering agent and Tween 20 is a non-ionic surfactant. Tween 20 was employed in 
order to improve the resolution of the microgel assembly patterns and in particular to reduce the 
surface tension (Du et al., 2010). Nonionic detergents are considered mild surfactants; they do 
not affect protein activity and they are effective in solubilization. They are widely employed as 
washing agents in immunoblotting and ELISA in order to minimize unspecific binding of 
antibodies (Kuczynska et al., 2010). 
A surfactant can affect polymerization kinetics and the final properties of the conjugated 
polymers. The incorporation of a surfactant into a conducting polymer can improve the electrical 
and morphological properties of the polymer as well as its thermal stability because 
of the introduction of a bulky hydrophobic component into the polymer structure (Yavuz and 
Gok, 2007). The same action can also improve the biocompatibility and conformation of the 
polymer and give porous surface morphology at the nanoscale to improve enzyme 
immobilization (Khan et al., 2009; Uygun et al., 2009). 
A flow rate of a peristaltic pump was empirically confirmed in order for 4 ml of mESC/alginate 
solution to produce approximately 500 beads using a 25G disposable needle (Becton Dickinson, 
Oxfordshire, UK) and dropped from a height of about 30 mm within 10 minutes. The droplets 
containing cells were gelled immediately on contact with the Ca2+ solution as a shape of bead 
(approximate diameter size: 2.3mm).  
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The mESC-hydrogel beads were allowed to set within the cross-linking gently stirred solution 
for 5 minutes at room temperature. The beads were then washed three times in PBS and placed 
into HepG2-CM for 3 days. Cells were fed with fresh HepG2-CM every day. 
 
 
 
Figure 3.3: Alginate encapsulation as performed in the BSEL laboratory. Adapted from 
(Hwang et al., 2009b) 
 
In order to carry out experimental analysis, cell release was performed after incubation of the 
required number of beads in depolymerisation buffer for 10 – 20 minutes at 37oC with gentle 
agitation. The buffer consisted of 0.22 μm filter sterilized 50 mM tri-sodium citrate dihydrate 
(Fluka, UK), 77 mM sodium chloride (BDH Laboratory supplies, UK) and 10 mM HEPES 
(Sigma, UK) in a PBS base at 7.4 pH. Cell pellet was obtained after samples were centrifuged 
for 5 minutes at 400g and washed twice with PBS.  
Alginate bead formation and the chemical interactions upon cell encapsulation in alginate have 
been described previously in detail by Bienaime and his collegues. They supported that hydrogel 
beads used to encapsulate cells are well-structured macromolecular constructions possessing an 
architecture that provides regular geometric structures throughout the gel network. As a result, 
characteristics such as bead porosity and gel density are closely linked to the gel molecular 
structures. Knowing the pore size and pore connectivity is neccessary in order to ascertain 
whether cells encapsulated within the alginate beads have access to all the nutrients in the 
external medium and also whether toxic metabolites, produced by the cells, are able to perfuse 
through the bead. They also indicated that bead production is highly reproducible when the same 
conditions and reagent concentrations are used (Bienaime et al., 2003). The pore size is also a 
critical factor for cellular activity (Lien et al., 2009). It has been indicated that cross-linking 
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density determines the final pore structure of the hydrogel, even when the same materials and 
experimental conditions are employed (Drury and Mooney, 2003).   
Dr Wesley Randle evaluated the permeability of the employed alginate beads using SDS-PAGE 
during his project. His results suggested that in a dynamic environment, such as the one provided 
by the RWV perfusion bioreactor, the beads allowed proteins of at least 66.2 kDa in size, 
possibly up to 97.4 kDa to permeate. The difference is related to the inherent bead heterogeneity 
during manufacture, as different time in calcium chloride solution may affect porosity (Randle, 
2006).  
The surface topography of the beads used in this study was similar to those produced in the 
literature (Fundueanu et al., 1999) with pore size on the external surface approximately 0.5 - 1 
μm in diameter (McConell et al., 2004). Beads of this size were found to be permeable to 
molecules ranging between 66.2 kDa and 97.4 kDa, similar to the permeability analysis 
performed in this thesis and suggesting that it would easily allow the diffusion of LIF (Guo et al., 
1989), which ranges in size from 20 to 60 kDa (Gascan et al., 1989; Hilton et al., 1988). This 
finding also indicates that mESCs (>20 μm in diameter) are not capable of leaving the beads 
when encapsulated unless they do so through growth and mechanical pressure. 
As far as bead morphology is regarding, the 25G needle size was chosen, after varying the gauge 
and it was employed for encapsulation leading to the generation of beads with almost perfect 
sphericity. Similar publications (Ma et al., 2003; Murphy and Sambanis, 2001) supported no 
major differences when varying needle size and the important goal was to allow viable cell 
growth. He investigated different cell densities per bead that would enable culture for long 
periods of time, up to 30 days, without causing overcrowding and he defined size of 2.3 mm 
diameter as an acceptable one to work with. The alginate-gelatin co-polymer beads were uniform 
in size and sphericity, before and after culture, regardless of the number of cells encapsulated 
within them. He also conducted scanning electron microscopy (SEM) analysis in an attempt to 
determine the pore size of the beads. However, the beads almost completely collapsed under the 
vacuum of the SEM and pore size could not be established.  
The total porosity is related to the amount of pore space present in the scaffolds and can be 
calculated by employing physical properties such as material or bulk density of the scaffolds. 
Various equipment and computer software can be also used to measure porosity and pore size of 
scaffolds (Loh and Choong, 2013). Pore size and porosity of hydrogels can only be determined 
during the fabrication process or using indirect methods of measurements of pure hydrogels with 
no cells and the assumption is that the material will behave the same way even in the presence of 
cells in its interior space.  
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Examples of such indirect methods are fluid intrusion for physical characterization or imaging 
techniques such as SEM to determine porosity. From SEM and liquid intrusion, only a rough 
estimate of diameters could be calculated. Obtained values were not accurate and were 
somewhat arbitrary. Liquid intrusion only gave the largest diameter pores and had high 
variability (Loh and Choong, 2013). 
An alternative approach to SEM for assessing pore size is to use indirect methods such as 
porometry and porosimetry. In particular, widely used is mercury porosimetry, which allows the 
determination of the total pore volume fraction, the average pore diameter and pore size 
distribution of 3D materials (Guarino et al., 2008; Thunemann et al., 2011). Mercury 
porosimetry is quite well accepted in the determination of the pore size of materials despite the 
fact that it does not take into account the shape of the pores.  
Scaffold permeability method has been also employed to determine the pore size of scaffolds 
(Sell et al., 2008). To be more specific, scaffold porosity was determined using a liquid 
displacement method similar to that reported by Zhang and Ma (Zhang and Ma, 1999) and Hsu 
and his collegues (Hsu et al., 1997). Techniques that measure the movement of probes through 
soft polymeric foam or hydrogel scaffolds can potentially generate more meaningful information 
than methods that can distort or disrupt the native scaffold. The identity of the probe may range 
from a small molecule including dissolved gases to proteins. 
One important thing that was also noticed was the clear fact that prolonged culture was possible 
and the beads were robust enough to support long-term culture. It was also beneficial for cell 
viability that beads were formed at 370C and for this reason, both alginate and calcium chloride 
solution were pre warmed at this temperature. It has been reported that the incorporation of 
gelatin with alginate can support the cell/hydrogel structure to keep mechanical stability after 
prolonged culture (Balakrishnan and Jayakrishnan, 2005). 
 
 
3.2.3 Mechanical properties of hydrogels 
 
It has been observed previously that ionically crosslinked alginates lose mechanical properties 
over time in vitro, presumably due to an outward flux of crosslinking ions into the surrounding 
medium (Shoichet et al., 1996). Such hydrogels were also employed in these experiments and 
obtained results indicated that there was not such an issue. To be more specific and for further 
validation, Dr Jae Min Cha and Dr Yushik Hwang (Cha, 2010; Hwang, 2007) performed 
mechanical testing of the alginate hydrogels alone or with undifferentiated mESCs inside on day 
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0 and also after 29 days of osteogenic differentiation in static configuration using tissue culture 
flasks and in dynamic configuration using the custom-made RWV perfusion bioreactor or the 
HARV bioreactor. The obtained results of the calculated Young’s modulus not only did not 
indicate loss in mechanical properties but they actually suggested a significant increase in the 
experimental group after osteogenic differentiation of 29 days compared to the alginate alone or 
combined with undifferentiated mESCs (Cha, 2010; Hwang, 2007) (Appendix 3.1, 3.2). 
Another significant indication was the fact that on day 29, beads were collected in order to 
perform several analyses and observation suggested that the hydrogels not only maintained their 
structure but also, due to the mineralisation, they were white and hardened compared to day 0.   
Furthermore, based on the literature, mechanical properties of the hydrogels are affected by 
changes in the crosslinking or the material properties (Ahmed, 2015; Wan et al., 2008). During 
all the performed experiments, the exact same protocol, experimental procedure and cross-
linking mehod were followed without changes in the alginate or calcium concentration. Based on 
that, it was not expected to observe changes in the mechanical properties of the generated beads. 
Finally, it has been reported that the incorporation of gelatin with alginate can help to overcome 
the inert nature of alginate, increase bead integrity and enhance cell ligand-specific binding 
properties. In this way, it can support the cell/hydrogel structure to keep mechanical stability 
after prolonged culture (Balakrishnan and Jayakrishnan, 2005). Normally alginate hydrogels lose 
Ca2+ cations after prolonged culture but it has been indicated that the incorporation of gelatin 
enables cell-mediated contraction and packing of the scaffold material (Awad et al., 2004). Due 
to the above-mentioned reasons, the employed hydrogels didn’t seem to have any flux of ions 
and seemed to maintain their mechanical properties during the whole experiment. 
 
 
 
3.2.4 RWV perfusion bioreactor set up 
 
A custom-made RWV perfusion bioreactor, consisted of autoclavable parts was used in this 
project (Figure 3.4). The bioreactor contained two cell culture vessels, which are located on a 
single base plate and they rotate alongside by a main servo motor system. Each vessel has the 
“centre rod” through which media is supplied and it is surrounded by a gas permeable membrane 
which facilitates efficient gas transfer. Each of the vessels has also its own set of peristaltic 
pumps controlling perfusion rate, oxygenators and fresh/waste medium bottles. Perfusion is 
performed in a rate of 60 ml/day. The medium follows a specific pathway which starts from its 
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collection from a fresh medium bottle, through an oxygenator, perfused into the culture vessel 
and finally discarded in a waste medium bottle. All the electric units are monitored by a 
computer system using tailor-made software, which controls rotary and feeding parameters.  
 
 
 
 
Figure 3.4: A brief schematic of the perfusion bioreactor set-up. Image adapted from (Cha, 
2010). 
 
 
 
The following images show actual photos of the employed culture platform where the main 
system components are labelled. 
 
                               
 
 
 
 
 
 
Figure 3.5: Main components of the perfusion bioreactor  
Peristaltic pump Waste medium bottle 
Fresh 
medium 
bottle 
Cell culture 
vessel 
Oxygenator 
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3.2.5 Culture in the perfusion bioreactor 
 
For one set of encapsulation, 10 million cells are mixed with 4ml of alginate and the mixture 
goes through a peristaltic pump and cross links in the end with a CaCl2 solution, thus creating 
500 beads each containing 20000 cells. These 500 beads are transferred in one vessel of the 
custom-made perfusion bioreactor (BSEL). One more set of 500 beads is performed and 
transferred to the other vessel of the perfusion bioreactor. Each of the vessels could 
accommodate 60ml of medium. A flow rate of a peristaltic pump was empirically confirmed to 
produce proper single droplets using a 25-gauge needle (Becton Dickinson, Oxfordshire, UK) 
and a drop height was 15 mm. The rotation speed was set between 10 rpm and 20 rpm based on 
the stability of suspended cellular constructs within the vessel. Perfusion was performed in a rate 
of approximately 60 ml/day. Once per week, a number of beads were collected from each vessel 
in order to perform various analyses either on the same day or later by the end of the experiment.  
More detailed information regarding the required number of beads for each analysis is described 
in the Materials and Methods section. 
Photographs of the cells inside the alginate beads were taken using a Leica DM IL microscope 
(Leica, Wetzlar, Germany) and were analysed using the analysis^D software (Olympus, Munich, 
Germany). 
 
 
 
 
3.2.6 Differentiation 
 
HepG2-CM was applied in each vessel for the first 3 days to get cell expansion while ‘forcing’ 
the cells to go to mesoderm formation. Differentiation to osteogenesis was triggered using alpha 
Minimal Essential Medium (α-MEM; Invitrogen) containing 15% (v/v) of FBS and 1% (v/v) of 
penicillin and streptomycin, which has been commonly used for EB formation (Desbaillets et al., 
2000; Martin and Evans, 1975) supplemented with 50 μg/ml of L-ascorbate-2-phosphate (Sigma- 
Aldrich) and 10 mM b-GP (Sigma-Aldrich) from the onset of osteogenic differentiation. 
Depending on the experimental group, 1 μM Dex (Sigma-Aldrich) was additionally 
supplemented on day 21 of culture for the last week or 0.1 nM of Sim on day 14 of culture for 
the last two weeks of the experiment.  
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Dex is a steroid acting as a strong osteoinductive agent. It is widely employed by many research 
groups in order to perform osteogenic differentiation of both MSCs and ESCs. Following 
published protocols by previous people in the lab (Hwang et al., 2006) and by other groups, 
(Moslem et al., 2015; Qiao et al., 2011; Smith et al., 2010; Zheng et al., 2013) concentration of 1 
μM Dex was supplemented in the osteogenic media without performing any optimization 
myself. Moreover, Dex was supplemented in the differentiation media on day 21 and for the last 
week of culture because it has been previously indicated that mineralisation was enhanced and 
the osteogenic differentiation was more efficient when Dex was supplied in the culture during 
the late stages of differentiation (Buttery et al., 2001) and specifically, after 14 days of culture. 
The reason for this effect is the fact that Dex is such a potent osteoinductive agent that when 
supplied early does not permit the expansion of the cells which stop proliferating and are 
directed to differentiate (Bielby et al., 2004)   
Sim is a small molecule widely used as a drug to lower cholesterol and prevent cardiovascular 
diseases. Apart from this main role, it has been also demonstrated that it exhibits a number of 
other pleiotropic effects, one of which is the anabolic effects on bone formation. Based on that, 
research using various cell types indicated its capacity to enhance osteogenic differentiation 
through upregulation of BMP2, the strongest osteoinductive factor. Following initially a 
published paper from previous people working in the lab (Pagkalos et al., 2010), concentration 
of 0.1 nM Sim was used and the chemical was supplied in the culture media from day 4 of the 
experiment. Initial results were not satisfactory, no matter the fact that the employed 
concentration was low and did not have toxic effects. Moreover, literature research indicated the 
role of Sim as a cell cycle inhibitor. For this reason, a short optimisation was performed 
regarding the time of supplementation of Sim in the osteogenic media and in the end, day 14 was 
chosen as a good time point in order to obtain enough cells and increased osteogenic 
differentiation. The previously suggested concentration was also tested without further 
optimization.   
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3.3 Experimental analysis 
 
3.3.1 Qualitative analysis 
 
3.3.1.1 Immunocytochemistry in 2D configuration 
 
Cells were seeded and cultured on chamber slides at a density of 104 cells per well. They allowed 
to attach and then, they were washed with PBS before proceeding and get fixed for 20 minutes at 
room temperature in 4% (w/v) paraformaldehyde (PFA; BDH Laboratory Supplies). Next step, 
cells were treated with 0.2% (v/v) Triton-X-100 (BDH Laboratory Supplies) for 15 minutes at 
room temperature for permeabilization and washed twice with PBS.       
The samples were then incubated with 3% (v/v) blocking goat or donkey serum (Vector 
Laboratories) for 30 minutes at room temperature in primary diluents composed of 0.05% (w/v) 
bovine serum albumin (BSA; Sigma-Aldrich), 0.01% (w/v) NaN3 (Sigma-Aldrich) in PBS to 
block unspecific binding of the antibodies. 
The serum solution was removed and the samples were incubated with primary antibodies 
diluted in primary diluents at 4oC overnight followed by two washes and incubation with 
secondary antibodies diluted in secondary diluents consisting of 0.05% (w/v) BSA in PBS for 30 
minutes at room temperature in the dark. For dual staining, the same steps after the first 
treatment of primary antibody were repeated for the second reaction. Finally, the samples were 
washed twice in PBS and mounted using Vectashield TM with 1.5 μg/ml 4', 6’ diamidino-2-
phenylindole (DAPI) (Vector Laboratories). Negative controls were also performed. Information 
on the employed antibodies is shown on Table 3.1. 
 
Table 3.1: Antibody list 
Antigens Primary antibodies 
(dilutions) 
Secondary antibodies 
(dilutions) 
Oct4 Rabbit polyclonal 
(Santa cruz Biotech) (1:80) 
Goat anti-rabbit IgG FITC 
(Santa cruz Biotech) (1:200) 
SSEA1 Mouse monoclonal 
(Santa cruz Biotech) (1:100) 
Donkey anti-mouse IgG Texas Red 
(Santa cruz Biotech) (1:200) 
 
FITC: fluorescein isothiocyanate 
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3.3.1.2 Conventional polymerase chain reaction (PCR) 
 
3.3.1.3 RNA extraction, Reverse transcription, PCR amplification and agarose gel 
electrophoresis  
 
After dissolving beads, total RNA from the samples was extracted by using Total RNA 
Purification Kit (Norgen Biotek Corporation, Canada), according to the manufacturer’ 
instructions.  
RNA was then reversed transcribed into complementary DNA (cDNA) using the Reverse 
Transcription System (Promega, Southampton, UK) following the manufacturer’s 
recommendations with some modifications. Briefly, Mastermix for cDNA synthesis was 
prepared with 1 μg of RNA adding 5 mM MgCl2, 1 mM of 2'-deoxynucleoside 5'-triphosphate 
(dNTP) mixture, 1 unit/μl recombinant RNasin ribonuclease inhibitor, 15 units/μl AMV reverse 
transcriptase and 0.5 μg/μl random primers in a total volume of 20 μl per reaction. The RNA 
samples were heated at 70oC for 10 minutes, briefly centrifuged and cooled on ice for 5 minutes. 
After the mastermix was added to RNA samples, they were incubated at 25oC for 10min and 
then reverse transcription was performed at 42oC for 40 minutes followed by denaturation at 
90oC for 5 minutes and a cooling step at 4oC for 5 minutes. 
50 μl of cDNA samples containing the mastermix, 1x PCR Buffer, 0.2 mM dNTP mixture, 1.5 
mM MgCl2, 0.2 μM each primer (sense and anti-sense), 1 unit of Platinum Taq DNA 
Polymerase, and DNase free water (all supplied by Invitrogen) were amplified with the 
following PCR conditions: Taq polymerase activation, 94oC for 10 min; thermal cycling, 94oC 
for 30 sec, annealing temperature (AT) for 30 sec, 72oC for 60 sec; followed by a final 
elongation step at 72oC for 10 min.  
The PCR products were analysed and visualized on a 1.5% (w/v) agarose gel by ethidium 
bromide staining with ultra-violet light.  
Gapdh was used as a housekeeping gene. Pluripotency markers Nanog and Rex 1 were tested. 
The expression of important bone markers COL 1 and BMP2 was also evaluated. Mesoderm 
marker Brachyury T, endoderm marker Gata4 and primitive ectoderm marker Fgf5 were also 
examined. 
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The information of specific PCR conditions employed for each primer is indicated on Table 3.2 
 
Table 3.2: Primers of genes tested for gene expression analysis 
 
GENES SEQUENCES SIZE 
(bp) 
AT 
(Co) 
CYCLES 
Nanog (fwd) CCTGATTCTTCTACCAGTCCCA (rvs)  GGCCTGAGAGAACACAGTCC 123 58 34 
Rex1 (fwd) TGGAAGCGAGTTCCCTTCTC (rvs) GCCGCCTGCAAGTAATGAG 127 58 32 
Fgf5 (fwd) AGTTTCCAGTGGAGCCCTTC (rvs) AATTTGGCACTTGCATGGAG 235 58 32 
Gata4 (fwd) CTC CTA CTC CAG CCC CTACC (rvs) GTG GCA TTG CTG GAG TTACC 571 58 30 
BrachyuryT (fwd) GCTTCAAGGAGCTAACTAACGAG (rvs) CCAGCAAGAAAGAGTACATGGC 116 58 32 
COL 1 (fwd) CGTGGCGACCAAGGTCCAGT (rvs) AGGGAGACCCAGAATACCGGGAG 165 58 30 
BMP2 (fwd) CCTTACCAAAAATGGAGGCTCA (rvs) GGCTCAGTGTCGTCATCATTAAA 201 58 32 
GAPDH (fwd) CATGGCCTTCCGTGTTCCTACCC (rvs) CCTCAGTGTAGCCCAAGATGCCCT 145 58 30 
 
3.3.2 Quantitative analysis 
 
3.3.2.1 ALP activity  
 
ALP activity was measured using r-nitrophenol phosphate (rNPP, Sigma-Aldrich) as a substrate. 
Cellular ALPase was determined colorimetrically by rNPP contents according to the reaction. 
Three beads (n=3) were collected from each group and dissolved in the depolymerisation buffer. 
The cells from beads were incubated in 200 μl of ALPase buffer (Sigma-Aldrich) and 200 μl of 
rNPP solution at 37oC for 30 minutes with gentle shaking in the dark. 400 μl of 3N sodium 
hydroxide (NaOH; BDH Laboratory Supplies) solution was added to each sample to stop the 
reaction and then 100 μl of the final solution was read at 410 nm with ELISA reader (MRX II 
plate reader; Dynex technologies, West Sussex, UK).  
 101 
The enzyme activity was calibrated with rNPP standard curve (Appendix 2) and expressed as 
micromoles of reaction product per minute per total cell number obtained from DNA 
quantification. 
 
 
 
3.3.2.2 DNA quantification 
 
Total DNA content was measured using Quant-iT PicoGreen double-stranded DNA (dsDNA) 
Reagent and Kits (Invitrogen), as an indirect method of evaluating cell numbers during the 
experimental procedure (Ng et al., 2005) following a previously used similar protocol (Randle et 
al., 2007), with minor modifications.  
Ten beads were collected from each group, dissolved in the depolymerisation buffer, washed in 
PBS and cell pellet was stored in -80oC until analysed. For the analysis, cell pellets from the 
samples were digested in 50 μg/ml proteinase-K solution (Sigma-Aldrich, Poole, UK) based on 
100 mM dibasic potassium phosphate, pH 8.0 (K2HPO4; Sigma-Aldrich) overnight at 37oC. 
Proteinase K was inactivated by heating at 90oC for 10 minutes and the samples were stored in 
the ice.  
A 24 well plate was prepared by putting in each well 50 μl of the sample with the digested DNA 
or 50 μl of 1x Tris-EDTA buffer (TE buffer) for the negative control. Then, 350 μl of 1x TE 
buffer were added to all of the wells and mixed thoroughly. After that step, the digested cell 
supernatant was combined with PicoGreen reagent. In particular, a 96 well plate was prepared by 
putting in each well 50μl of the mix in the 24 well plate along with 50 μl of PicoGreen reagent 
(Invitrogen, Paisley, UK) which has been diluted in DNase free TE buffer (10 mM Tris-HCl, 1 
mM EDTA, pH 7.5).  
Finally, the 96-well plate was read in a fluorometer (skanIT Varioskan fluorometer, Thermo 
scientific) at the excitation wavelength of 480 nm and the emission wavelength of 520 nm. The 
amount of total DNA from a known cell quantity produced from routinely cultured mESCs was 
enumerated in order to calibrate the number of cells per sample (DNA quantification standard 
curve in the Appendix 1).  
Taking into consideration the limitations of the various techniques and the results from this 
study, it is suggested that measuring total DNA is the most reliable strategy for quantifying cell 
proliferation in high cell density (100.000 cells/cm2) and 3D cultures (Ng et al., 2005). 
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3.3.2.3 Alizarin Red S staining (ARS)-based quantification of bone mineralisation 
 
Mineralisation of ESC-based osteogenic constructs was quantified by the method developed by 
Gregory et al (Gregory et al., 2004), which is based on ARS assay, with some modifications. 
Twenty beads from each group on days 21 and 29 were collected (n=3), dissolved in the 
depolymerization buffer and centrifuged at 400g for 10 min. The cell pellets were immerged in 
4% paraformaldehyde at room temperature for 20 min and washed with PBS followed through 
centrifugation in the same way above. 2 ml of 40 mM ARS (pH 4.2, filtered) was added on the 
PBS-washed cells and incubated with shaking at RT for 20 min, followed by 3 times washing 
process with double distilled water. 0.8 ml of 10% acetic acid was added to each sample, which 
was subsequently incubated with shaking at room temperature for 30 min, followed by 
incubation at 85oC for 10 min and centrifugation at 20,000g for 15 min. The measurement with 
150 μl of the supernatant was done in 96 well plates at 405nm using ELISA reader (Dynex 
technologies) after adding 200 μl of 10% (v/v) ammonium hydroxide. 
 
 
 
3.3.2.4 MTS 
 
The number of viable cells was determined with a colorimetric method using the CellTiter 96 
AQueous One Solution Cell Proliferation Assay (Promega). The CellTiter 96® AQueous One 
Solution Reagent contains the MTS tetrazolium compound (Owen’s reagent) which is 
bioreduced by cells into a colored formazan product that is soluble in tissue culture medium. 
This conversion is accomplished by NADPH or NADH produced by dehydrogenase enzymes in 
metabolically active cells. The quantity of formazan product as measured by the absorbance at 
490 nm is directly proportional to the number of living cells in culture. For the analysis, a 48 
well plate was used in the first step. One bead was placed to each well (n=5) and media was 
sucked out. 40 μl of the CellTiter 96 Aqueous One Solution Reagent and 200 μl of basal medium 
were added per well with lights closed (Dilution 1:5). Negative control wells with no beads were 
also prepared. The plate was put in a shaker for 20 min and then was transferred in 37oC in an 
incubator for 2h 40 min. After the 3 hours, the samples were transferred in a 96-well plate to be 
measured. 100 μl from each well from the 48-well plate were put in a well in the 96-well plate. 
Two readings were performed for each well. Finally, the absorbance was recorded at 490 nm in 
an ELISA reader (MRX II plate reader; Dynex technologies, West Sussex, UK). 
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3.3.2.5 Real-time polymerase chain reaction (RT-PCR) 
 
Extended gene expression analysis was performed during the experimental procedure in order to 
evaluate the progress of osteogenic differentiation from mESCs. Analysis of bone markers, 
cartilage and hypertrophic chondrocyte markers and three germ layer markers, was tested. The 
procedure consisted of three major steps. It started with RNA extraction, followed by reverse 
transcription of mRNA to cDNA to finish with RT-PCR for amplification of the end product and 
semi-quantitative gene expression analysis. Each step is analysed separately on the following 
sections. 
 
3.3.2.6 RNA extraction 
 
 
Cell pellets from the samples to be analysed were stored in -80oC after each experiment. Before 
proceeding with RNA extraction, cell pellets were removed from the freezer and allowed to thaw 
at room temperature. RNA was extracted using Total RNA purification kit (Norgen Biotek, 
Canada) following the kit instructions. Briefly, cells were dissolved with a lysis solution 
supplemented with 1% of b-mercaptoethanol and mixed by vortex. 100% ethanol was added to 
the lysate to precipitate the binding of RNA to the RNeasy membrane and mixed again by 
vortex. The lysate went through a provided column in order for the RNA to bind on it. Total 
RNA that bound to the membrane column was washed once with the washing solution provided 
in the kit. Before use for the first time, the washing solution was supplemented with 100% 
ethanol.  Next step is on-column DNA removal which was performed using DNase treatment as 
an additional step to digest contaminating DNA followed by washing of the column two more 
times with the washing solution provided. RNA was then eluted in a 1.7 ml elution tube provided 
with the kit using 50ul of Elution Solution. Every time a reagent was added in the column, 
centrifugation was performed twice in 14000g for one minute. RNA quantification was 
performed on a UV spectrometer and the A260/A280 ratio of greater than 1.70 was required to 
ensure purity of RNA sample quality. RNA samples then were employed for cDNA synthesis or 
stored at -80oC until used. 
 
3.3.2.7 cDNA synthesis 
 
RNA was reversed transcribed into cDNA using the Reverse Transcription System (Promega, 
Southampton, UK) following the manufacturer’s recommendations with some modifications. 
Briefly, samples containing 1 μg of RNA were prepared and were heated at 70oC for 10 minutes; 
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left them to cool on 4oC until used in the next step. During the incubation, mastermix for cDNA 
synthesis containing 25 mM MgCl2, RT 10X buffer, 10 mM of 2'-deoxynucleoside 5'-
triphosphate (dNTP) mixture, 1 unit/μl recombinant RNasin ribonuclease inhibitor, 15 units/μl 
AMV reverse transcriptase and 0.5 mg/μl random primers in a total volume of 10.1 μl per 
sample, was prepared. The mastermix was added to RNA samples giving a total volumeof 20ul 
per reaction. The samples were incubated at 25oC for 10min and then reverse transcription was 
performed at 42oC for 40 minutes followed by a cooling step at 4oC for 5 minutes. cDNA was 
stored in -20oC.  
 
 
3.3.2.8 Quantitative real-time PCR (qRT–PCR) 
 
Gene expression was determined using qRT-PCR in the StepOnePlus Real-time PCR instrument 
(Applied Biosystems). A number of different genes were tested in order to get information 
regarding bone formation and how osteogenic gene expression was evolved during the 29 days 
of differentiation. To get more insight details about which pathway of osteogenesis was used, a 
number of cartilage markers were also tested. Markers from the three germ layers were tested to 
show the progress of differentiation and give significant information about bone development 
(Table 3.5). The usual candidate GAPDH was not giving satisfying results as control gene. For 
this reason and after looking into the literature, the housekeeping gene RPL27 with more stable 
expression was employed.  
For the reactions, the SensiFAST SYBR Hi-ROX Kit (Bioline, London, UK) was employed. The 
composition of the reaction mix is shown on Table 3.3. The total volumeof reaction was 20 μl. 
 
 
Table 3.3 Reaction mix composition 
REAGENT VOLUME FINAL CONCENTRATION 
2X SensiFAST SYBR Hi-ROX Mix 10 μl 1X 
10μM Forward primer 0.8 μl 400 nM 
10μM Reverse primer 0.8 μl 400 nM 
CDNA 2 μl 100 ng 
H2O up to 20 μl  
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A 2-step cycling protocol was used. The thermal cycling conditions consisted of 40 cycles and 
details are shown in Table 3.4.  
 
 
Table 3.4 2-step cycling protocol 
 
Cycles Temperature Time Notes 
1 950C 2 min Polymerase activation 
 
40 
950C 5 sec Denaturation 
600C 20 sec Annealing/extension 
 
 
After completing the PCR in the end of the 40 cycles, melting curve analysis was performed in 
order to control for primer–dimer formation. A product melting curve can be obtained during 
PCR by monitoring the fluorescence of dsDNA dyes as the temperature passes through the 
product denaturation temperature referred to as the melting temperature, Tm. Melting curve’s 
shape is a function of GC content, length, and sequence. Based on that, primer-dimer products 
are shorter than the targeted product and they will melt at a lower temperature, something that 
can be recognized by melting curve analysis (Kubista et al., 2006; Ririe et al., 1997). 
 
Relative gene expression analysis was conducted using the 2-ΔΔCT method (Livak and 
Schmittgen, 2001) where the amount of target, normalized to an endogenous reference and 
relative to a calibrator, is given by amount of target = 2-ΔΔCT where : 
 
∆∆CT = (CT, Target - CT, Rpl27) Time x - (CT, Target - CT, Rpl27) Time 0. 
 
The 2-ΔΔCT method requires the assignment of a housekeeping gene, which is assumed to be 
uniformly and constantly expressed in all samples and of a reference sample. The expression of 
the tested samples is compared with that of the reference sample (Pfaffl, 2001). 
In this project, ribosomal protein L27 (Rpl27) was used as a housekeeping gene and day 0 cells 
as a reference sample. The expression of the gene of interest was determined by the difference of 
its expression normalized with the housekeeping gene expression for the specific time point 
minus the difference between the mentioned samples for time zero. All the obtained gene 
expression results were statistically analysed.  
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Table 3.5 The sequences of primers used for real-time PCR to amplify the region of interest  
                     Abbreviations: (A) antisense/reverse primer, (S) sense/forward primer 
 
 
 
Gene Primer Sequence Amplicon size (bp) 
RPL27 
 
(S) AAAGCCGTCATCGTGAAGAAC 
(A) GCTGTCACTTTCCGGGGATAG 100 
ALP (S) CCAACTCTTTTGTGCCAGAGA (A) GGCTACATTGGTGTTGAGCTTTT 109 
RUNX2 (S) TCGTCAGCATCCTATCAGTTCCCA (A) CCATCAGCGTCAACACCATCATTCTGGTTAG 145 
OSTERIX (S) TTGAGGAAGAAGCTCACTATGGCTCCAG (A) GCTGAAAGGTCAGCGTATGGCT 142 
COLLAGEN 1 A1 (S) GCATGGCCAAGAAGACATCC (A) CCTCGGGTTTCCACGTCTC 82 
BMP2 (S) TCTTCCGGGAACAGATACAGG (A) TGGTGTCCAATAGTCTGGTCA 125 
BGLAP (S) CAGCGGCCCTGAGTCTGACAAA (A) TCACAAGCAGGGTTAAGCTCACACTG 149 
BSP (S) CAGAGGAGGCAAGCGTCACT (A) CTGTCTGGGTGCCAACACTG 80 
OSTEONECTIN (S) GTGGAAATGGGAGAATTTGAGGA (A) CTCACACACCTTGCCATGTTT 104 
OSTEOPONTIN (S) AGCAAGAAACTCTTCCAAGCAA (A) GTGAGATTCGTCAGATTCATCCG 133 
MSX2 (S) TCCGCCAGAAACAGTACCTG (A) TTGCAGTCTTTTCGCCTTAGC 121 
DLX5 (S) CACCACCCGTCTCAGGAATC (A) GCTTTGCCATAAGAAGCAGAGG 125 
ATF4 
 
(S) CCTGAACAGCGAAGTGTTGG 
(A) TGGAGAACCCATGAGGTTTCAA 134 
PTHR1 
 
(S) CAGGCGCAATGTGACAAGC 
(A) TTTCCCGGTGCCTTCTCTTTC 125 
SOX9 
 
(S) TGGCAGACCAGTACCCGCATCT 
(A) TCTTTCTTGTGCTGCACGCGC 135 
AGGRECAN 
 
(S) AGGTGTCGCTCCCCAACTAT 
(A) CTTCACAGCGGTAGATCCCAG 96 
COLLAGEN 10 A1 
 
(S) TTCTGCTGCTAATGTTCTTGACC 
(A) GGGATGAAGTATTGTGTCTTGGG 115 
GATA 4 
 
(S) TCAACCGGCCCCTCATTAAG 
(A) GTGGTGGTAGTCTGGCAGT 88 
SOX 17 
 
(S) ACCTACACTTACGCTCCAGTC 
(A) GCCGTAGTACAGGTGCAGAG 141 
NESTIN (S) CCCCTTGCCTAATACCCTTGA (A) GCCTCAGACATAGGTGGGATG 115 
PAX 6 
 
(S) TAGCCCAGTATAAACGGGAGTG 
(A) CCAGGTTGCGAAGAACTCTG 132 
DESMIN 
 
(S) GTTTCAGACTTGACTCAGGCAG 
(A) TCTCGCAGGTGTAGGACTGG 105 
HAND 1 
 
(S) CTACCAGTTACATCGCCTACTTG 
(A) ACCACCATCCGTCTTTTTGAG 101 
BMP 4 
 
(S) TTGATACCTGAGACCGGGAAG 
(A) ACATCTGTAGAAGTGTCGCCTC 117 
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3.3.2.9 Attenuated Total Reflection-Fourier Transform Infrared (ATR-FTIR) analysis 
 
 
ATR-FTIR spectroscopic imaging is a highly versatile, label free and non-destructive chemical 
imaging method, which can be applied to study a wide range of samples and systems. Two of the 
major advantages of measuring in ATR mode are the opportunity to measure samples that absorb 
strongly in the IR spectrum, such as aqueous systems, without significant sample preparation and 
the ability to increase the spatial resolution of the measured image. The chemical specificity of 
FTIR imaging originates from the interaction (via absorption) of infrared light with the 
vibrational modes of the molecules being interrogated (Kazarian and Chan, 2013). 
ATR-FTIR imaging was conducted using a continuous scan FTIR spectrometer (Varian 7000 
FT-IR, Varian Inc. CA, USA) in conjunction to a large sample compartment extension (Varian 
LS) and a 64 x 64 focal plane array (FPA) detector. Further details about the ATR-FTIR imaging 
setup can be found in the suggested literature (Chan and Kazarian, 2003). Sample beads were 
placed onto the measuring surface to be in contact with the ATR crystal (oil analyser, Specac 
Ltd., Kent, UK). Excess water was removed and the sample was enclosed to prevent further 
evaporation, thus ensuring that the bead remains hydrated during the measurement. Three to five 
beads were measured from each sample. 
 
 
3.3.2.10 Media analysis 
 
 
 
Nutrient and metabolite concentrations were analyzed in the Bioprofile 400 Analyzer (Nova 
Biomedical, Flintshire, UK) using culture supernatant samples (1.0 ml) collected on day 29, the 
last time point of the experiment. Comparison was performed between samples treated either 
with Dex or with Sim protocol.  
 
 
 
3.3.2.11 Statistical analysis 
 
SigmaStat (Systat Software UK, UK, version 3.5) was used for one-way or two-way analysis of 
variance (ANOVA). Samples for the quantitative analyses were measured for different protocols 
and the mean values were calculated. The results were expressed as mean ± standard deviation 
and were analyzed using ANOVA, comparing all data pairs. Error bars on all graphs represent 
the standard deviation (SD) of the mean. Statistical significance was considered at p<0.05. 
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RESULTS 
 
 
4th CHAPTER    
 
 
4. OSTEOGENIC DIFFERENTIATION OF MESCS WITH THE USE OF 
CONDITIONED MEDIA AND BY BYPASSING EB FORMATION 
 
 
4.1 Introduction 
 
ESCs are a unique population of cells with two distinctive properties: unlimited self-renewal 
capacity and pluripotency, meaning potential to differentiate into all adult cell types, including 
the germ cells (Bradley et al., 1984; Pera et al., 2000; Smith, 2001). These features make them 
an attractive option for cell therapies as they can provide a theoretically unlimited source of 
different cells needed.  
The field of research that is the centre of attention in this thesis is osteogenic differentiation. 
Traditionally, osteogenic differentiation of ESCs begins with their aggregation in suspension 
culture leading to the formation of EBs. EBs are 3D structures that recapitulate early aspects of 
mammalian development (Doetschman et al., 1985; Shen and Leder, 1992) and contain cells 
from all three germ layers (Desbaillets et al., 2000). The problem with EBs is that it is difficult to 
control spontaneous differentiation and to direct cells to the specific cell lineage needed.  
An alternative strategy to bypass this step and to direct more efficiently and enhance osteogenic 
differentiation of ESCs is with the use of conditioned culture medium. It is known from 
developmental biology that ESCs generate derivatives of the three germ layers via a primitive 
ectoderm intermediate (Shen and Leder, 1992). Research on EB formation indicated the 
existence of important inductive signals involved in primitive ectoderm formation and mesoderm 
differentiation (Coucouvanis and Martin, 1999; Johansson and Wiles, 1995; van den Eijnden-van 
Raaij et al., 1991). 
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Based on that, it has been previously reported that the use of medium conditioned by HepG2 cell 
line induced the differentiation of ESCs to a homogeneous pluripotent cell population, termed 
early primitive ectoderm-like (EPL) cells. Characterization of EPL cells revealed that they are 
close related with primitive ectoderm of the pre-gastrulation embryo (Rathjen et al., 1999). 
Moreover, it has been suggested that liver cell lines possess characteristics similar to those of 
visceral endoderm, an early regulator of embryogenesis, which directs cell fate (Rodda et al., 
2002). This is the first report of factors affecting ES differentiation to a homogenous cell 
population without intermediate cellular aggregation constituting EB formation (Rathjen and 
Rathjen, 2001). Differentiation of mESCs with the use of HepG2-CM resulted in the generation 
of a restricted repertoire of cell types comprised of mesoderm and parietal endoderm. This 
method could provide an efficient way to enhance mesoderm formation and eliminate the 
generation of the other germ layers (Kang et al., 2009b). 
Based on the above findings, it has been also shown from previous people in the group that 
treatment of mESCs with conditioned medium from the HepG2 enhanced mesoderm formation 
and derivation of osteogenic cells without the need for the step of EB formation (Hwang et al., 
2006). Finally, osteogenic differentiation is widely performed in osteogenic media containing b-
GP, AA and Dex. In particular, it has been shown that when Dex was supplied in the late stages 
of the differentiation protocol, mineralisation was enhanced (Buttery et al., 2001). 
 
4.2 Aim and Objectives 
 
The aim of this chapter was to show that successful osteogenic differentiation could be 
performed from mESCs, by using either traditional protocols with the step of EB formation or 
newly developed protocols with the employment of conditioned medium. Dex was used as an 
osteoinductive factor and was supplied in the last week of culture. 2D and 3D culture 
configurations were tested. 
 
In particular: 
 
1. To evaluate and compare the osteogenic differentiation of mESCS between 3D static and 
dynamic culture platforms. 
 
2. To estimate the efficiency of the conditioned medium and assess the osteogenic 
differentiation without the EB formation step.  
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4.3 Methodology 
 
2D culture was initially performed in tissue culture flasks for cell expansion. Cells were then 
transferred in Petri dishes for EB formation and finally, in six-well plates for osteogenic 
differentiation. The differentiation protocol lasted for 29 days. 
Immunocytochemistry analysis in 2D culture was performed in order to examine and confirm the 
initial pluripotent status of the cells before the beginning of the experiment. Photos under the 
microscope were obtained from each stage, in particular from EB formation and bone nodules, in 
order to observe the morphology. ARS was also used to evaluate calcium deposition and 
mineralisation.  
For 3D static and dynamic culture, cells were encapsulated in alginate and were cultured in 
HepG2-CM for 3 days either in flasks or in the perfusion bioreactor. After that period, media 
was replaced with osteogenic media containing b-GP and AA until day 21, when osteogenic 
media was further supplemented with Dex for the last week of culture. 
In 3D cultures, a number of different analyses were employed in order to examine the osteogenic 
process. Conventional PCR was performed in samples obtained from the early days of culture 
where expression of pluripotency and initial germ layer formation markers was evaluated. DNA 
quantification was employed as an indirect method to calculate cell numbers. Measurement of 
ALP activity was used as an efficient way to prove osteogenic differentiation. ARS was 
employed as a method to test for calcium deposition and mineralisation. ATR-FTIR was used to 
confirm the presence of HA. Photos of the hydrogels under the microscope indicated cell 
morphology. Finally, gene expression studies using qRT-PCR provided some more insight 
information and quantitative results on the progress of osteogenic differentiation. 
 
 
4.4 Results 
 
 
4.4.1 2D BIOPROCESS OF MESCS TOWARDS OSTEOGENESIS USING EB FORMATION 
AND DEX 
 
The standard protocol for osteogenic differentiation of ESCs in a 2D configuration started with 
their expansion, then continued with the step of EB formation and it ended up with bone nodule 
formation, which proved osteogenic differentiation. It was important to evaluate and indicate the 
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initial pluripotent status of the cells before beginning any experimental procedures. For this 
reason, immunocytochemistry for two main pluripotency markers was performed and they both 
indicated positive expression. Oct4 is the most well known nuclear factor associated with 
pluripotency. Another important pluripotency factor is the surface marker SSEA1.  
Photos under the fluorescence microscope were taken and are presented in this section. Mouse 
primary antibodies against Oct-4 and SSEA1 were employed. Next step involved the incubation 
of cells with secondary antibodies raised in different species and labelled with different 
fluorochromes in each case. In particular, secondary antibody against Oct-4 was FITC-
conjugated and was visualised under the green light while secondary antibody against SSEA1 
was Texas Red-conjugated and was visualised under the red light in the fluorescence 
microscope. Samples were subsequently counterstained with DAPI and photos were taken under 
the blue light. Dual stained photos acquired under the microscope are also presented where 
FITC-conjugated cells and Texas Red-conjugated cells are combined with DAPI (Figure 4.1). 
 
 
            
 
        
 
 
                                                                
 
 
 
     
Figure 4.1: Immunocytochemistry photos indicating the expression of pluripotency markers 
Oct4 (a) and SSEA-1 (b). Nuclear DAPI counterstain was also performed (a’, b’). Dual stained 
photos, combining FITC and DAPI staining for the expression of the nuclear marker Oct4 (c) 
and Texas Red and DAPI staining for the expression of the surface marker SSEA-1 (d), were 
analyzed. Negative controls for FITC and Texas Red were also conducted (c’, d’). Scale bar is 
200μm. 
 
a b 
c d 
a’ b’ 
c’ d’ 
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After confirming the pluripotent status of the starting cell population, the 29 days procedure of 
osteogenic differentiation began. It started with the initial expansion of the cells, followed by EB 
formation and ended up with bone nodule formation. Photos under the microscope were taken 
from each stage (Figure 4.2).  
 
 
       
 
 
Figure 4.2: Photos obtained under the microscope indicate the formation of EBs (a) and of bone 
nodules (b). Scale bar is 200μm. 
 
 
 
 
To further validate and confirm osteogenic differentiation and mineralisation, after 21 and 29 
days of culture, ARS was used as a method to indicate calcium deposition and mineralisation. 
Photos using a conventional camera were obtained from the stained six well plates (Figure 4.3). 
 
 
          
 
Figure 4.3: ARS was performed in order to evaluate calcium deposition on the six well plates on 
day 21 (a) and on day 29 (b) of the experiment. 
 
 
 
 
 
ARS was performed in a six well plate where the same number of cells was initially seeded in 
each of the six wells. ARS was performed on day 21 and day 29, as it can be observed from the 
photos of the stained plates. On day 21, all the six wells indicated about the same amount of 
a b 
a b 
 staining suggesting similar quantity of 
had similar amount of calcium 
reason for this is probably related to technical issues that had to do with the procedure followed 
for quantification of the staining. To be more specific, 
good washing to remove excess
water and there is a chance for some cells to be detached during this proce
for the fewer stained cells observed in the two wells compared 
Subsequent quantification of the ARS was also performed and results are presented in
following graph (Figure 4.4). Statistical analysis 
significant higher calcium deposition
 
Figure 4.4: Quantification of 
statistical analysis. Asterisk 
significant difference between the tested time points.
 
 
 
 
4.4.2 3D BIOPROCESS OF 
 
As mentioned in the literature review, 2D cultures pose a 
mimicking the in vivo microenvironment. They cannot also provide and support the high cell 
numbers needed for cellular therapies due to the limited space for the cells to grow in 
al., 2014). 3D culture platforms can overcome these problems and elicit a more physiological 
state, which can offer high number
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calcium deposition. On day 29, however, four of the wells 
deposition while the other two had less amount of staining. The 
the first step to quan
 staining. This procedure takes place in the sink under the tap 
ss. This is the reason 
to the rest of the plate. 
indicated that on day 29, there was statistically 
 compared to day 21, as expected.  
 
ARS on day 21 and day 29. One-way ANOVA was used for 
indicates p < 0.05 and shows that there is statistically 
 
MESCS TOWARDS OSTEOGENESIS USING DEX
number of limitations and they are
 of better quality cells (Baker and Chen, 2012
day 21 day 29
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tify ARS involves 
 
 the 
 
 
 not 
2D (Xu et 
). One widely 
 used protocol for the osteogenic 
and employs the steroid Dex, which has been shown to enhance 
types (Blum et al., 2004; Kirton et al., 2006
In this chapter, cells were encapsulated in alginate and then transferred in tissue
with HepG2-CM for three days. After that, media was replaced with osteogenic media 
containing b-GP and AA. There were two
cultured in tissue culture flasks in static configuratio
cultured in the RWV perfusion bioreactor. On day 21 of the experiment, osteogenic media was 
further supplemented with Dex 
were collected from static and perfusion cultures to perform, either on the same day or later, a 
number of different analyses and evaluate the differentiation status of the cells.
 
 
 
Figure 4.5: The protocol
 
 
 
 
In this PhD project, a custom made 
experimental procedures. This bioreactor combined the advantages and disadvantages of two 
types of environments: the one generated by the 
culture configuration. Following t
other research groups, static cultures
controls. In order to make the systems comparable, the same 
amount of culture media was employed. This static configuration is widely employed by the 
majority of research groups because of the experimental convenience. 
 
differentiation of ESCs comprises of 29 days of different
mineralisation 
; Mori et al., 1999; Yamanouchi et al., 2001
 experimental groups. The first grou
n and the second group composed
for the last week of culture (Figure 4.5). Once per week samples 
 
 employed for osteogenic differentiation 
RWV perfusion bioreactor was employed for the 
RWV and the one created by the perfusion 
he example of previous people working in the lab and also of 
, performed in tissue culture flasks
number of hydrogels and the same 
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in various cell 
). 
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p included beads 
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of mESCs 
, were employed as 
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However, it is not an accurate and good control that is really comparable with the dynamic 
configuration. It would be more appropriate to employ the same culture platform, the bioreactor, 
for both conditions and culture the hydrogels inside in static configuration. Culturing the cells in 
the same environment would offer more comparable conditions. Based on that, it would be 
appropriate for the performed experiments to have two separate controls. One for the RWV 
would be hydrogels in the bioreactor vessel cultured as a static non-rotating control and another 
one for the perfusion would be hydrogels cultured in the vessel with rotation but without 
perfusion.  
Simple PCR analysis and gel electrophoresis were performed to evaluate the pluripotent status of 
the cells in the beginning of the experiment and to follow the initial profile of gene expression 
and the time line of differentiation during the early culture period. MESCs grew in the presence 
of LIF to maintain their pluripotent status. As soon as LIF was removed from the culture media, 
mESCs started rapidly decreasing the expression of pluripotency markers and increasing the 
expression of lineage markers (Trott and Martinez Arias, 2013). 
Nanog and Rex1 are two well-known markers of pluripotency. Results from gel electrophoresis 
(Figure 4.6) indicated that these two markers were highly expressed in both culture 
configurations the first six days and they started to decrease by day 12 where the bands were less 
intense. Starting from day six and increased by day 12, there was expression of the epiblast-
affiliated gene Fgf5. Fgf5 has been shown to start its expression when Rex1 expression starts to 
decrease (Haub and Goldfarb, 1991; Hebert et al., 1991; Rogers et al., 1991; Trott et al., 2012). 
Rex1 is a marker of naïve population of ESCs while Fgf5 is a marker of primed population of 
ESCs (Nichols and Smith, 2009; Yeo et al., 2013).  
Gata4 is a marker of visceral endoderm and Brachyury T a marker of mesoderm, the first germ 
layers to be formed. Results obtained from the analysis of the experiment indicated that these 
markers started to be expressed on day 12. Finally, COL 1 is an early marker of osteogenic 
differentiation and the most abundant matrix protein. It started to be expressed on day 12 for 
both culture configurations. In static culture, there was a brighter band compared to the perfusion 
indicating a higher level of expression at this time point. This result indicated a delayed 
expression of COL 1 in perfusion culture in comparison to static.  
Gapdh was used as a housekeeping gene and its expression was stable at all tested time points. 
Negative controls were performed for all the tested genes.  
In the obtained photos of the results from the gel electrophoresis, it is not easy to observe and 
distinguish the suggested decrease and increase in the expression of the genes from the acquired 
bands. Moreover, there are no data obtained from time points after day 12. However, for 
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confirmation of the above results, there are gene expression data from these markers obtained 
with qRT-PCR from Dr Jae Min Cha who was working previously in the lab. He tested the 
expression of these markers on day 6 and day 11 and observed the suggested decrease in the 
expression of Nanog and Rex1 and increase in the one of Fgf5 (Appendix 5). 
 
GENES 
Day 2 Day 6 Day 12 
NEG 
Static Bioreactor  Static Bioreactor Static Bioreactor 
Nanog      
123 bp 
 
Rex 1        
127 bp 
Fgf 5           
235 bp 
Gata 4       
571 bp 
Brachyury T 
116 bp 
COL 1 
 165 bp 
GAPDH   
145 bp 
 
Figure 4.6: Gene expression results after gel electrophoresis 
 
 
 
DNA quantification was used as an indirect method to calculate cell numbers (Figure 4.7). Cells 
cultured in the perfusion bioreactor showed higher proliferation rate resulting in higher cell 
numbers throughout the whole duration of the experiment. This finding confirmed previous 
results from other research groups who observed improved cell proliferation in the perfusion 
culture (de Peppo et al., 2013a; de Peppo et al., 2013b; Zhao and Ma, 2005). This outcome was 
expected, as the perfusion bioreactor offers a more favorable environment for the expansion of 
these cells, with continuous supply of fresh media and removal of metabolites. The experiment 
started with 20.000 cells per bead, which proliferated and reached their maximum number after 
one week of culture in both tested platforms. Static culture achieved around 100.000 cells/bead 
while perfusion culture reached a bit more than 200.000 cells/bead. After the first week of the 
experiment, in static culture cell numbers maintained the same density until the end of the 
 culture. On the other hand, in the perfusion culture cell 
then, there was a small increase on day 29 where they reach
cells/bead.   
 
Figure 4.7: DNA quantification throughout the 29 days of the experiment. Comparison was 
performed between static and dynamic
statistical analysis. Asterisks        
difference between these time points
0.05 and shows that there is statistically significant difference between
within the same time point. Values are mean ± 
 
 
The important thing to consider was that 
This finding suggested that there was a heterogeneous cell populati
to Dex. This population consisted of progenitor cells and of more mature cells. The majority of 
the cells completed the osteogenic process and 
were probably still some not fully differentiated cells, which continued t
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ALP was measured biochemically during the 29 days of the experiment and comparison was 
made between perfusion and static 3D culture configuration. By day 7, both platforms achieved 
similar and maximum amount of ALP activity. After that, in perfusion culture, ALP activity 
maintained the same high level until day 21 and marked a small decrease by day 29. In static 
culture, ALP activity gradually decreased until day 21 and marked a small increase by the end, 
on day 29.  
DNA quantification was also used to estimate cell numbers throughout the 29 days of the 
experiment. In both platforms, experiments started with the same number of cells. By day 7, both 
cultures proliferated and reached maximum cell density with perfusion achieving double the 
amount of cells compared to static. In perfusion configuration, cell numbers remained the same 
as day 7 throughout the whole experiment. In static configuration, cell density maintained the 
same high amount until day 21 and marked a small increase by day 29.  
ALP activity was subsequently converted to concentration units and expressed as μM and 
divided with the cell numbers at each time point. Based on the previous mentioned results, 
normalized ALP throughout the experiment indicated the expression profile presented in Figure 
4.9 where in perfusion bioreactor, ALP was maximized by day 7 and then maintained the same 
amount until day 21 and marked a small drop in the end on day 29 whereas in static culture, ALP 
reached maximum activity by day 7 which maintained until day 14, followed by a drop on day 
21 and marking again an increase in the end by day 29.  
In order to make ALP results more clear, it is important to examine the tested cell population. To 
be more specific, initial cells were pluripotent mESCs characterized by high proliferative 
capacity and high ALP activity. These cells decrease ALP expression as they proceed towards 
differentiation. Moreover, the aim of this project was to differentiate mESCS into osteoblast 
cells, which are characterized by high ALP expression. Based on this information, different cell 
populations can be distinguished in Figure 4.9. To be more specific, in the bioreactor cells 
maintained their pluripotent stage for longer and by day 29 decreased ALP activity suggesting 
the development of a more progenitor phenotype. On the other hand, in static platform cells 
started decreasing ALP expression earlier, by day 21, indicating the transition to the progenitor 
stage and subsequently, by day 29 ALP was increased again suggesting the progression to the 
osteoblast lineage.  
The above results showed the existence and maintenance of progenitor osteoblastic cells in 
perfusion culture while cells in static configuration were in a more advanced stage of 
differentiation towards maturation.    
 Mineralisation capacity was the next thing to be analysed. 
deposition (Figure 4.10). For both culture configurations, there was statistically significant 
increase from day 21 to day 29 as expected. Both 
deposition on day 21 but perfusion culture
day 29 compared to static configuration. 
 
 
 
Figure 4.10: ARS was used to evaluate 
static and dynamic culture configuration
used for statistical analysis. Asterisk
significant difference between the two tested platforms within the same time point. Asterisks 
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time points within the same platform
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HA deposition by day 29 was confirmed by FTIR imaging. Images present the distribution of the 
integrated absorbance of the HA band at ~ 1030 cm
-1
, where red indicates higher abundance. 
Quantitative comparisons could not be made at this point. ATR-FTIR analysis showed distinct 
peaks of phosphate and carbonyl, indicating mineralised calcium/phosphate formation, which is 
major component of bone mineral (Hunter and Goldberg, 1993).  
FTIR spectroscopic imaging has significant advantages compared to many other imaging 
methods for the characterisation of biomedical materials because it relies on the characteristic 
absorbance of corresponding molecular vibrations in the sample. Therefore, FTIR imaging does 
not require the use of added dyes or labelling methods for visualisation of different chemical 
components in the sample.  
The three major IR-spectroscopic sampling modes are transmission, transflection and attenuated 
total reflection (ATR). Each mode offers convenience for some samples and challenges for 
others (Baker et al., 2014).    
FTIR imaging using ATR mode represents a complementary approach to the use of FTIR 
imaging in transmission or reflection modes. One of the key advantages of ATR-FTIR imaging 
is that it requires minimal or no sample preparation prior to spectral measurements. This is due 
to the fact that the penetration depth of IR light in the sample for ATR measurements is 
independent of sample thickness. Consequently, this approach is particularly suitable to measure 
substances with strong infrared absorption such as water. Significantly enhanced spatial 
resolution was also achieved (Kazarian and Chan, 2006). 
Furthermore, in order to observe cell distribution within the constructs, photos of two hydrogels, 
one from perfusion and one from static culture, both using Dex in their differentiation protocol, 
were acquired under the light microscope on day 21 (Figure 4.12) and are presented in the 
following section. 
From the photos presented in Figure 4.12, bigger and more homogenously distributed colonies 
can be distinguished in the perfusion culture compared to static. Moreover, fewer cells were 
observed in static configuration, probably due to the existence of necrotic parts, which are not 
easy to see in the above photos.  
However, results from live-dead analysis, obtained by Dr Wesley Liam Randle indicated that in 
3D static culture configuration, there were large pieces of viable tissue that had numerous 
necrotic areas by day 29 (Randle, 2006) (Appendix 4).  
Moreover, results from different research groups indicated that engineered constructs cultured 
under static conditions, where culture media is not properly mixed, are frequently 
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inhomogeneous in structure and composition, containing a hypoxic necrotic central region and 
dense layers of viable cells encapsulating the construct periphery (Wendt et al., 2005). When 
formed in static cultures, usually in tissue culture flasks, agglomerated large EBs revealed 
extensive cell death and eventually large necrotic centers due to mass transport limitations 
(Gerecht-Nir et al., 2004).  
 
 
                                                                BIOREACTOR     STATIC 
 
Figure 4.12: Light microscopy images of encapsulated mESCS within one alginate hydrogel 
from perfusion bioreactor (a, c, e) and one from static configuration (b, d, f) at different 
magnifications acquired on day 21. Scale bar is 1000μm for the images a and b and 200μm for 
the images c, d, e and f. 
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 Finally, gene expression analysis 
2001). The housekeeping gene RPL27 was
several bone markers was tested in order to get some quantitative information and obtain a 
complete image of the osteogenic differentiation process followed by the mESCs when cultured 
under the influence of Dex.  
ALP is one of the most important enzymes to participate in osteogenic differentiation and 
subsequent mineralisation. For this reason, apart from the biochemical analysis, it was also tested 
fot its gene expression profile (Figure 4.13
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Figure 4.13: Gene expression of 
culture configuration and among day 21 and day 29. One
analysis. Asterisk      indicates p < 0.05 and shows that there is statistically significant difference 
between these samples. Values are mean ± 
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Figure 4.14:  Gene expression analysis of the transcription factors Runx2 and 
was performed between static and 
Two-way ANOVA was used for statistical analysis. Asterisk
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Figure 4.16: Gene expression of 
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Figure 4.17: Gene expression of 
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Figure 4.18: Gene expression of 
culture configuration and among day 21 and day 29. One
analysis. Asterisk        indicates p < 0.05 and shows that there is statistically significant 
difference between these samples.
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4.5 Discussion and conclusions    
 
 
 
The primary aim of this chapter was to test traditional and widely employed, by many research 
groups, protocols for osteogenic differentiation of mESCs (Buttery et al., 2001; Sottile et al., 
2003; zur Nieden et al., 2003). The majority of these protocols, after initial expansion, goes 
through the step of EB formation and ends up with bone nodule formation and mineralization.  
EBs are aggregates grown in suspension and contain cells from all the three germ layers (Figure 
4.2). They recapitulate early aspects of embryonic development. EB formation is considered an 
essential part for the proper osteogenic differentiation and it constitutes one of the major steps in 
various protocols. However, it has been recognised that it poses a high risk of spontaneous 
differentiation and makes difficult to direct cell differentiation towards the desired cell type 
(Kurosawa, 2007). 
For this reason, the recent years, many research groups looked for alternative ways to avoid the 
EB formation step in order to reduce the risk of spontaneous differentiation into cell types beside 
the desired one. In particular, it has been shown from previous people in the group that the use of 
HepG2-CM could bypass the EB formation and could enhance osteogenic differentiation 
(Hwang et al., 2006). HepG2-CM has been also indicated to enhance both cell proliferation and 
cell growth (Hwang et al., 2006; Kim et al., 2012).  
A commonly used protocol for osteodifferentiation is the DAG, consisting of Dex, AA and b-
GP. The steroid Dex is a widely used chemical to promote osteogenic differentiation and 
mineralisation. It has been shown to be more efficient when supplied at a late time during the 
differentiation (Buttery et al., 2001).  
Based on the above information, a novel protocol was generated by previous colleagues in the 
laboratory and was employed for the osteogenic differentiation of mESCs during the performed 
experiments (Figure 4.5). 3D configuration was tested and comparison was performed between 
static and dynamic culture. In particular, cells were encapsulated in alginate hydrogels and 
cultured either in tissue culture flasks or in a custom made RWV perfusion bioreactor developed 
in the Biological Systems Engineering Laboratory (BSEL) at Imperial College London.  
DNA quantification, confirming previous observations by other research groups (Akmal et al., 
2006; Crabbe et al., 2015; Song et al., 2008), supported enhanced proliferation rate of the cells 
cultured within the RWV bioreactor compared to the ones in static, resulting in higher cell 
densities achieved by the end of the experiment (Figure 4.7). This is due to the environment 
provided by the perfusion bioreactor, by continuous supplying fresh media and removing 
metabolites. It is important to take into account the fact that the experimental procedure started 
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with a pluripotent population of stem cells characterized by high proliferation capacity while 
later during the culture, cells began acquiring the osteoblast phenotype which has limited 
proliferation ability if it includes progenitor cells or even no proliferation capacity referring to 
the mature phenotype (Bernhardt et al., 2011). 
ALP activity was evaluated to estimate osteogenic differentiation and results indicated that 
continuous perfusion maintained high and similar ALP activity throughout the whole 
experimental procedure (Figure 4.8), thus confirming previous findings from other research 
groups which noticed that perfusion culture enhanced ALP activity in comparison to static 
control (Bernhardt et al., 2011; Wang et al., 2003), a fact that confirms the validity and accuracy 
of the obtained results.  
Following that, ARS analysis indicated significantly higher calcium deposition in the bioreactor 
platform compared to static configuration, something that has been previously supported by 
other research groups as well (Yu et al., 2004; Zhang et al., 2009) (Figure 4.10). Further 
confirmation of the apatitic nature of the observed mineral was provided through ATR-FTIR 
analysis, which indicated the presence of HA in the hydrogels (Figure 4.11). 
Finally, gene expression analysis during the early and late stage of mESCs osteogenic 
differentiation provided significant information regarding the gene profile during the followed 
procedure. It has been indicated that removal of LIF from the culture media allowed the 
generation of precursors representative of all three germ layers (Desbaillets et al., 2000; 
Mansergh et al., 2009). Cells gradually became less naïve and more primed by reducing the 
expression of pluripotent markers and at the same time increasing the expression of markers of 
the first germ layers that would be formed (Karwacki-Neisius et al., 2013). 
Following the above information, similar findings were observed in the performed experiments 
(Figure 4.6).  
Pluripotent markers Nanog and Rex1 were highly expressed during the first days of the culture 
and they gradually downregulated their expression. At the same time, epiblast marker Fgf5 and 
germ layer markers Gata4 and Brachyury T started to be expressed followed by markers of early 
bone formation, such as COL 1.  
The expression of characteristic bone markers was also evaluated during the last week of culture 
and comparison was performed between 3D static and dynamic culture configuration.  
Following biochemical analysis, the gene expression of ALP was initially tested (Figure 4.13) 
and results indicated significantly higher expression level in the bioreactor compared to the low 
level in static configuration at both tested time points. These findings followed the trend of the 
biochemical results, but it is important to consider that changes in gene expression would need 
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more time to occur (Chechik and Koller, 2009) and they are also influenced by the potential 
existence of metabolic stress (Yeo et al., 2013). Similar results supporting the idea that perfusion 
culture enhanced ALP activity in comparison to static were observed previously by other 
research groups (Bancroft et al., 2002; Gomes et al., 2003; Sikavitsas et al., 2003).  
Moreover, it is important to consider that different cell types appear during the experiment. 
Pluripotent mESCs, which are characterized by high ALP, exist in the beginning of the culture. 
There is a gradual transition to the progenitor phenotype and subsequent differentiation towards 
osteoblastic cells, which are also characterized by high ALP. Discrepancies between biochemical 
and genetic results of ALP have been observed by other research groups as well. To be more 
specific, Liao and his colleagues tested ALP activity on day 10 and day 20 and while there was 
an upregulation in the gene expression, the biochemical results marked a decrease during the 
same time (Liao et al., 2013). Similar findings supported by Datta and his collegues who 
examined ALP on day 3 and day 7 between two different scaffolds and they observed an 
increase in the biochemical activity and a reduction in the gene expression during the same time 
points. They suggested that genetic expression occurred earlier in one of the scaffolds compared 
to the other (Datta et al., 2013). Finally, Hoemann and his colleagues noted that levels of ALP 
activity are not proportional to the mineralisation process (Hoemann et al., 2009). 
Gene expression of the transcription factors Runx2 and OSX was then examined (Figure 4.14). 
They are considered the most important factors which drive osteogenic differentiation and 
research suggested that OSX acts downstream of Runx2. Results acquired from the experiments 
indicated expression of these genes on day 29 for both configurations, with higher level in the 
bioreactor in comparison to static culture. Similar observations, indicating increased expression 
of these early stage markers in dynamic culture have been noticed previously by other groups 
(Cartmell et al., 2003; Mygind et al., 2007). 
The expression of COL 1 and BMP2 early stage bone markers was then tested (Figure 4.15). 
COL 1 is the most abundant bone matrix protein while BMP2 is considered the strongest 
osteoinductive factor. The expression of COL 1 was significantly higher in static culture 
compared to the bioreactor. Similar observation was made by another research group which 
noticed significant decrease of COL 1 expression in the groups cultured in the bioreactor in 
comparison to the static control group (Plunkett et al., 2010). BMP2 expression was upregulated 
in static culture at an earlier time point, something that has been observed previously by another 
research group (Bjerre et al., 2008; Stiehler et al., 2009). 
Gene expression analysis continued with the late stage markers of mature osteoblasts, OCN and 
BSP (Figure 4.16) which both indicated significantly higher expression in the bioreactor 
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compared to static culture. These results suggested a better support of osteogenic differentiation 
and an enhanced expression of the late stage markers by the perfusion bioreactor culture in 
comparison to the static, due to the significantly lower expression levels achieved. Similar 
findings were noticed by other research groups, which supported the increased expression of 
OCN and BSP in dynamic culture configuration (Mygind et al., 2007; Rath et al., 2012).  
Finally, the gene expression of two major non-collagenous proteins of bone matrix, OPN (Figure 
4.17) and ON (Figure 4.18) was tested. OPN has been shown to be expressed during the stage of 
active proliferation, decreases immediately after the post-proliferative stage and increases again 
at the onset of mineralisation, achieving the greatest level of expression during mineralisation 
(Lian and Stein, 1995). ON indicated early expression (Stiehler et al., 2009) and decreased when 
cells acquired more mature phenotype. Acquired results supported the late expression profile of 
OPN and the early expression profile of ON.  
To summarize, gene expression outcome indicated a higher expression level of bone proteins in 
perfusion configuration in comparison to static, suggesting the better support of osteogenic 
differentiation in the favorable and well mixing environment created by the RWV perfusion 
bioreactor, with continuous supply of fresh media and removal of metabolites, creating 
metabolically less stressful conditions for cell culture (Yeo et al., 2013). Moreover, dynamic 
culture not only increased the expression of osteogenic markers but also caused a shift and genes 
in the dynamic environment of the bioreactor were peaked earlier than in static cultivation 
(Mygind et al., 2007). The bioreactor also supported high cell numbers and enhanced bone 
formation and mineralisation.  
 
 
To summarize, the important conclusions that can be drawn from this chapter are the following 
ones: 
- 3D bioprocess of mESCs using Hepg2-CM allowed more uniform cell differentiation 
towards mesoderm and production of a more homogeneous cell population. 
- Perfusion platform supported and allowed the generation of high cell numbers. 
- Gene expression analysis suggested that Dex significantly enhanced the expression of 
important bone markers in 3D dynamic culture environment. 
- The well mixing environment offered by the bioreactor enhanced bone formation and 
mineralisation. 
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5th CHAPTER 
5. EVALUATION OF THE USE OF SIM AS AN OSTEOINDUCTIVE FACTOR: 
INITIAL PROBLEMS, OPTIMIZATION OF TIME OF SUPPLEMENTATION AND 
COMBINATION WITH ADHESION MOLECULE  
 
 
5.1 Introduction 
 
Considerable progress has been made in directing the osteogenic differentiation of ESCs. 
However, the exact mechanism of action is not fully elucidated and makes urgent the need to 
develop well-defined protocols that would improve the efficiency of osteogenic differentiation 
and reduce incidents of spontaneous differentiation. Moreover, gene and protein expression 
profiles differ between cell lines making it difficult to create a protocol that could be potentially 
applied to all different cell types (Hwang et al., 2007).  
Widely used osteoinductive factors are BMPs, in particular BMP2 and BMP7. These two 
proteins are also FDA approved for clinical treatment of open tibial shaft fractures and long bone 
nonunions respectively. The problem with these proteins is that in order to be effective in vitro, 
they are supplied in very high super-physiological concentrations. They have also suspicion of 
carcinogenicity and they need appropriate carriers. Moreover, one significant issue with these 
proteins is their high cost due to the recombinant technology applied for their production. For 
these reasons, an alternative osteoinductive factor is needed that would replace the use of BMPs. 
Dex is a steroid commonly used for osteogenic differentiation and it has been shown to enhance 
osteogenic differentiation and mineralisation (Mikami et al., 2007; Song et al., 2009). It is not as 
efficient as BMPs though and as a steroid, it can have some uncontrolled side effects.  
Based on these observations, Mundy and his group in 1999 had the idea to try to find a small 
molecule that could activate the promoter of BMP2 gene and enhance osteogenic differentiation. 
They examined a collection of natural products and identified the statin lovastatin as the 
candidate to have this function. Statins are widely used drugs to lower cholesterol and prevent 
cardiovascular diseases. They inhibit the synthesis of the enzyme HMG Co-A reductase. There 
are lipophilic and hydrophilic statins. Lipophilic statin Sim was used in these experiments 
because it could cross the cell membrane with passive diffusion.  
Statins have another interesting characteristic that should be taken into account. They have been 
shown to inhibit cell cycle progression by blocking events critical for G1/S transition (Sala et al., 
2008). In the literature, there are examples of this mechanism on mouse fibroblasts (Vogt et al., 
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1996) and on glioma cells (Crick et al., 1998). Another possible mechanism is also the induction 
of apoptosis, for example in vascular smooth muscle cells (Blanco-Colio et al., 2002; Buemi et 
al., 1999). In a more recent study, statins inhibited the proliferation and led to loss of self-
renewal capacity of mESCs (Lee et al., 2007b). For this reason, statins need to be supplemented 
in the culture media at specific time point during cell culture, after cells have completed 
proliferation and reached the desired number. 
Statins have been also used as anticancer agents based on preclinical evidence of their anti-
proliferative, pro-apoptotic, anti-invasive and radio-sensitizing properties (Chan et al., 2003). 
They have been shown to induce anti-proliferative effects in various cancer cells (Ishikawa et al., 
2014) or to inhibit tumor cell proliferation and to induce apoptosis (Graaf et al., 2004). These 
antitumor effects result in retardation of tumor growth and/or inhibition of the metastatic process 
(Jakobisiak and Golab, 2003). To summarize, antitumor effects of statins include growth 
inhibition caused by cell cycle arrest and the induction of apoptosis, the reduction of metastatic 
potential, the inhibition of angiogenesis and the differentiation of tumors (Osmak, 2012). 
Finally, cell adhesion molecules are well known factors used for coating plates in order to 
improve cell adherence and help to study in vitro cell-ECM interactions (Kuschel et al., 2006). 
Controlled cell adhesion to the ECM is essential for coordinated morphogenesis and growth of 
functional tissue during embryonic development, tissue differentiation and regeneration (Albelda 
and Buck, 1990). ECM receptors of the integrin family have been implicated as important 
regulators of the proper development of various tissues. Integrins have as main function to 
properly regulate the balance between proliferation and differentiation (Watt, 2002). Integrins 
have been implicated in bone development, regulating bone remodeling and influencing the 
expression of differentiation-related genes (Danen and Sonnenberg, 2003).  
One of these molecules belonging to the integrin family is fibronectin. It is widely used for 
coating surfaces for various adherent cells. Fibronectin contains the RGD peptide, which is the 
main area that cells bind to. Fibronectin has been shown recently from previous people in the 
group to also enhance osteogenic differentiation of mESCs (Kang et al., 2015). To take it one 
step further, fibronectin coating in 2D culture plates was tested together with Sim media to 
evaluate if this protocol could ameliorate osteogenic differentiation.  
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5.2 Aim and Objectives 
 
 
The aim of this chapter was to try the efficacy of Sim as an osteoinductive factor in performing 
osteogenic differentiation of mESCs.  
 
 
In particular: 
 
 
1. To establish a new protocol for osteogenic differentiation using the small molecule Sim. 
 
2. To combine the Sim protocol with fibronectin adhesion molecule and evaluate if there is 
improvement in osteogenic differentiation. 
 
 
 
5.3 Methodology 
 
 
Following previously published data from the group (Pagkalos et al., 2010), Sim was tested in 
2D and 3D static culture in six well plates. Different analyses to evaluate osteogenesis were 
performed including ALP for osteodifferentiation and ARS for mineralisation. The next step was 
to find the optimal time to supplement Sim in the culture media in order to get higher osteogenic 
differentiation and mineralisation without significant reduction in cells numbers. Two different 
time points were tested and evaluation was performed based on ALP and ARS analysis both in 
2D and 3D static configuration. The time points tested were day 21 and day 14. The choice of 
day 21 was based on the currently used traditional protocol where Dex was supplied in the media 
on day 21 because it has been shown to have better outcome when supplemented in the culture 
media later in the differentiation process. Day 14 was chosen based on the general osteogenic 
process followed by mESCs, the different stages and time needed for each of them.  
The idea was based on the three stages followed by the cells in order to differentiate. Cell 
expansion was initially performed, followed by matrix formation to support subsequent 
osteogenic differentiation and mineralisation. Based on previous results from DNA 
quantification, mESCs proliferated and reached maximum numbers after one week of culture 
and then started synthesising bone matrix to support subsequent bone formation and 
mineralisation. Thinking that cells were quite stable after having started synthesising bone 
matrix, this was the reason for the choice of day 14.  
 Finally, following recently published data from the group 
intention to improve more this osteogenic differentiation protocol, 
molecule fibronectin was tested in 2D culture and compared with the currently used molecule for 
coating, gelatin. Media containing 
fibronectin was based on the analysis of the co
indicated the significant role this molecule played in mesoderm induction 
 
 
5.4 Results 
 
 
5.4.1 CHEMICAL OSTEOINDUCTION USING SIM
CONFIGURATION: EMERGING PROBLEMS
 
 
In this chapter, the aim was to try a new promising osteoinductive factor, 
possibility to replace Dex. Following published data 
culture of mESCs took place in six well plates where the
was followed. The first three days
with osteogenic media supplemented with b
differentiation protocol with Dex
 
 
Figure 5.1: The two protocols followed in these experiments:
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Figure 5.2: ARS in 2D culture 
Comparison was performed between 
was used for statistical analysis. 
significant difference between the two chemicals within the same time point while asterisk
p < 0.05 and shows that there is statistically significant difference between the two tested time points
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Using the same protocol, 3D static culture was also performed. The results of ARS were similar 
to the 2D culture after quantification; 
comparison to the Dex protocol 
 
Figure 5.3: Quantification of ARS 
and Dex protocol, on day 21 and day 29. Two
        indicates p < 0.05 and shows that
chemicals within the same time point while asterisk
statistically significant difference between the two tested time points within 
 
Next analysis was to test for ALP activity, the most important marker of bone formation 
5.4). Biochemical analysis revealed that ALP in the 
week of culture but after that exhibited a significant reduction un
0
0,01
0,02
0,03
0,04
0,05
0,06
Le
ve
l o
f m
in
er
al
iz
at
io
n 
de
po
si
tio
n
Ab
so
rb
an
ce
 4
05
 n
m
Dexamethasone Simvastatin
a 
numbers
 
     
 
configuration (a). Obtained results after quantification of 
Sim and Dex protocol, on day 21 and day 29. Two
Asterisk      indicates p < 0.05 and shows that there is statistically 
calcium deposition in the Sim protocol was lower in 
(Figure 5.3). 
 
 
 
in 3D static configuration. Comparison was performed between 
-way ANOVA was used for statistical analysis. 
 there is statistically significant difference between the two 
       indicates p < 0.05 and shows that there is 
Dex group.
Sim-containing wells increased the first 
til the end of the experiment on 
0
0,5
1
1,5
2
2,5
3
day 21 day 29Le
ve
l o
f m
in
er
al
iza
tio
n 
de
po
sit
io
n
Ab
so
rb
an
ce
 4
05
 n
m
day 21 day 29
 
139 
 were very low and 
 
ARS (b). 
-way ANOVA 
        indicates 
 
 
Sim 
Asterisk  
 
(Figure 
simvastatin
dexamethason
e
simvastatin
dexamethasone
b 
SIM 
DEX 
 
SIM 
DEX 
 day 29. On the other hand, in the 
and maintained the same high level throughout the whole experimental period. 
 
Figure 5.4: ALP activity in 2D culture configuration throughout the 29 days of the experiment. 
Comparison was performed between 
analysis. Asterisk        indicates p < 0.05 and shows that there is statistically
between the two chemicals within the same time point while asterisk
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ALP activity was also tested in 3D static culture for both protocols 
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Figure 5.5: ALP activity in 3D static configuration throughout the 29 days of the experiment. 
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 Dex was provided in the osteogenic media on day 21 and for the last week of culture. Such 
protocol allowed time for the cells to proliferate and gradually change their phenotype to 
osteoblastic one, which was induced even more by 
culture media. This means that on the obtained results, on day 14 and day 21 there was no 
the osteogenic media and as mentioned previously, ALP activity was due to the extracellular 
phosphate provided in the culture media through b
the culture media from day 4 of culture, following a previously published protocol 
al., 2010) and induced earlier osteogenic cell differentiation without allowing cells to reach high 
cell numbers and acquire a more stable phenotype after matrix synthesis. 
indicated to act as cell-cycle inhibitor 
(Ahmed et al., 2013; Crosbie et al., 2013
2010). The obtained results indicate
The previous finding suggested that 3D culture configuration better supported the osteogenic 
differentiation of the cells and helped them not to experience the negative effects of 
severe and probably lethal way. 
Finally, to evaluate the effects of 
(Figure 5.6) and DNA quantification on 3D static 
Cells cultured with Sim exhibited lower proliferation rate
throughout the whole duration of the experiment as shown from the lower values obtained from 
optical density measurements.  
 
Figure 5.6: MTS in 2D culture configuration throughout the 29 days of the experiment. Comparison was 
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 In the beads from 3D static culture DNA quantification was performed as a more accurate and 
reliable measurement of cell growth. DNA is more stable
that used in MTS measurement. Similar to the proliferation result
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Figure 5.7: DNA quantification in 3D static configuration throughout the 29 days of the experiment. 
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the two chemicals within the same
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humans (Corsini et al., 1999) and to the concentrations that have been used previously in in vitro 
studies. Specifically, Sim at 10-6 to 10-9 M has been tested on MC3T3-E1 cells (Hwang et al., 
2004; Maeda et al., 2001), human osteoblast-like (hOB) and MG-63 cells (Ruiz-Gaspa et al., 
2007) and bone marrow stromal cells (Baek et al., 2005).   
The reason for this choice was also the fact that based on published data from other research 
groups (Kupcsik et al., 2009; Li et al., 2003; Viereck et al., 2005), the use of higher doses of 
statins, in the micromolar range, was found to be toxic for the cells and to have a negative effect 
on cell viability and proliferation, an effect also observed in Pagkalos experiments (Pagkalos et 
al., 2010). On the other hand, the employed concentration was effective for osteodifferentiation 
as indicated by ARS and ALP results. The tested concentration in the nanomolar scale was low 
enough to induce differentiation without eliciting cell death. Lower amount would probably be 
ineffective.  
To summarize, literature data suggested that statin concentrations in the 10-9 M range should not 
inhibit cellular proliferation and were not toxic to the cells, which corresponded well with the 
optimal Sim concentration (0.1 nM) obtained in the study performed by Pagkalos and his 
collegues. The problem with the observed cell death was not the employed concentration of the 
small molecule but the early time supplemented in the media. For this reason, a short 
optimization on the time of supplementation was performed and the updated protocol included 
addition of Sim on day 14 until the end of the culture.  
 
5.4.2 OPTIMISATION OF TIME OF SUPPLEMENTATION OF SIM IN THE MEDIA 
 
 
Currently employed osteogenic differentiation protocol of mESCs using Dex lasts for 29 days. 
Culture begins with 3 days incubation in HepG2-CM, followed by osteogenic media 
supplemented with b-GP and ascorbate-2-phosphate until day 21, when Dex is added to the 
culture media for the last week of the experiment (Figure 4.5). Based on that protocol, in Figure 
5.8, the timeline of the tested osteogenic differentiation protocol of mESCs with Sim is 
presented. The first 14 days of the protocol are the same. Optimization is related with the 
addition of Sim in the culture media either on day 14 or on day 21 (Table 5.1). An extended 
literature research was performed in order to try to explain the observed outcome. Significant 
information regarding the cell cycle effects that Sim has and its use for cancer cells because of 
this characteristic feature were obtained. The acquired information gave the idea that probably 
Sim should be supplemented in the culture media at a later time point, after cells had proliferated 
and reached high cell numbers, similar to Dex. In order to define the optimal time, a short 
 optimisation experiment with 2 time points
configuration. Similar to the Dex
media for the last week of culture. Day 14 was chosen as an earlier time point that left 
time for the cells to proliferate
indicating a more stable status. To e
analysis were performed as a fast and easy way to get quick 
Figure 5.8: The 29
Table 5.1: The two-tested time points 
PROTOCOL
Protocol
Protocol
 
Analysis of 2D experiment was first performed. ARS was tested on day 21 and day 29 in 2D 
experiment and results revealed similar levels of 
time points and for both protocols tested 
 
 
 
 
      
 
       
Figure 5.9: Quantification of ARS
protocol 2 and protocol 3 of Sim
Asterisks            indicate p < 0.05 and shows that there is statistically significant difference between 
the samples of day 21 and day 29 within the same protocol
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 significantly higher in the protocol 2, where 
protocol 3, where Sim was supplemented on day 
Figure 5.10: ALP activity in 2D culture configuration. Comparison was performed between protocol 
2 and protocol 3 of Sim optimization. One
indicates p < 0.05 and shows that there is statistically significant difference between the tested 
time points within the same group while asterisk      
statistically significant difference between day 21 and the other time p
 
Based on these two analyses in 2D culture, both protocols indicated similar results without any 
major differences. This outcome suggested that earlier supplementati
factor, Sim in that case, generated similar 
observation could potentially lead to the generation of a new, shortened protocol for osteogenic 
differentiation. For this reason, day 14 looked as a good time point
supplementation in the culture media and an optimal protocol to be applied in the future. 
Analysis in 3D static samples was then performed. 
and calcium deposition between the two 
supplementation of Sim can have
for osteogenic differentiation. 
Figure 5.11: Quantification of ARS
protocol 2 and protocol 3 of Sim
Asterisks             indicate p < 0.05 and show
day 21 and day 29 within the same protocol.
0
0,8
1,6
2,4
3,2
4
day7
Al
ka
lin
e P
ho
sp
ha
ta
se
 
Ab
so
rb
an
ce
at
 4
05
nm
0
0,07
0,14
0,21
0,28
Le
ve
l o
f 
m
in
er
al
is
at
io
n 
de
po
si
tio
n
Ab
so
rb
an
ce
 4
05
nm
Sim was supplemented on day 14 in comparison
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 In 3D static culture, ALP was also tested between the two protocols 
configuration, ALP activity was the same between the two protocols until day 21. 
 
Figure 5.12: ALP activity in 3D static configuration throughout the 29 days of the experiment. 
Comparison was performed between protocol 2 and protocol 3 of 
ANOVA was used for statistical analysis. Asterisk      
statistically significant difference between the two protocols within the same time point 
asterisks         indicate p < 0.05 and show 
tested time points within the same protocol
 
 
 
 
 
On day 29, ALP expression was different between the two protocols with protocol 2 maintaining 
the same high expression as day 21 while ALP expression reduced significantly in protocol 3 
where Sim was supplied on day 21. Higher ALP activity suggested
differentiation. 
Based on the above results in 3D culture, the protocol where 
culture looked like the optimal to be used. ARS results didn’t reveal any significant differences 
between the two protocols and ALP suggested a poten
To summarize, the short optimisation in 2D and 3D static configuration indicated that addition of 
Sim in the culture media on day 14 could lead to improved osteogenic differentiation and 
mineralisation of mESCs without affecting cell 
cell cycle.  
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After defining the optimal time to supplement 
one step further and try to improve even more the protocol and get higher osteogenic 
differentiation. Based on recently 
2015), the adhesion molecule fibronectin has
A small trial took place to test this finding
observe the possible outcome. To test 
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as a control and were seeded with mESCs.
first three days. HepG2 was then
until day 14 when the osteogenic media was further supplemented with 
and ALP analysis were used to evaluate osteogenesis and 
ARS test indicated that calcium
compared to gelatin both on day 21 and day 29 
 
 
Figure 5.13: Quantification of 
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for statistical analysis. Asterisk 
significant difference between the tested
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this hypothesis, 2D culture in six
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 The cells were incubated with HepG2
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Sim
mineralisation.  
 deposition was significantly higher in the fibronectin group 
(Figure 5.13). 
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 ALP activity was also measured 
wells, possibly because not the same cell 
the experiment. Experiment would need to be repeated to reach final conclusions and have a 
more clear view of potential osteogenic ability of fibronectin. Optical densities presented in the 
following graph indicated that gelatin coating maintained a high level of ALP throughout the 
whole experiment. Fibronectin coating indicated similar findings apart from the last time point, 
on day 29 where there was reduction in ALP activity.          
Figure 5.14: ALP activity in 2D culture configuration
fibronectin and gelatin coating and for day 21 and day 29
statistical analysis. Asterisk 
significant difference between the two adhesion molecules within the same time point 
asterisk         indicates p < 0.05 and shows 
the tested time points within the same group
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The above preliminary results indicated that fibronectin coating followed the expected ALP 
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it has been supported by several groups previously that ALP expression augments during 
osteoblast maturation but subsequently declines during the osteoid mineralisation phase 
(Kulterer et al., 2007; Liu et al., 2003; Malaval et al., 1999). ALP is often used as an indication 
that cells are undergoing osteogenic lineage specification. The ALP enzyme is an important 
component of osteogenesis, which typically peaks in expression prior to mineralisation 
(Arpornmaeklong et al., 2009; Lian et al., 2006). 
Based on the above information, it can be jutified why fibronectin indicated reduced ALP 
activity and thus, supported better osteogenic differentiation. Moreover, gelatin coating used as a 
control because this is the standard way mESCs were cultured in the lab so there wouldn’t be a 
proper comparison without a coating material. Finally, it was mentioned that there was much 
heterogeneity between wells based on personal observation and in order to justify the need for 
repeating the analysis. However, results were acquired and analysed only from the wells with 
similar cell attachment.  
 
 
5.5 Discussion and conclusions 
 
In this chapter, the novel osteoinductive factor Sim was evaluated for its ability to enhance 
osteogenesis and potentially replace the use of the steroid Dex. Sim has been shown to increase 
BMP2 expression. It is also a relatively safe drug that is widely used to reduce cholesterol. It has 
a number of pleiotropic effects not related to its anti-cholesterol action. Sim has been used in 
clinical trials for reducing cholesterol levels and it has been shown to decrease the risk of bone 
fracture and to enhance bone formation. Following initially a published protocol (Pagkalos et al., 
2010), Sim was supplemented in the culture media on day 4 of culture until the end, on day 29. 
The protocol was tested in 2D and 3D static configuration and comparison was performed with 
the previously described Dex protocol (Figure 5.1).  
Several problems appeared after performing a number of analyses to evaluate the final product. 
ARS indicated the existence of stained bone nodules in the Sim-containing wells but there were 
very few cells in comparison to the Dex-containing wells and also there was no matrix formation 
(Figure 5.2). To further support this outcome, ARS quantification in static culture indicated 
lower calcium deposition in the beads cultured with the Sim protocol compared to those cultured 
with the Dex protocol (Figure 5.3). ALP activity was then evaluated and obtained results 
indicated a significant low level of ALP after Sim treatment compared Dex treatment suggesting 
a non-favorable environment created by Sim (Figures 5.4 – 5.5).  
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MTS in 2D (Figure 5.6) and DNA quantification in 3D (Figure 5.7) were employed to evaluate 
cell proliferation. In both culture configurations, there was significantly lower proliferation rate 
in the cells cultured with Sim compared to the cells cultured with Dex throughout the whole 
experiment. It is important to take into account two facts. In 2D culture, there was not much 
space for the cells to grow and they reached confluence much faster compared to 3D culture. 2D 
configuration could not support high cell numbers. Moreover, MTS is a test based on metabolic 
activity and the initial cell population was comprised of mESCs with high proliferation potential 
while in the end, there should be osteoblast-like cells, which had very low or no proliferation 
capacity at all. Metabolic activity would probably be different between these two cell types. 
Another important thing to notice was the fact that static culture was not promoting high cell 
numbers because of the limitations related to fresh media supply and removal of metabolites. 
Extended literature research was performed to identify the source of the problem. It has been 
indicated that statins inhibit cell cycle (Forero-Pena and Gutierrez, 2013; Liao, 2002; Sala et al., 
2008). They are also employed with cancer cell lines. However, statins have been also shown to 
enhance bone formation both in vivo and in vitro (Edwards and Spector, 2002; Garrett and 
Mundy, 2002). Based on the above information, it seemed a good idea to first allow cells to grow 
and proliferate reaching a high cell density and start synthesizing bone matrix before providing 
the necessary signals to guide them towards osteogenic differentiation.  
As it was described in the Materials and Methods section, a short optimization was performed to 
define the optimal time of supplementation of Sim in the culture media, with the use of two time 
points, day 14 and day 21; their choice was explained previously. Evaluation of the outcome was 
based on ARS and ALP analysis both in 2D and 3D static configuration (Figures 5.9, 5.10, 5.11, 
5.12). The obtained results suggested that there was not a big difference between the two time 
points and the supplementation of Sim on day 14 of culture seemed a good time point that 
allowed enough time for the cells to grow, proliferate and start matrix synthesis before force 
them to go through differentiation and mineralisation. In this way, the time of 
osteodifferentiation could be reduced to less than 29 days, but this is something to be tested in 
the future if there is adequate time. 
Finally, to take the protocol one step further and try to improve more osteogenic differentiation, 
recently published data from previous people in the lab were evaluated (Kang et al., 2015). 
These data suggested that the adhesion molecule fibronectin enhanced osteogenic differentiation 
of mESCs. Trying to confirm those results and improve them even more, 2D culture was 
performed using the new Sim protocol and coating the six-well plates with fibronectin. There 
were also wells coated with gelatin as a control. ARS indicated higher calcium deposition 
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(Figure 5.13) and ALP showed the expected time-dependent expression profile (Figure 5.14) on 
the fibronectin-coated wells suggesting potential improvement in the osteogenic differentiation.  
The composition of the ECM substrate and the existing integrins in vitro can determine cell fate 
and in particular, the important role of ECM cell adhesion molecules in osteogenic 
differentiation has been previously indicated (Gattazzo et al., 2014; Lavenus et al., 2011).  
It has been indicated that plating ES cells on laminin or fibronectin induces differentiation, 
whereas self-renewal is maintained when the cells are plated on type I or type IV collagen 
substrates (Hayashi et al., 2007). Laminin-322 stimulates osteogenic differentiation of MSCs, 
whereas laminin-111 promotes neural differentiation (Klees et al., 2005; Klees et al., 2007; 
Mruthyunjaya et al., 2010). In adult stem cells, fibronectin can promote differentiation along 
skeletal lineages while suppressing adipogenic differentiation (Martino et al., 2009; Ogura et al., 
2004; Wang et al., 2010). Moursi and his colleagues indicated that the a5b1 integrin mediates the 
binding of osteoblasts to fibronectin and is required for osteogenic differentiation, suggesting a 
pivotal role of fibronectin in osteoblast differentiation (Moursi et al., 1997).  
Salasznyk and his colleagues demonstrated that even though hMSCs can adhere to various 
ECM-coated substrates (COL 1, fibronectin, vitronectin and COL IV), the greatest osteogenic 
differentiation occurs among cells plated on vitronectin and COL 1 (Salasznyk et al., 2004). 
Rowlands and his colleagues (Rowlands et al., 2008) used MSCs and investigated the osteogenic 
potential of various substrates coated with covalently bound tissue-specific ECM proteins (COL 
1, COL IV, laminin or fibronectin). Higher osteogenic differentiation was supported by COL 1 
coating probably due to the fact that it better mimics the in vivo environment of bone formation.  
To summarize, a new protocol for osteogenic differentiation of mESCs was developed in this 
chapter. The protocol comprised 29 days in total, starting with 3 days incubation in HepG2-CM 
followed by osteogenic media supplemented with b-GP and ascorbate-2-phosphate and further 
supplementation with Sim on day 14 until the end of the culture. Moreover, there were 
indications that potential combination of Sim in the culture media with the adhesion molecule 
fibronectin could enhance osteogenic differentiation.  
 
To summarize, the major conclusions that could be drawn from this chapter are the following 
ones: 
- Sim can be an effective osteoinductive factor when applied at specific time points during 
cell growth and differentiation.  
- The employment of fibronectin as an adhesion molecule shows indication of enhanced 
osteogenic differentiation. 
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6th CHAPTER 
 
 
 
6. 3D BIOPROCESS OF MESCS TOWARDS OSTEOGENESIS USING SIM: 
COMPARISON OF FED-BATCH VS PERFUSION CULTURE  
 
 
6.1 Introduction 
 
Sim is a commonly prescribed drug to lower serum cholesterol. It acts by inhibiting HMG-CoA 
reductase, which is the main enzyme involved in the isoprenoid biosynthetic pathway and leads 
in the production of cholesterol. Sim prevents cholesterol synthesis in the liver by increasing the 
number of LDL receptors, which in their turn remove higher amount of plasma LDL cholesterol 
from the circulation (Stancu and Sima, 2001). In addition to the depletion of cholesterol, the 
inhibition of HMG-CoA reductase by statins leads to decreased production of the isoprenoids 
farnesylpyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). Depletion of FPP and 
GGPP, leads to several other pleiotropic effects, which are not related with the anti-cholesterol 
action (Liao and Laufs, 2005; Wang et al., 2008). It interferes with cell cycle and inhibits tumour 
growth and metastasis and for this reason, it has been used for cancer studies. It has been also 
reported to promote angiogenesis. Mundy et al. demonstrated that statins stimulate osteoblast 
differentiation and bone formation through the induction of BMP-2 expression. These results 
have been subsequently supported by several in vitro and in vivo studies, which showed that 
administration of lipophilic statins has been positively correlated with higher BMD in post-
menopausal women (Safaei et al., 2007; Uzzan et al., 2007). Sim has been shown to promote 
fracture healing by enhancing osteoblast formation (Maeda et al., 2001; Mundy et al., 1999; 
Ruiz-Gaspa et al., 2007; Tikiz et al., 2004) and by inhibiting osteoclast activity (McFarlane et 
al., 2002; Staal et al., 2003).  
To our knowledge, this is where the novelty of this project lies. It is the first time where 
Sim is used as an osteoinductive factor supplemented in the osteogenic media in very low 
concentration of the nanomolar scale in a 3D culture for the osteogenic differentiation of 
mESCs encapsulated in alginate hydrogels and cultured in a custom made RWV perfusion 
bioreactor. 
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It is also the first time where extended gene expression analysis, including a number of 
recently discovered transcription factors, is performed in order to evaluate not only the 
osteogenic differentiation of the cells but also to get more insight information regarding the 
followed ossification pathway. The expression of genes from all the three germ layers was 
also tested for the first time to assess the potency of the embryonic cells and if they still 
possess the capacity as progenitors with the appropriate incentive to be differentiated to 
other cell types.  
 
 
 
 
6.2 Aim and Objectives 
 
The aim of this chapter was to test the osteoinductive capacity of Sim in 3D static and perfusion 
culture configuration using the new established protocol after optimisation of the time of 
supplementation of Sim in the culture media. 
 
 
 
In particular: 
 
 
1. To evaluate the efficiency of the newly established protocol with Sim in 3D configuration 
 
2. To compare 3D bioprocess between static and dynamic culture configuration 
 
3. To obtain information regarding the whole differentiation process followed, from the 
initial undifferentiated status, through germ layer formation, up to the final osteogenic 
phenotype. 
 
 
6.3 Methodology 
 
Evaluation of the new optimized protocol for osteodifferentiation using Sim was performed in 
3D static and perfusion culture configuration. A number of analyses were employed to evaluate 
the outcome. DNA quantification helped to calculate the total number of cells at each time point. 
Calcium deposition and mineralisation were tested with ARS and ATR-FTIR. ALP activity was 
measured in order to confirm osteogenesis. Photos of the hydrogels under the microscope were 
 obtained to observe cell morphology. Finally, extended gene expression analysis was performed 
in order to evaluate osteogenic differentiation, to identify the pathway of ossification that was 
followed and also to get some more insight information regarding
the three germ layers.  
 
Figure 6.1: The optimized
 
 
6.4 Results 
 
 
After the short optimization performed in C
supplement Sim in the osteogenic media, experiments to test the efficiency of the new protocol 
were performed in 3D static and perfusion culture. The protocol that was followed consisted of 
29 days, starting with incubation for 3 d
containing b-GP and ascorbate
Sim until the end of the experiment
evaluate the progress of osteogenesis, 
DNA quantification was used as a reliable method to indirectly calculate cell 
time point (Figure 6.2). The experiment started with 20
culture, cells proliferated and reached 
bead and they maintained this number
fold increase in cell numbers 
numbers by day 7, around 200.
14 to less than 100.000 cells per bead but then cell 
150.000 cells per bead. This indica
 the expression of genes from 
 
 protocol for osteogenic differentiation using Sim
hapter 5 in order to identify the best time to 
ays in HepG2-CM, followed by osteogenic
-2-phosphate and finally, on day 14 further supplemented with 
 (Figure 6.1). A number of analyses were performed to 
mineralisation and also possible effects on cell growth. 
.000 cells per bead. In the perfusion 
maximum numbers by day 14, around 400
 until the end of the experiment on day 29
compared to day 0. In static culture, cells reached
000 cells per bead, then there was a significant reduction on day 
numbers recovered and on day 29
ted a 7.5 times fold increase compared to day 0. 
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 These results followed similar observations 
environment of the perfusion bioreactor, with continuous supplementation of fresh media and 
removal of metabolites, increased viability and p
2003; Liu et al., 2012; Wang et al., 2013
 
 
Figure 6.2: DNA quantification throughout the 29 days of the experiment. Comparison was 
performed among dynamic and static culture configuration. Two
statistical analysis. Asterisk 
significant difference between the platforms on the same time point while asterisks 
p < 0.05 and show that there is statistically significant difference between different time points 
within the same platform. 
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the cells was the significant reduction in cell 
assumption for this event was that
confluent state. Due to the fact that media and oxygen transport only took place with simple 
diffusion, it has been proved that static configuration cannot support high cell 
Increased cell death combined with
hydrogels (Appendix 4) could explain 
day, however, Sim was supplemented in the culture media and this event probably activated 
again the proliferation capacity of the cells which were still in a progenitor stage and did not 
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 ALP activity was determined biochemically throughout the experiment in order
progress of osteogenesis (Figure 6.3
with Sim treatment, ALP was maintained in h
experiment, from day 7, where it reached 
contrary, in static culture, ALP activity was 
dropped gradually until day 21 and 
 
 
Figure 6.3: ALP activity throughout the 29 days of the experiment. Comparison was performed 
between static and dynamic culture 
analysis. Asterisk indicates p
difference between the platforms on the same time point
that there is statistically significant difference between different time points within the same 
platform. 
 
 
  
The obtained results indicated that continuous media perfusion maintained high ALP activity 
throughout the whole experimental procedure suggesting that cells in 
progenitor like phenotype. In static culture, there was lower ALP activity but the profile 
followed during time was closer to what was expected to appear with ALP increasing during 
osteoblast differentiation and subsequently 
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 The acquired results were then 
(Figure 6.4). The image of the ALP profile was different now. In many time points tested, static 
culture indicated higher activity because of the 
perfusion culture where increased proliferation resulted in higher cell 
exhibited significantly higher le
was expected if the DNA quantification results would be considered
a significant reduction in cell population in static culture. On day 0 and on day 29, ALP activity 
after normalization with DNA was in similar le
In perfusion culture, normalized ALP exhibited the highest activity on day 7 and then it was 
significantly reduced on the following time points. In static culture, normalized 
highest level, later, on day 14 a
progression to osteogenic differentiation in perfusion culture.
 
 
Figure 6.4: ALP activity normalized with cell 
expressed as μM/cells/min throughout the 29 days of the experiment. Comparison was 
performed between static and dynamic 
statistical analysis. Asterisks    
significant difference between different time points within the same platform
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Figure 6.5: ARS was used to evaluate 
static and dynamic culture configuration and among day 21 and day 29. Two
used for statistical analysis. Asterisk 
statistically significant difference 
indicate p < 0.05 and show that there is statistically significant difference 
and day 29 within the same platform
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HA deposition was confirmed by FTIR imaging. Images present the distribution of the integrated 
absorbance of the HA band at ~ 1030 cm-1, where the red areas indicate field with higher 
concentration of phosphate. Quantitative comparisons could not be made at this point. ATR-
FTIR analysis showed distinct peaks of phosphate and carbonyl, indicating mineralised 
calcium/phosphate formation, which is major component of bone mineral (Hunter and Goldberg, 
1993).  
Photos of two hydrogels, one from perfusion and one from static culture, both using Sim in their 
differentiation protocol, were acquired under the light microscope on day 21 in order to observe 
cell morphology (Figure 6.7). 
 
                                                        BIOREACTOR    STATIC 
 
Figure 6.7: Light microscopy images of encapsulated mESCS within one alginate hydrogel from 
perfusion bioreactor (a, c, e) and one from static configuration (b, d, f) at different 
magnifications acquired on day 21. Scale bar is 1000μm for the images a and b and 200μm for 
the images c, d, e and f. 
a b 
 
c 
 
d 
 
e 
 
f 
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From the photos in Figure 6.7, it can be observed, similar to the previous findings, the better 
colony formation and cell distribution in the perfusion culture compared to static platform. By 
day 21, hydrogels cultured under Sim appeared to have already reached a confluent state, as 
observed under the microscope. To further support that observation, DNA quantification results 
(Figure 6.2) indicated that maximum cell density was achieved by day 14 and maintained until 
the end of the experiment in the bioreactor platform. Moreover, fewer cells were calculated in 
static configuration, probably due to the existence of necrotic parts, which are not easy to see in 
the above photos. However, as mentioned previously, it has been indicated through live-dead 
analysis by Dr Wesley Liam Randle the existence of large pieces of viable tissue that had 
numerous necrotic areas in 3D static culture configuration (Randle, 2006) (Appendix 4). 
Moreover, results from different research groups indicated that engineered constructs cultured 
under static conditions, where culture media is not properly mixed, are frequently 
inhomogeneous in structure and composition, containing a hypoxic necrotic central region and 
dense layers of viable cells encapsulating the construct periphery (Wendt et al., 2005). When 
formed in static cultures, usually in tissue culture flasks, agglomerated large EBs revealed 
extensive cell death and eventually large necrotic centers due to mass transport limitations 
(Gerecht-Nir et al., 2004).  
 
6.4.1 GENE EXPRESSION 
 
Extended gene expression analysis was conducted using the 2-∆∆CT method (Livak and 
Schmittgen, 2001) in order to get information regarding several different things and various 
events that took place throughout the 29 days of the experiment. The expression of bone markers 
was initially tested in order to evaluate the progress of osteogenesis using the Sim protocol, how 
efficient it was and how it could have affected gene expression in a positive or negative manner. 
The housekeeping gene RPL27 was used for normalization (de Jonge et al., 2007). 
Moreover, it is well known that in vivo bone formation takes place via two possible pathways: 
either through intramembranous ossification where mesenchymal cells directly differentiate to 
osteoblasts or through endochondral ossification where mesenchymal cells first condensate and 
create a cartilage template. The template gets invasion from blood vessels, chondrocytes become 
hypertrophic and finally, they differentiate to osteoblasts and start synthesizing bone matrix. In 
order to get information on the pathway followed through 3D culture and with the use of Sim, 
the expression of a number of cartilage and hypertrophic chondrocyte markers was also tested.  
 Finally, to estimate the differentiation status and the potency of the cells on the last week of the 
experiment, on day 21 and day 29, various markers from the three germ layers, mesoderm, 
endoderm and ectoderm, were also tested. In this way, it was intend
were fully and homogenously differentiated towards a mature stage or they had acquired a more 
progenitor phenotype where they could still be tuned to differentiate to any cell type of the three 
germ layers.  
The expression of several bone markers was first tested and the results are presented in the 
following graphs. Comparison was performed between day 21 and day 29 and also between the 
two culture platforms, static versus perfusion. 
The expression of ALP gene was 
significant factors affecting osteogenic differentiation. Experimental results in the bioreactor 
configuration showed that ALP increased 
ALP expression on day 21 was similar to the perfusion but decreased significantly by day 29.
 
 
Figure 6.8: Gene expression of 
culture configuration and among day 21 and day 29. One
analysis. Asterisk     indicates p < 0.05 and shows 
between these samples. Values are mean ± 
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 It has been suggested that Runx2 regulates early differentiation of mesen
preosteoblastic cells, whereas 
immature osteoblasts (Komori, 2006
most important factor that guides bone formation and activates other bone markers as well, was 
first calculated (Figure 6.9). Runx2 expression exhibited low expression at both time points and 
both platforms tested. To be more specific, expression was the same between day 21 and day 29 
for each platform and perfusion bioreactor had sli
static.   
OSX is an important transcription factor essential for osteoblast differentiation that has been 
shown to act downstream of Runx2 
(Karsenty, 2008). OSX expression indicated a different 
exhibited relatively high expression levels
specific, in the bioreactor, OSX
culture, OSX expression was high on day 21 and then decreased significantly to very low level 
by day 29.  
 
 
Figure 6.9: Gene expression of the transcription factors Runx2 and 
performed between static and 
Two-way ANOVA was used for statistical analysis. Asterisk
that there is statistically significant difference between the tested samples
of N=3.  
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 OSX expression reached maximum
bioreactor platform, the expression increased from day 21 to day 29. This finding indicated an 
earlier expression of this marker in static culture, 
mature phenotype compared to the bioreactor, which probably maintained cells in a more 
progenitor state for longer time.
Gene expression analysis continued with the examination of several bone markers.
COL 1 is the most abundant protein of
differentiation (Figure 6.10). In the perfusion
day 21 and then marked a 5-
expressed on day 21 and then was significantly reduced by day 29. 
The expression of BMP2 was also 
COL 1 but with significantly 
bioreactor was low on day 21 but showed a 2.
BMP2 expression was relatively high on day 21 and then decreased significantly to a very low 
level by day 29.  
 
 
 
Figure 6.10: Gene expression of 
and dynamic culture configuration and among day 21 and day 29. 
for statistical analysis. Asterisks
significant difference between these samples.
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 bone matrix. It is expressed early during osteogenic 
 culture, COL 1 was expressed in a low level 
fold increase by day 29. In static culture, 
 
tested (Figure 6.10) and the profile was similar to the one 
lower levels achieved. In particular, BMP2 expression 
5 fold increase by day 29. In static configuration, 
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 COL 1 and BMP2 are both early stage markers of osteogenic differentiation. Their expression 
profile was similar in the above experiments, with the only difference being the lo
level of BMP2 compared to COL 1
genes were similar between day 21 in static culture and day 29 in perfusion culture.
This finding suggested an earlier maturation stage in static culture, which ach
expression level at an earlier time point in comparison
could be assumed that the environment created by the perfusion bioreactor maintained the cells 
in a more progenitor-like stage, maybe 
longer time and more time was needed to achieve a fully mature phenotype. On the contrary, 
cells in static culture were in a more mature stage
OCN and BSP are two late state markers of bone fo
the obtained results, OCN was highly expressed on day 21 in the perfusion culture and increased 
even more by day 29. In static configuration, 
slightly increased by day 29, remaining however to significantly 
perfusion.  
BSP expression presented a similar profile with 
lower at both time points tested. In particular, on day 21 both platforms had very low and similar 
level of expression. Then, by day 29, perfusion culture indicated a 4
culture maintained the same low level of expression. 
 
Figure 6.11: Gene expression of 
dynamic culture configuration and among day 21 and day 29. 
statistical analysis. Asterisks         
difference between these samples.
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OCN expression was much lower on day 21 and 
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OCN but the level of expression was many times 
-fold increase while static 
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 The above findings indicated a preference for the expression of late stage markers of bone 
formation in the perfusion culture whereas a very low level presented in static culture. It is likely 
that the favorable environment creat
phenotype with the generation of appropriate bone matrix to further support bone formation and 
mineralisation. 
OPN is a non-collagenous protein of bone matrix. It is usually expressed during the proliferative 
phase, and then is downregulated and it is again upregulated during 
Stein, 1995; Neve et al., 2011). In the results 
expression was low on day 21 in the perfusion platform and then showed a significant 5.5 fold 
increase by day 29. In static culture, 
marked a 6-fold decrease by day 29. In general, 
time points and platforms tested. 
 
Figure 6.12: Gene expression of 
culture configuration and among day 21 and day 29. One
analysis. Asterisk      indicates p < 0.05 and shows that there is statistically significant difference 
between these samples. Values are mean ± 
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 ON is the major non-collagenous bone matrix protein. It is highly expressed early 
osteogenic differentiation and decreases when cells acquire more mature phenotype 
Hankenson, 2009; Kusafuka et al., 1999
expressed on day 21, showing about three
comparison to the bioreactor. On day 29, there was a statistically significant downregulation for 
both platforms reaching the same very low level o
 
 
 
Figure 6.13: Gene expression of 
culture configuration and among day 21 and day 29. One
analysis. Asterisk       indicates 
between these samples. Values are mean ± 
 
 
ON was highly expressed early on day 21 and subsequently decreased by the end of the 
experiment. Downregulation of 
towards a maturation stage at that time point. It was also interesting the fact that the level of 
expression was much lower in perfusion culture
perfusion culture indicated high 
To summarize, results from the expression of bone markers
maintained in the cells cultured in the bioreactor after 
was in a more mature stage but the low gene expression of bone markers questioned the proper 
osteogenic differentiation. 
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 Apart from the tested osteogenic markers to evaluate osteogenic differentiation, a couple of 
cartilage markers and markers of hyperth
information regarding the followed 
intramembranous.  
SOX9 is well known to drive cartilage formation and is the first marker to be expressed
al., 1999). SOX9 is expressed in all
not in hypertrophic chondrocytes
particularly inhibits the transition of chondrocyte into hypertrophic
way, it controls subsequent endochondral
undifferentiated mesenchymal cells to a cell type that is both a chondroprogenitor
osteoprogenitor (Akiyama et al., 2002
indicated high SOX9 expression in perfusion culture, which maintained on the same high level 
until the end of the process, on day 29. In static culture, there was significantly much l
of SOX9 expression compared to the bioreactor, which was simi
 
 
Figure 6.14: Gene expression of the transcription factor SOX9. Comparison was performed 
between static and dynamic culture
ANOVA was used for statistical analysis. 
statistically significant difference between these samples.
 
This finding provided another proof of evidence that cells on day 29 in the bioreactor 
configuration were progenitor cells, probably pre
were in a more advance stage towards osteoblast
expression. SOX9 marks the mesenchymal progenitors that give rise to all osteoblasts. It is not 
expressed by mature osteoblasts 
mature osteoblasts in the bioreactor.
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 Aggrecan is one of the major components of 
resist compression is primarily due to the 
Experimental analysis (Figure 6.15
day 21 and then increased more by day 29 in the perfusion configuration. In static culture, there 
was very low to insignificant level of aggrecan expression on day 21 which noted a 4
increase by day 29.  
COL10a1, a marker of hypertrophic chondrocytes was also 
expression was high on day 21 in the perfusion culture and decreased by day 29. In static culture, 
on day 21 there was very low to insignificant C
by day 29.  
 
Figure 6.15: Gene expression of 
static and dynamic culture configuration and among day 21 and day 29. 
used for statistical analysis. Asterisk
significant difference on Aggrecan gene expression 
indicates p < 0.05 and shows 
expression between all the tested samples
 
The expression of hypertrophic chondrocyte marker and cartilage matrix protein suggested that 
differentiation was taking place through endochondral ossification and the high ex
in the perfusion culture indicated that cells were in the common progenitor stage expressing 
markers from both bone and cartilage while cells in static culture indicated lower level of 
expression of these markers suggesting they had proceed 
differentiation.  
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 Two transcription factors, which are not osteoblast specific and may act through 
and Msx2. These proteins affect the differentiation and regulation of the osteoblast phenotype. 
Low levels of expression are observed early in the differentiation and their expression seems to 
increase in a later stage. DLX5 has been shown to possess an important role in up
expression of the master gene Runx2 while MSX2 has the opposite function 
expression of Runx2 (Holleville et al., 2007
In the results obtained from the 
relative mediumlevel of expression at both time points measured in the bioreactor culture. In 
static culture, the level was again the same at both time points, b
compared to the bioreactor. DLX5 expression in the perfusion culture was low on 
increased significantly, exhibiting a 2.5 fold increase by day 29. In static configuration, DLX5 
expression was very low on day 21 and indicated a 6
expression was again many times lower in comparison
 
Figure 6.16: Gene expression of transcription factors Msx2 and Dlx5. Comparison was 
performed between static and 
Two-way ANOVA was used for statistical analysis. 
that there is statistically significant difference between these samples.
N=2. 
 
The above results indicated a better support of osteogenic differentiation in th
platform in comparison to static as proved 
transcription factor, which has been shown to enhance osteoblast differentiation. However, it 
could be observed that MSX2 expression, which acts as an inhibitor, was also higher 
perfusion culture but in a significantly lower level
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 the competition between the two transcription factors, DLX5 expression would probably 
dominate if the previous results on enhanced 
Parathyroid hormone 1 receptor
revealed to have important physiological role in bone development a
(Datta and Abou-Samra, 2009)
low levels relatively early in the differentiation cascade, with increasing expression as 
osteoblasts mature (Liu et al., 2003
“globally” expressed marker for osteoblastic cells 
In the results obtained from the use of 
a mediumlevel of expression on day 21 with similar l
significant difference appeared on day 29
significantly in the perfusion culture while it decreased significantly in static culture. 
 
 
Figure 6.17: Gene expression of 
performed between static and 
Two-way ANOVA was used for statistical analysis
that there is statistically significant difference between these samples.
N=2. 
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(Candeliere et al., 2001). 
Sim (Figure 6.17), the expression of the 
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As it was mentioned previously in this chapter regarding gene expression, markers of the three 
germ layers were also tested in order to primarily evaluate the differentiation status and 
secondary, understand more about the progenitor stage of the cells. 
PAX6 is a transcription factor considered as a marker of neuroectoderm and has a vital role in 
early regulation of neurogenesis (Zhang et al., 2010a). Results from the experiments (Figure 
6.17) indicated high level of PAX6 expression on day 21 in the perfusion culture, which 
significantly increased by day 29. On the other hand, in static culture, there was very low to 
insignificant level of PAX6 expression at both time points tested.  
The above results suggested that cells in the perfusion culture were not yet fully committed to 
the osteoblastic lineage and they were in a progenitor status where they were still expressing 
markers of the three germ layers.  
Nestin is another marker of ectoderm (Figure 6.18). Following the results of the transcription 
factor Pax6, Nestin expression was higher in perfusion culture at both time points tested 
compared to static. In particular, Nestin expression was high on day 21 and then marked a small 
decrease by day 29 in the bioreactor. On the other hand, in static culture, Nestin expression was 
low and maintained the same level until the end of the experiment. 
In general, between the two tested ectoderm markers, it could be noticed that Pax6 expression 
was much higher than Nestin expression and this difference was easier to observe in the 
perfusion bioreactor gene expression results.  
Next step was the evaluation of the expression of two mesoderm markers, the BMP4 
transcription factor and the Desmin protein (Figure 6.18). 
The expression of the gene encoding for Desmin protein was relatively high on day 21 in the 
perfusion culture and then decreased by day 29. In static culture, its expression profile followed 
the one of perfusion, with Desmin expression getting significantly downregulated from day 21 to 
day 29. The expression level in static culture was always lower in comparison to the bioreactor.  
BMP4 has been indicated to be significant for mesoderm formation (Winnier et al., 1995). 
BMP4 expression was relatively high on day 21 in the perfusion culture, following the 
expression level of desmin and decreased significantly by day 29. In static culture, there was low 
expression on day 21 which marked a 2.5 fold increase by day 29. 
The expression of the two mesoderm markers was relatively high on day 21 in the perfusion 
culture indicating an earlier induction towards mesoderm in that configuration compared to 
static, where in general the expression level of the two tested mesoderm markers was low for 
both time points tested.  
 In Figure 6.18, the expression of 
crucial and essential for bone formation
osteoblast differentiation (Yang et al., 2004
osteoblast proliferation and differentiation
bone formation by promoting osteoblast (
the synthesis of Col I and proliferation and survival of OBLs
et al., 2008). Recent findings also suggest
PTH to increase bone formation
 
 
Figure 6.18: Gene expression of 
between static and dynamic culture
ANOVA was used for statistical analysis. Asterisk
there is statistically significant difference between these samples
four tested genes. Values are mean ± 
 
The results collected from the experiments indicated generally a very low level of ATF4 
expression. Specifically, in the bioreactor, ATF4 expressed in a low level on day 21 and then 
marked a small increase by day 29. In static culture, there was very low expression on day 21, 
which almost disappeared by day 29. This outcome
ATF4, reinforced the idea that there were not mature cells by the end of the experiment at both 
culture platforms.  
Continuing the analysis of germ layer markers, the transcription factors Gata4 and Sox17, 
markers of endoderm and the 
(Figure 6.19).  
Transcription factor Gata4 belongs to a family of zinc finger proteins involved in lineage 
determination. It is first expressed in yolk sac endoderm of the developing mouse and later in 
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when ESCs differentiate into endoderm 
expression was low day 21 and slightly increased by day 29 in the perfusion culture. In static 
culture, on day 21 there was relatively low level of expression, which was, however, 2 times 
higher compared to perfusion and 
Transcription factor Sox17 has been shown to facilitate and induce the differentiation program of 
mESCs towards primitive and definitive endoderm 
endoderm determinant factor 
exhibited a mediumlevel on day 21 for both tested platforms. Its expression maintained on the 
same level in the bioreactor until day 29 while increased significantly in static culture. 
 
 
Figure 6.19:  Gene expression of 
static and dynamic culture configuration and among day 21 and day 29. 
used for statistical analysis. Asterisk
significant difference between these samples
Values are mean ± SD of N=2. 
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at both platforms tested. However, by day 29, Hand1 expression exhibited a significant increase 
in perfusion culture while it remained on the same low level in static culture.
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mesoderm marker Hand1 while on day 29 in static configuration, there was significant 
expression of the endoderm marker Sox17. This finding indicated a better control of the 
environment in the bioreactor towards mesoderm formation and subsequent osteogenic 
differentiation whereas in static configuration, high expression of markers from other germ 
layers suggested uncontrolled and heterogeneous differentiation, which would probably result in 
low osteogenic differentiation efficiency.  
Gene expression results for markers of the three germ layers suggested that the protocol used for 
osteogenic differentiation of mESCs employing b-GP, AA and Sim generated a cell population 
that retains in a very low level the expression of markers from all the three germ layers 
suggesting the more progenitor status of the cells and the possibility of having also other cell 
types before committing to fully mature osteogenic phenotype.  
 
 
 
 
 
 
 
6.5 Discussion and conclusions    
 
 
 
In this chapter, the new updated protocol with the optimised time for the supplementation of Sim 
in the culture media was tested and comparison was performed between 3D static and dynamic 
culture. Several analyses were performed to evaluate the efficiency of the protocol.  
DNA quantification was used as an indirect method to calculate cell numbers (Figure 6.2). 
Perfusion bioreactor culture supported significantly higher cell numbers and achieved higher cell 
densities compared to static throughout the whole duration of the experiment due to the fact that 
the created conditions allowed the cells in that platform to proliferate for longer time. This 
outcome indicated that the favorable environment of perfusion culture with continuous 
supplementation of fresh media and removal of metabolites provided the cells with a better 
culture milieu to thrive. The perfusion bioreactor system enabled the support and culture of 
clinically relevant cell numbers needed for potential application in cell therapies. Static culture 
conditions possess the diffusion limitation of nutrients and oxygen transport (Buchwald, 2009; 
Lovett et al., 2009) leading to restricted proliferation of the cells and increased cell death 
observed usually with the creation of a necrotic core (Kasinskas et al., 2014; Mehta et al., 2012) 
in the middle of the hydrogel. Similar findings have been noticed by other groups, which 
supported that perfusion culture increased proliferation rate of the cells (Farack et al., 2011; 
Gomes et al., 2003; Sonnaert et al., 2014; Xie et al., 2006) and contributed to the achievement of 
higher cell numbers.  
 176 
ALP activity was also tested to evaluate osteogenic differentiation (Figure 6.3). Following the 
previous findings of DNA quantification and as it was expected, the environment created by the 
perfusion bioreactor improved significantly the cell viability and at the same time increased ALP 
activity. In particular, literature suggests that Sim stimulates ALP activity (Liu et al., 2009; Park 
et al., 2012b).  
Mineralisation was then evaluated using ARS and the obtained results indicated significantly 
higher calcium deposition in the bioreactor culture compared to static (Figure 6.5). Similar 
observations were made by other research groups, which noticed increased mineralisation after 
Sim application (Maeda et al., 2001; Pagkalos et al., 2010; Park et al., 2012b) and also with the 
use of perfusion bioreactor culture (Bancroft et al., 2002; Sikavitsas et al., 2003). 
Further confirmation of the apatitic nature of the mineralized deposition was provided by ATR-
FTIR analysis (Figure 6.6), which indicated the presence of HA, the main component of bone. 
The ATR-FTIR analysis suggested that the mineralised nodules were apatitic due to the 
characteristic PO4 (at 1016 cm-1) vibrations, which were typical of apatitic minerals. Two major 
additional peaks, hydroxyl and H2O, centered at around 1650 and 3250 cm-1, were observed in 
the FTIR spectra of the mineralised constructs. Moreover, the existence of the amide I band 
(between 1565 and 1500 cm-1), which is related to the cellular origin of mineralised nodules, was 
observed. Finally, the carbonyl (CO3-2) minor peak provided an indication of the biological 
mineralisation of bone tissue (Aparicio et al., 2002). 
Finally, extended gene expression analysis was performed in order to get more insight 
information regarding different processes involved in the osteogenic differentiation of mESCs. 
Several bone markers were first examined to confirm osteogenic differentiation and to observe 
the different time pattern followed in the perfusion culture compared to static. The different 
environment created by the two tested culture configurations resulted in different expression 
times of the various bone markers. One important thing to underline before the beginning of the 
gene expression analysis is the fact that in 3D static culture, diffusion was the only way for 
nutrient transport to the cells while in the perfusion bioreactor, convection supported the efficient 
transport of nutrients and oxygen inside the constructs. It is essential to refer to this difference 
between the two platforms, which suggests different metabolic stress that can potentially have an 
impact on the gene expression profile of the tested bone markers. 
The expression of ALP was the first to be evaluated (Figure 6.8). The obtained results confirmed 
previous findings by other groups suggesting increased ALP expression during perfusion 
bioreactor culture (Barron et al., 2012; Campos et al., 2013; Gaspar et al., 2012; Gomes et al., 
2003; Papantoniou et al., 2014).  
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It is well known and it has been previously shown that osteoblast differentiation is controlled by 
the sequential expression of several transcription factors (Franceschi et al., 2007).  
Runx2 is considered one of the most important of these factors. It is a transcriptional activator 
essential for initial osteoblast differentiation from mesenchymal precursors and subsequent bone 
formation, development and matrix mineralisation (Ducy et al., 1997; Franceschi et al., 2003; 
Komori et al., 1997; Otto et al., 1997). Runx2 has been shown specifically to be necessary for 
the production and maintenance of progenitors (Long, 2012). 
OSX is another transcription factor important for bone regulation and it has been shown to be 
located downstream of Runx2 (Nakashima et al., 2002). Runx2 is essential for the differentiation 
of mesenchymal cells into preosteoblasts. As a downstream gene of Runx2, Osx is required for 
the differentiation of preosteoblasts into mature osteoblasts (Zhang, 2010). Committed 
osteoprogenitors have been shown to express both Runx2 and OSX (Karner et al., 2009). 
Both factors indicated a higher expression level in the bioreactor compared to static culture, with 
Runx2 indicating very low levels at both tested time points compared to OSX (Figure 6.9). The 
relatively low expression level of Runx2 has been noticed previously by other group, which 
observed that during culture of either primary osteoblasts or the MC3T3-E1 osteoblast cell line, 
there were no major changes observed in the level of Runx2 expression during in vitro 
differentiation (Franceschi et al., 2003). 
There is one more possible reason for the significantly low Runx2 expression in comparison to 
OSX expression. It has been observed that PTH regulation of Runx2 transcription is 
predominantly mediated via protein kinase A (PKA) signaling, whereas the regulation of OSX 
might involve protein kinase C (PKC) activation as well, although it seems a pathway of minor 
importance compared with PKA signaling (Wang et al., 2006a). On the other side, there are 
several publications referring to the ability of statin to activate PKC (Lee et al., 2010; Sassano et 
al., 2012; Yang et al., 2010). This could indicate a possible reason for the significantly higher 
OSX expression level in comparison to Runx2. 
Continuing with gene expression analysis, two important early stage markers of osteogenic 
differentiation were tested, COL 1 and BMP2 (Figure 6.10). COL 1 represents the predominant 
collagen in mineralised bone (Sodek and McKee, 2000) and together with ALP is considered an 
early marker of bone differentiation (Altmann et al., 2014; Orimo, 2010). BMP2 is known as the 
strongest osteoinductive factor. The expression of both genes was upregulated in the perfusion 
culture while it was downregulated in static culture during the tested time points suggesting an 
earlier transition of static culture to the more mature phenotype and a longer maintenance of a 
more progenitor pre-osteoblastic status of the cells in the perfusion culture. 
 178 
Next step was the evaluation of the expression of two significant late stage markers of 
osteogenic differentiation, OCN and BSP (Figure 6.11). OCN is one of the few bone-specific 
proteins whereas BSP is the first late stage marker to be expressed indicating mature stage. In the 
performed experiments, both genes indicated a significantly higher expression level in the 
bioreactor culture compared to static at both tested time points. This finding suggested that the 
dynamic environment created in the bioreactor stimulated and supported better osteogenic 
differentiation. 
Similar to that, another group also noticed that OCN was significantly increased in rotating 
bioreactors as compared to static controls, indicating that the phenotypic expression of 
osteoblasts under rotating conditions was enhanced. The higher expression level at an earlier 
time point could also support the idea that dynamic flow conditions stimulate osteoblastic cell 
function in rotating bioreactors (Yu et al., 2004). 
The expression of two major non-collagenous proteins of bone matrix, OPN (Figure 6.12) and 
ON (Figure 6.13) was then examined. OPN expression profile suggested an earlier expression 
and maybe earlier maturation in static configuration. ON has a significant role in regulating 
bone-matrix mineralisation. Higher expression was indicated in static configuration, something 
that was observed previously by another group, which noticed high expression levels of ON in 
static microchips, while significant lower mRNA expression levels were noticed in bioreactors 
(Altmann et al., 2014). 
To summarize, the majority of the important bone marker genes indicated higher expression 
level in the perfusion bioreactor culture compared to static configuration suggesting better 
support of osteogenic differentiation in the bioreactor platform.  
Continuing with gene expression analysis and in order to elucidate what type of ossification took 
place, a couple of cartilage genes, genes of hypertrophic chondrocytes and matrix protein genes 
were evaluated. The expression of the transcription factor SOX9 (Figure 6.14), the cartilage 
matrix protein Aggrecan, which is expressed in mesenchymal condensations (de Crombrugghe et 
al., 2001) and the hyperthrophic chondrocyte marker COL 10 (Figure 6.15) was tested. 
SOX9 is considered an essential transcriptional regulator of chondrocyte cell fate (Bi et al., 
1999) and it is needed for formation of mesenchymal condensations (de Crombrugghe et al., 
2001). SOX9 marks the mesenchymal progenitors that give rise to all osteoblasts. It is not 
expressed by mature osteoblasts (Long, 2012). SOX9 is expressed in all chondroprogenitor cells 
and all chondrocytes but its expression is abolished in hypertrophic chondrocytes and there is no 
expression of SOX9 in osteoblasts (de Crombrugghe et al., 2001). Moreover, it has been shown 
that SOX9 enhanced aggrecan promoter activity (Sekiya et al., 2000) and activated its gene 
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expression (Leung et al., 2011). Based on the above information, the two genes indicated similar 
profile of expression and they were highly expressed in the perfusion bioreactor compared to 
static configuration at both tested time points. The acquired results suggested that cells in the 
bioreactor were in a progenitor stage and had the possibility of becoming mature osteoblasts or 
chondrocytes. At the tested time points, there were probably no mature osteoblasts in the system. 
On the other side, in static configuration, SOX9 expression was very low suggesting the possible 
existence of a more mature phenotype.  
The COL 10 gene is specifically expressed in hypertrophic chondrocytes and marks their 
transition stage to osteoblasts, favouring endochondral ossification (Linsenmayer et al., 1991). 
Previous studies suggested that the mechanism to facilitate endochondral ossification is 
performed through regulation of matrix mineralisation and compartmentalization of matrix 
components (Shen, 2005). Similar to the previous tested genes, its expression was significantly 
higher in the perfusion bioreactor at both time points compared to static.  
The above results suggested the existence of hypertrophic chondrocytes and the proper 
progression of osteogenic differentiation through endochondral ossification in the perfusion 
bioreactor, as indicated by the gene expression levels of the tested markers. The low expression 
level in static configuration suggested that this platform didn’t follow a proper osteogenic 
differentiation pathway.  
Another two transcription factors, which affect osteoblast differentiation, are Dlx5 and Msx2 
(Figure 6.16). Dlx5 has been proposed to up regulate Runx2 expression (Holleville et al., 2007) 
while Msx2 has the opposite effect (Kirkham et al., 2012; Lee et al., 2005). Following previous 
observations, the expression of both factors was higher in the bioreactor.  
The expression of PTHR1 (Figure 6.17), another early marker of osteoblast differentiation 
(Kondo et al., 1997), was also evaluated. It is considered a “global” marker expressed by all 
osteoblasts in vivo (Aubin, 1998). It was highly expressed in the bioreactor, similar to the 
previously tested bone markers suggesting once more the more appropriate osteogenic 
differentiation performed within perfusion platform compared to static, as indicated by the gene 
expression level of important markers. 
Finally, wishing to get more insight information regarding the differentiation process, markers 
from the three germ layers were tested to evaluate the efficiency of the differentiation. Starting 
with ectoderm, the expression of the transcription factor Pax6 (Figure 6.17), which has been 
shown to be a cell fate determinant of neuroectoderm (Zhang et al., 2010a) and the Nestin 
protein (Figure 6.18) was evaluated. Both markers were highly expressed in the bioreactor 
compared to static configuration.  
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Next step involved the examination of markers from the endoderm and in particular, the 
transcription factors Gata4 and Sox17 (Figure 6.19). It has been reported that Gata4 RNA is one 
of the transcripts induced during differentiation of embryoid bodies (Arceci et al., 1993). Both 
markers indicated a preference and were expressed in static culture but high levels appeared at 
different time points for each gene.  
Continuing with gene analysis, the expression of three mesoderm markers, BMP4 and Desmin 
protein (Figure 6.18) and the transcription factor Hand 1 (Figure 6.19), was evaluated. All the 
three markers were highly expressed in perfusion culture suggesting an induction of mesoderm 
formation in perfusion bioreactor culture.  
To summarize, results suggested there was a preference for mesoderm expression in perfusion 
culture and for endoderm in static culture.  
This interesting observation suggested the more progenitor status of the cells in the bioreactor 
proved by the expression of markers of other germ layers in comparison to static which has been 
in a more advance stage expressing only osteoblastic markers.  
The low expression level in static culture reinforced the previous results indicating probably a 
more mature phenotype on static configuration. 
The obtained results suggested the better support of osteogenic differentiation in the perfusion 
bioreactor culture as proved by the enhanced expression of mesoderm markers and increased 
expression level of various important markers of osteoblastic differentiation. Results need to be 
repeated for further validation, as similar analysis hasn’t been performed previously from other 
groups to make comparisons.  
Several conclusions could be drawn from the gene expression analysis. Based on the expression 
of the various bone markers tested, it seemed that cells in static culture started to differentiate 
and to express the respective markers earlier compared to cells cultured within the RWV 
perfusion bioreactor.  
To go one-step further, evaluation of a number of cartilage markers was performed and 
confirmed the fact that endochondral ossification pathway was followed through the Sim 
differentiation protocol. Together with the expression of bone markers, these results reinforced 
the idea that cells in static culture were in a more mature status compared to cells cultured within 
the bioreactor.   
The obtained results suggested the existence of progenitor cells, pre-osteobleasts, which were not 
fully mature and could still proliferate and differentiate into more differentiated phenotype. 
These gene expression results indicated that Sim in combination with the perfusion culture could 
support osteogenic differentiation of the mESCs and there were strong indications that probably 
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this happened through endochondral ossification pathway. Moreover, obtained cells were not 
fully mature and had a progenitor phenotype; in this way, they could be used to activate 
endogenous mechanism of the body to regenerate the defect where they will be implanted.  
To our knowledge, the important contribution of this chapter lies on the fact that this is the first 
time that an extended gene expression profile following osteogenic differentiation, ossification 
pathway and germ layer formation, was followed and major insight information can be obtained 
regarding the followed process. The majority of studies focus on the gene expression of the final 
desired product, ignoring the in between status of the cells.    
 
 
To summarize, the conclusions that could be drawn from this chapter are the following ones: 
 
 
- Sim enhanced cell proliferation and supported better and increased osteogenic 
differentiation and subsequent mineralisation in the 3D dynamic culture environment 
generated by the perfusion bioreactor. 
-  Gene expression indicated high level of bone markers in the dynamic environment of the 
bioreactor, thus confirming improved bone formation. 
- Gene expression analysis suggested that endrochondral ossification was followed through 
the existence of an intermediate cartilage template. 
- Germ layer analysis indicated high expression of mesoderm markers. There was, 
however, low expression of markers from the other two germ layers  
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7th CHAPTER 
 
 
 
7. 3D BIOPROCESS OF MESCS: COMPARISON OF OSTEOINDUCTIVE 
MOLECULES SIM VS DEX AND CULTURE MODES FED-BATCH VS 
PERFUSION 
 
 
 
7.1 Introduction 
 
 
Chemical osteoinduction of mESCs is widely performed with the use of b-GP, AA and the 
steroid Dex. Dex has been shown to promote osteogenic differentiation of both embryonic 
(Buttery et al., 2001; Sottile et al., 2003; zur Nieden et al., 2003) and adult stem cells (Rogers et 
al., 1995).  
In this PhD project, a new small molecule named Sim, that is a well-known and widely used 
drug to lower cholesterol, was tested as an osteoinductive factor. Sim has been shown to have 
anabolic effects on bone formation (Phillips et al., 2001) and also to upregulate BMP2 
expression (Ohnaka et al., 2001; Sugiyama et al., 2000).  
In the previous chapter, 3D osteogenic differentiation was tested in static and perfusion culture 
using Sim supplemented in the media at specific time point defined after a short optimisation. 
Results were encouraging showing upregulation of mineralisation, ALP activity and expression 
of several bone markers. In this chapter, the intention was to compare this newly developed 
protocol containing Sim with the standard protocol currently used with the employment of Dex. 
The aim was to evaluate the differences of the two protocols and which one supported higher cell 
numbers of better osteogenic quality. It was also important to identify the similarities and the 
differences between the two molecules in their mode of action and the different profile exhibited 
through gene expression analysis.   
 
 
7.2 Aim and Objectives 
 
 
The aim of this chapter was to compare the two molecules used for osteogenic differentiation of 
mESCs, Dex versus Sim.  
 In particular: 
 
1. To evaluate similarities and differences between the two tested chemicals for osteogenic 
differentiation  
2. To assess their efficiency and analyse the quality and the 
constructs 
3. To compare 3D bioprocess between static and dynamic culture configurations among the 
two molecules 
 
7.3 Methodology 
 
Comparison of the two protocols employed for 
and perfusion culture was performed using the previously mentioned 29 days differentiation 
protocols starting with HepG2
supplemented with b-GP and ascorbate
0.1nM Sim for the one protocol and on day 21, supplementation with 1
protocol (Figure 7.1).  
 
Figure 7.1: The two tested
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Osteogenic differentiation, in general terms, is following three characteristic steps, starting with 
cell expansion, followed by matrix synthesis to support osteogenic diferentiation and subsequent 
mineralisation in the end. Based on this principle, both tested protocols for osteogenic 
differentiation in these experiments lasted for 29 days starting with 3 days incubation in HepG2-
CM to expand cell numbers and enhance mesoderm formation. In the next step, cells were 
incubated in osteogenic media containing b-GP and ascorbate-2 phosphate to initiate matrix 
formation and osteogenic differentiation. For the last step, the osteoinductive agents Dex in one 
protocol and Sim in the other were provided to support and increase calcium deposition, at 
different time point in each case.  
The above information indicated that both protocols followed the same principle idea for 
osteogenic differentiation and the only difference was the osteoinductive agent provided and the 
chosen time point. This suggests that results obtained after the application of the two tested 
protocols are comparable. Similar results comparing osteogenic differentiation protocols with the 
employment of different osteoinductive factors at distinct time points for each protocol, were 
performed previously (Pagkalos et al., 2010) and proper comparison was also carried out.  
 
 
 
7.4 Results 
 
 
DNA quantification was used as an indirect method to calculate cell numbers at each time point 
throughout the 29 days differentiation protocol (Figure 7.2). In the graph in Figure 7.2, 
comparison of two protocols for osteogenic differentiation, one that used Sim versus one that 
employed Dex was presented. Comparison between two culture platform configurations, static 
and perfusion, was also performed. It was easy to notice that perfusion culture, with both 
protocols, supported higher cell numbers throughout the whole experiment compared to static 
culture. To be more specific, all four different groups started with 20.000 cells per bead. In 
perfusion culture with Sim protocol, there was increased proliferation and cells achieved about 
400.000 cells per bead by day 14 of culture and maintained the same number until the end of the 
experiment, on day 29. Perfusion culture with Dex supported about 200.000 cells per bead by 
day 7 of culture and maintained this density until day 21. There was an observed increase in cell 
numbers reaching about 250.000 cells per bead by day 29. In static culture with the Sim 
protocol, cells achieved about 200.000 cells per bead by day 7, then there was a decrease by day 
14 and on day 21, they recovered back to the density of day 7, which they maintained until the 
 end of the culture. In static culture with the 
by day 7 and maintained this density until the end of the 
 
Figure 7.2: DNA quantification throughout the 29 days of the experiment. Comparison was 
performed between Sim and 
configuration. Two-way ANOVA was used for statistical analysis. Asterisk 
and shows that there is statistically significant difference 
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Figure 7.3: ALP activity throughout the 29 days of the experiment. Comparison was performed 
between Sim and Dex protocol and also among static and 
ANOVA was used for statistical analysis. 
statistically significant difference between the two tested 
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Figure 7.4: ALP activity normalized with cell 
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 Both tested protocols, Dex and 
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There was no pronounced difference between the mechanism of action of each compound that 
would influence differently ALP activity. Results supported the idea that perfusion platform can 
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7.4.1 GENE EXPRESSION 
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 The earliest and most important osteogenic marker to be expressed and evaluated was ALP. 
From the following graph (Figure 7.6
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Figure 7.7:  Gene expression of the transcription factors Runx2 and 
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configuration for day 21 and day 29
Asterisk        indicates p < 0.05 and shows that there is statistically significant difference
Runx2 expression between the tested 
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findings, Plunkett and his collegues noticed that all groups cultured in the bioreactor showed 
significant decreases in COL 1 expression compared to the static group (Plunkett et al., 2010). 
Bjerre and his collegues tested different sizes of a particular scaffold and observed that collagen 
expression in both cases showed a statistically significant preference for static culture at all time 
points (Bjerre et al., 2011).  
Several groups attributed the collagen reduction to the microgravity condition simulated in a 
RWV bioreactor after performing several experiments. In particular, rotating wall bioreactor has 
been shown to decrease COL 1 expression (Wang et al., 2009). To be more specific, 
microgravity has been indicated to reduce COL 1 expression by disrupting integrin signaling 
(Meyers et al., 2004). Analysis during spaceflight or experiments in simulated microgravity 
indicated changes in bone metabolism and reduction in the gene expression of COL 1 (Carmeliet 
and Bouillon, 1999; Carmeliet et al., 1997; Nichols et al., 2006; Uddin and Qin, 2013). 
As far as BMP2 results were concerned, the expression of BMP2 was significantly induced at 
early time points and after Dex treatment. In particular, it could be noticed that the expression 
levels were high on day 21 in the Dex group and reduced significantly by day 29. In the Sim 
group, there was low expression on day 21 which marked a small increase by day 29. Sim has 
been previously shown to induce BMP2 expression by other research groups (Baek et al., 2005; 
Chen et al., 2010).  
The interesting finding was the high BMP2 activity on day 21 in the Dex group where actually 
Dex was provided in the culture media on day 21, which means there was another factor 
inducing BMP2 expression at that point. Looking in the literature, it has been observed that 
extracellular phosphate (Pi), provided in the osteogenic media through b-GP, increases BMP2 
expression (Langenbach and Handschel, 2013; Tada et al., 2011). By day 29, when Dex has been 
supplied in the culture media, BMP2 expression reduced, following other people’s observations 
(Chang et al., 2006). BMP2 expression was also maintained in relatively high level for longer in 
the perfusion culture while decreased by the end of the experiment in static, suggesting better 
support of osteogenic differentiation in the perfusion configuration. 
Next markers to be tested were two bone matrix proteins, OCN and BSP considered as late stage 
markers of osteoblast differentiation (Figure 7.9). 
Bglap is the gene encoding for the protein OCN, one of the few bone specific proteins 
characteristic of mature bone. In the performed experiments, Bglap was highly expressed by day 
21 in the perfusion bioreactor using the Sim protocol and its expression was induced more by 
day 29. In static culture with the same chemical, Bglap indicated a similar expression pattern 
with increased activity from day 21 to day 29. The expression level, though, was on average 4 
 times lower in comparison to the bioreactor. On the contrary, in the 
configurations, Bglap expression was significantly low on day 21 and decreased more by day 29, 
with perfusion exhibiting slightly higher levels
BSP is another late stage marker of bone formation and an important matrix protein. Results 
obtained from the experiments indicated general
platforms and both chemicals tested. In particular, in the bioreactor configuration using the 
protocol, BSP expression increased from day 21 to day 29 while in static culture using the same 
protocol, there was very low expression on day 21, which remained th
Dex protocol, BSP expression was significantly low in the bioreactor until day 29 whereas in 
static culture, there was very low
 
 
Figure 7.9: Gene expression of 
Dex protocol and also among static 
Two-way ANOVA was used for statistical analysis. Asterisk 
that there is statistically significant differ
time point and within the same platform
is statistically significant differ
are mean ± SD of N=3. 
 
 
The above results indicated a higher level of expression for both 
bioreactor platform in comparison
followed in that configuration. Moreover, 
late stage markers, in particular of 
treatment. This outcome suggested an induction of late stage markers 
could also explain the low level of early stage markers.
0
2
4
6
8
10
12
DAY 21 
BIOR 
DEX
DAY 21 
BIOR 
SIM
Re
la
tiv
e g
en
e 
ex
pr
es
si
on
fo
ld
ch
an
ge
Dex protocol fo
 compared to static culture. 
ly a low expression level of BSP for both 
e same until day 29. In the 
 expression level.  
Bglap and BSP. Comparison was performed between 
and dynamic culture configuration for
      indicates p < 0.05 and shows 
ence in BSP expression between chemical at the same 
 while asterisk      indicates p < 0.05 and shows that there 
ence in Bglap expression between all the tested 
tested late stage markers i
 to static suggesting a better osteogenic differentiation process 
Sim treatment significantly induced the expression of 
OCN in comparison to the low expression observed after 
after
 
DAY 21 
STAT 
DEX
DAY 21 
STAT 
SIM
DAY 29 
BIOR 
DEX
DAY 29 
BIOR 
SIM
DAY 29 
STAT 
192 
r both culture 
Sim 
 
Sim and 
 day 21 and day 29. 
samples. Values 
n 
Dex 
 Sim treatment and 
DEX
DAY 29 
STAT 
SIM
BGLAP
BSP
 OPN is a non-collagenous protein of bone matrix, which is characterised as an inhibitor of 
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glucose and glutamine levels from the employed culture media were analyzed with Biofrofiler 
and confirmed the expected levels. A-MEM media was used as a basal media with initial glucose 
level 5.55 mmol/L and glutamine level 2 mmol/L.  
 
 
Table 7.1: Metabolic analysis was performed for glucose, glutamine and lactate using 
Bioprofiler. Comparison was performed between Sim and Dex protocol within 3D static 
configuration, on day 29.  
 
 GLUCOSE GLUTAMINE LACTATE 
A-MEM MEDIA 5.55 mmol/L 2 mmol/L - 
STAT DAY 29 SIM 5.6 mmol/L 0.39 mmol/L 4.2 mmol/L 
STAT DAY 29 DEX 1.8 mmol/L 0.22 mmol/L 11 mmol/L 
 
 
The acquired values indicated that samples obtained from Sim treated cultures maintained high 
glucose, in the same level as the initial a-MEM media whereas samples from Dex treated 
cultures indicated much lower glucose level by day 29. Glutamine level was reduced for both 
tested chemicals, with Sim sample maintaining a higher level in comparison to Dex. Finally, 
following the glucose consumption rate, lactate production was significantly higher in the Dex 
treated cultures compared to the Sim ones.  
Glucose and lactate concentrations are related with metabolic stress affecting cell viability and 
gene expression. The above results suggested that Sim treatment at the appropriate time during 
culture maintained the system in low metabolic rate with high glucose level and low lactate and 
could be better for cell viability compared to Dex culture. However, Bioprofiler analysis would 
need to be repeated to further confirm these preliminary indications and probably be also 
combined with a more developed metabolic method in order to get more insight information 
regarding the metabolism and how it affects osteogenic differentiation and cell death. 
 
7.5 Discussion and conclusions 
 
In this final chapter, the aim was to compare the new protocol for osteogenic with the use of Sim 
to the old and widely used protocol with the use of Dex in 3D static and perfusion culture 
configuration. The aim was to identify similarities and differences regarding cell growth 
capacity, osteogenic differentiation, mineralisation and gene expression profile. 
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DNA quantification was performed to evaluate cell numbers (Figure 7.2). The obtained results 
indicated that perfusion culture enhanced cell proliferation and supported significantly higher 
cell numbers compared to static culture. This outcome was valid for both tested protocols and 
confirmed results from other groups which supported that the environment created by the 
perfusion culture, with continuous supplementation of fresh media and removal of metabolites, 
was favorable for cell growth and could support high cell numbers (Grayson et al., 2008; Yeo et 
al., 2013) with high viability. Moreover, it could be observed that the Sim-containing protocol 
allowed higher cell proliferation resulting in significantly higher cell numbers by the end of the 
experiment compared to the Dex-containing protocol, for both tested platforms. This finding 
follows previous observations supporting the idea that Dex is such a potent osteoinductive agent 
that when supplied does not permit the expansion of the cells, which start differentiating before 
completing proliferation (Bielby et al., 2004)  
ALP activity (Figure 7.3) and ARS (Figure 7.5) were tested to evaluate osteogenic 
differentiation and mineralisation. Perfusion bioreactor increased and maintained high ALP 
activity throughout the whole experiment whereas in static configuration, ALP activity indicated 
the expected profile with initial increase, subsequent decrease and finally, increase again to 
support mineralization. ARS showed augmented calcium deposition in the bioreactor compared 
to static culture. Obtained results were the same for both tested chemicals. The above findings 
suggested that the combination of one of these osteoinductive factors together with the perfusion 
culture configuration possessed the superior capacity to promote osteogenesis and mineralisation 
of mESCs as proved by the increased ALP and ARS levels. 
Comparison of the gene expression level of important bone markers between the two tested 
protocols was then performed. Results revealed different pattern of osteogenesis between the two 
tested chemicals. Early stage markers were initially tested. Starting with ALP (Figure 7.6), 
results indicated that perfusion culture supported higher ALP expression compared to static for 
both tested chemicals thus confirming previous results from other groups, which indicated that 
the favorable environment of perfusion bioreactor supported high ALP activity and high viability 
of the cells (Bjerre et al., 2008; Botchwey et al., 2001; Meinel et al., 2004). Moreover, ALP 
expression was significantly induced after Dex treatment compared to Sim treatment.  
The transcription factors Runx2 and OSX, the master regulators of osteogenic differentiation, 
were then tested (Figure 7.7). Earlier expression of these two genes was observed after Sim 
treatment whereas treatment with Dex induced a later expression.  
The expression of COL 1, the most abundant bone matrix protein constituting the majority of the 
organic content and of BMP2, the strongest osteoinductive agent, was then measured (Figure 
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7.8). Both genes were significantly upregulated after Dex treatment and their level was higher in 
static configuration compared to the bioreactor but at different time points, earlier for BMP2 and 
later for COL 1. It has been shown previously that rotating wall bioreactors decrease the 
expression of COL 1. In particular, Bjerre and his colleagues tested two sizes of the same 
scaffold and noticed that collagen expression in both construct types showed a statistically 
significant preference for static culture at all time points (Bjerre et al., 2011). For further support, 
Plunkett and his colleagues noticed that all groups cultured in the bioreactor showed significant 
decreases in COL 1 expression compared to the static group. Based on their findings, they also 
suggested that the mechanism of action for this could be either that culture in the bioreactor 
downregulated COL 1 expression or accelerated osteoblast maturation (Plunkett et al., 2010). 
BMP-2 expression in the bioreactor maintained in relatively high expression level for both tested 
time points.  
To summarize, the higher gene expression of early bone markers supported the idea that 
bioreactor platform could support better osteogenic differentiation compared to static culture.  
Gene expression of late stage bone markers was then performed. Bglap is one of the few 
osteoblast-specific genes and is considered a marker of mature osteoblasts. BSP is another bone 
matrix protein indicating late stage bone differentiation (Figure 7.9). They were both highly 
expressed in the perfusion bioreactor after Sim treatment while their level was very low after 
Dex treatment. This finding provided an indication on the role of Sim in promoting earlier matrix 
maturation and late stage bone formation. 
Finally, the expression of two bone matrix non-collagenous proteins OPN (Figure 7.10) and ON 
(Figure 7.11) was calculated. OPN is expressed early during cell proliferation, then is 
downregulated and finally is upregulated again to inhibit mineralisation. Both genes were 
significantly expressed after Dex treatment compared to the low expression level after Sim 
treatment with ON get upregulated at an early time point whereas OPN at a later stage. They 
both indicated higher level in the bioreactor compared to static culture.  
It has been suggested previously that increased OPN expression coupled with decreased COL-1 
expression may indicate that bioreactor culture has enhanced expression of post-proliferative 
genes at the expense of those found during proliferation (Partap et al., 2010a).  
Gene expression results suggested that Dex treatment provided better support and induction of 
osteogenic differentiation compared to Sim treatment, as indicated by the high gene expression 
of important bone markers. Similar to that, it has been indicated that cells retain a greater 
osteogenic capacity when Dex is present in the medium immediately after harvest (Holtorf et al., 
2005) suggesting that Dex acted as a stronger osteoinductive compound. Sim seemed to better 
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support high cell numbers of more progenitor type of cells. Longer differentiation protocol is 
probably needed with the use of Sim in order to acquire a more mature cell phenotype. 
Moreover, perfusion bioreactor platform indicated superior properties to support osteogenic 
differentiation in comparison to static culture.  
 
In the Tables 7.2 and 7.3, gene expression results of major bone markers tested between Sim and 
Dex and also between static and perfusion configuration are presented for day 21 and day 29.  
 
Table 7.2: Summary of the gene expression level of bone markers on day 21 is presented. Comparison was 
performed between Siim and Dex protocol and also among bioreactor and static platform. 
 
 
 ALP BGLAP BSP RUNX2 OSTERIX COLLAGEN 1  BMP2 OSTEOPONTIN OSTEONECTIN 
BIOR 
DEX 
+++ ++ + + + +++ 
+++ 
+++ 
++++ 
++ ++++++++++ 
++++++++++ 
BIOR 
SIM 
+ ++++ + + ++ ++ ++ + +++++++ 
+++++++ 
STAT 
DEX 
+ + - + + ++++ 
++++ 
+++++
+++ 
++ +++++++++ 
+++++++++ 
STAT 
SIM 
+ ++ + + ++++ +++++ +++ +++ ++++++++ 
++++++++ 
 
Table 7.3: Summary of the gene expression level of bone markers on day 29 is presented. Comparison was 
performed between Sim and Dex protocol and also among bioreactor and static platform. 
 
 
 ALP BGLAP BSP RUNX2 OSTERIX COLLAGEN 1  BMP2 OSTEOPONTIN OSTEONECTIN 
BIOR 
DEX 
+++
+ 
+ + ++ ++++ +++ 
+++ 
+++ 
+++ 
+++++ ++++++++ 
++++++++ 
BIOR 
SIM 
++ ++++ ++ ++ +++ +++++ +++ +++ ++++++ 
++++++ 
STAT 
DEX 
+ + _ ++ +++ +++++ 
+++++ 
+++ ++++ ++++++++ 
++++++++ 
STAT 
SIM 
- +++ + + + ++++ ++ + ++++++ 
++++++ 
 
 
Finally, there were some metabolic data collected from media from static configuration samples 
on day 29 comparing and analyzing Sim-containing with Dex-containing differentiation media 
(Table 7.1). Acquired results using Bioprofiler indicated that Sim-containing media preserved 
higher glucose and lower lactate concentration compared to Dex-containing media. The glucose 
level measured was similar to the initial amount provided with fresh media suggesting there was 
no consumption and a less metabolically stressful environment for the cells. 
Similar outcome was observed by another research group. In particular, Dominika Nowis and 
her collegues incubated human skeletal muscle cells and human hepatocellular carcinoma cells 
with lovastatin and they observed decreased glucose uptake as shown by increased glucose 
concentration in culture medium as compared with controls indicating that glucose is not 
efficiently transported into cells treated with lovastatin. They attributed this outcome to the 
induction of conformational changes in the glucose transporters (Nowis et al., 2014).  
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Reduction of glucose metabolism in tumor cells and adipocytes has been also indicated 
(Takaguri et al., 2008). Similar findings on cancer cells indicating higher glucose concentration 
in the conditioned cell medium have been obtained (Ganapathy-Kanniappan et al., 2013; 
Malenda et al., 2012). Smith and his colleagues observed a dose-dependent decrease in glucose 
uptake in human myotubes after exposure to Sim in concentrations not influencing cell viability. 
They suggested that the observed reduction in glucose uptake could be an indirect effect of 
impaired oxidation of glucose. Knowing more about this glucose dysregulation could help 
understanding the myotoxicity observed by statins (Smith et al., 2014). 
Metabolic analysis results supported the previous findings indicating the high differentiation 
activity of the cells cultured with Dex and their fast maturation compared to cells cultured with 
Sim, which were maintained in a low differentiation rate system with gradual and slower 
transition to more mature phenotype and acquisition of a progenitor stage for longer. However, 
more analysis should be performed on metabolism to get more clear data and view of what 
exactly is going on with the metabolism through the osteogenic differentiation of mESCs and 
how that may affect important parameters like the expression of genes and proteins. 
To summarize, two culture platforms and two osteogenic differentiation protocols were 
compared and the important observations included the fact that gene expression was significantly 
higher in the majority of the tested bone markers in the bioreactor culture compared to static. 
Moreover, Dex treatment induced significant upregulation and high gene expression of bone 
markers compared to Sim suggesting that Dex acted as a stronger osteoinductive compound. 
Gene expression of bone markers was in general terms in low expression levels, with few 
exceptions, something that has been observed previously by other groups as well (Evans et al., 
2012). The important contribution of this work was the fact that significant novel information 
were provided regarding osteogenic differentiation in 3D configuration using different 
osteoinductive substances.  
 
The conclusions that could be drawn from this chapter are the following: 
 
 
- 3D bioprocess in dynamic culture indicated superior properties in matters of cell expansion, 
proliferation and osteogenic differentiation compared to static configuration 
- Sim treatment resulted in the production of high numbers of more osteoprogenitor cells while 
Dex treatment generated fewer cells of a more mature phenotype 
- Gene expression analysis of important bone markers demonstrated higher expression level 
after Dex treatment in comparison to Sim 
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8th CHAPTER 
 
8. GENERAL DISCUSSION, CONCLUSIONS AND FUTURE 
DIRECTIONS 
 
 
8.1 The need for TE strategies 
 
Nowadays, due to the increased life expectancy and the augmenting aging population, there is a 
prevalence of musculoskeletal diseases around the world. People live with pain for many years 
and this fact deteriorates the quality of their everyday life. The loss of skeletal tissue that can 
accompany trauma, injury, disease or advancing years can result in significant morbidity and 
significant socio-economic cost. Currently employed grafting solutions are inefficient and 
emphasise the need for new, more reliable skeletal regeneration strategies with low cost.  
To address the unmet need for bone augmentation, TE has come to the fore in recent years with 
new approaches for de novo skeletal tissue formation, which seek to harness stem cells, 
innovative scaffolds and biological factors that promise enhanced and more reliable bone 
formation strategies to improve the quality of people’s lives (Black et al., 2015).  
To be more specific, TE products and their applications are widely investigated as a potentialy 
effective treatment for large-scale bone defects. The challenge presented with the repair of these 
injuries is the need for high cell numbers in order to fill the created defect. TE is offering a 
solution to this problem by combining the use of high proliferative cell populations, such as 
ESCs with the 3D environment provided by the scaffold that better mimics in vivo conditions 
and the scale up of the culture with the employment of the appropriate bioreactor platform. By 
understanding the principles of tissue growth, TE allows the production of functional tissue for 
clinical use, without the need for grafting, in order to promote tissue regeneration (Roberts et al., 
2008).  
 
8.2 Important components of the study 
 
In this project, mESCs were used as a cell source due to their unlimited self-renewal capacity 
and pluripotency, meaning the ability to differentiate into all different cell types of the three 
germ layers of an embryo, apart from the placenta. This feature renders these cells a promising 
source capable of generating the high cell numbers needed for cell therapies.  
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Recreation of the 3D environment was based on the employment of a hydrogel made from 
alginate as a supportive scaffold. Alginate is a water-based biocompatible material that can be 
easily created through cross-linking strategies and can be also manipulated to incorporate 
adhesion molecules.  
The important element to scale up cell production is the use of the necessary platform, meaning a 
bioreactor system. A custom made RWV perfusion bioreactor was employed for the experiments 
of the osteogenic differentiation. This novel, scalable perfusion bioreactor has been shown to 
create an ideal environment for the cells to thrive due to the continuous supply of fresh media 
and removal of metabolites, which provided a robust and controlled metabolic environment that 
is conducive to high cell growth and quality ESC bioprocessing (Yeo et al., 2013). 
Finally, two different osteoinductive molecules were employed and compared for their efficiency 
in osteodifferentiation and mineralisation in these experiments. The steroid Dex was used as a 
control and the small molecule Sim as a novel tested compound that has indicated bone anabolic 
properties. Dex is a common osteogenic additive currently widely employed in various protocols 
to enhance osteogenic differentiation. However, Dex is a synthetic glucocorticoid (GC), which 
can have some uncontrolled effects on osteogenic differentiation, such as induction of 
osteoporosis (Eastell, 1995; Patschan et al., 2001) by inhibition of osteoblast differentiation 
(Canalis and Delany, 2002) and for this reason, an alternative molecule that could replace it has 
been extensively researched. In 1999, Mundy and his group examined a number of small 
molecules and identified only Sim to be able to increase the expression of BMP2 promoter. 
Previous people in the lab supported the idea that Sim enhanced osteogenic differentiation of 
mESCs (Pagkalos et al., 2010). 
 
 
8.3 Necessity and importance of 3D culture 
 
The necessity and importance of 3D culture configuration for the proper and efficient cell 
expansion and differentiation in order to obtain high cell numbers needed for cellular therapies 
has been highlighted by many different groups (Handa et al., 2014; Lee et al., 2008). 
3D platforms better mimic the in vivo environment and allow cells to settle and start growing. 
Cell-cell communication and also secretion of osteoinductive molecules is better achieved 
leading to the faster and better expansion and subsequent induction of the differentiation of the 
employed cell population.  
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The choice of the appropriate bioreactor is crucial depending on the required application. 
Examples from people with experience on utilising specific platforms are very useful and can 
support the decisions and the choices made by the researcher.  
 
 
 
 
 
8.4 Osteogenic differentiation protocols 
 
 
The aim of this project was to perform osteogenic differentiation of mESCs. Osteogenic 
differentiation is a complex procedure that is widely performed in vitro. A number of different 
cell types have been used and differentiated to osteoblastic cells, but the exact mechanism has 
not been elucidated yet. Most of the research groups employ ASCs, which are easy to direct 
towards osteoblasts. These cells, however, have restricted renewal capacity and increased 
senescence, a fact that means they cannot support high cell numbers of good quality. ESCs are a 
good candidate source with the capacity to generate high cell numbers of good quality 
homogenous populations. The issue with these cells is that they need to go through more stages 
to finally achieve osteogenic differentiation. In contrast to the adult cells, they first need to 
commit to a germ layer before proceeding to the desired cell type (Sui et al., 2013). 
The majority of the currently used protocols for osteogenic differentiation go through the stage 
of EB formation. EB recapitulates aspects of early embryo development and contains cells from 
the three germ layers. EB formation poses the major disadvantage of spontaneous differentiation 
and difficulty to guide the cells towards only one specific cell type.  
Alternative methodologies were explored and tested to bypass EB stage and enhance 
differentiation towards the required germ layer and cell type. It has been previously indicated 
that by omitting the EB step, a significantly greater number of osteogenic cells can be generated 
(Karp et al., 2006). Moreover, it has been shown previously in the lab that conditioned media 
derived from HepG2 cells could enhance mesoderm formation and lead to the creation of a 
restricted repertoire of mesodermal cells (Hwang et al., 2006). 
A very common protocol used for osteogenic differentiation employs b-GP as a phosphate 
source, AA, which is responsible for secretion of Col I in the ECM and Dex, which has been 
shown to induce the expression of bone markers and the mineralisation of the bone matrix 
(Langenbach and Handschel, 2013). This is known as the DAG protocol and it has been 
validated with different cell types.  
 
 
 8.5 The two tested protocols 
 
Osteogenic differentiation was 
between static and perfusion bioreactor platform
also compared for their efficiency in osteodifferentiation and 
was used as a control and the small molecule 
bone anabolic properties. 
The two protocols lasted for 29 days, starting both with 3 days incubation in HepG2
enhance mesoderm formation, followed by o
phosphate, to end up with further supplementation of Dex or Sim
induce mineralization (Figure 8.1)
 
Figure 8.1: The two tested protocols for osteogenic differentiation of mESCs
8.6 Experiments, analysis and major findings
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and supported high cell numbers (Cartmell et al., 2003; Gomes et al., 2003; Hosseinkhani et al., 
2005b; Papantoniou et al., 2014; Sonnaert et al., 2014; Wang et al., 2013) compared to static 
configuration (Sonnaert et al., 2014; Yeo et al., 2013). The advantage of this platform is that 
nutrient and oxygen transport are performed not only by simple diffusion but also with 
convection, allowing the efficient transport even in the centre core of the hydrogel whereas in 
static culture, diffusion is the only available mechanism. When cells proliferate and increase in 
numbers, diffusion is not capable to support cells in the interior of the hydrogel resulting in the 
creation of a necrotic core, thus explaining the reduction in cell numbers (Anada et al., 2012; 
Carpenedo et al., 2007; Keogh et al., 2011; Lyons et al., 2008; Partap et al., 2010a).  
Between the two tested chemicals, treatment with Sim protocol resulted in significantly higher 
cell densities and generated about double the amount of cells by the end of the experiment 
compared to Dex protocol and this was valid for both culture platforms.  
One important element to point out was the fact that experiments with Sim were performed in a 
stage of the PhD where bioreactor operation was relatively optimized and the possible problems 
that could appear were minimized. This is the possible reason for better performance and higher 
cell numbers achieved in comparison to the Dex protocol, the first couple of weeks of the 
experiment, where common media was employed in both experimental conditions. Due to the 
better culture configuration and the more efficient operation of the bioreactor, higher 
proliferation rate was induced suggesting the possible reason for the reduction appeared on day 
14 in static culture which cannot support high cell numbers due to diffusion limitations in the 
transport of nutrients and oxygen.     
ALP was tested biochemically to evaluate osteogenic differentiation and ARS was used to 
indicate mineralisation. ALP is considered an important marker characteristic of bone formation.  
It is expressed early during bone formation and it has a siginificant role to support 
mineralisation. In the performed experiments, the obtained profile was the same for both 
chemical compounds and for both platforms tested with ALP maintaining similar and high level 
throughout the whole experiment in the perfusion bioreactor whereas in static, ALP followed the 
expected pattern for osteogenic differentiation with initial increase, followed by reduction and 
subsequent upregulation to support mineralisation. Due to continuous perfusion, ALP activity 
maintained in the same high level throughout the whole experiment in the bioreactor suggesting 
a possible maintenance of a more progenitor phenotype for longer before committing and 
beginning to differentiate into a specialized cell type while in static configuration, cells acquired 
a more mature phenotype as indicated by the acquired profile. There were no major differences 
exhibited between the two protocols and within the same platform. 
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ARS analysis indicated significantly higher calcium deposition in the perfusion bioreactor in 
comparison to the static configuration for both tested time points, thus confirming previous 
findings (Fassina et al., 2005; Gomes et al., 2006; Gomes et al., 2003; Sikavitsas et al., 2003; 
Yeatts and Fisher, 2011). Mineralisation levels were similar between the two protocols and 
within the same platform. Results suggested that treatment with Sim or with Dex induced the 
same level of calcium deposition at each platform tested.  
To summarize, ALP and ARS analysis indicated similar outcome with no major differences 
observed between the Sim-containing and the Dex-containing protocols.  
To further interrogate that, ATR-FTIR analysis verified the distinct presence of phosphate in the 
mineralised constructs and confirmed HA deposition, through the presentation of characteristic 
peaks of phosphate and carbonyl, which indicated the presence of mineralised calcium/phosphate 
as a major component of bone mineral (Hunter and Goldberg, 1993). However, the obtained 
images presented a relatively diffuse mineral accumulation in mESC cultures, something that has 
been previously observed by another group, which suggested the possibility of non-specific 
accumulationof mineral in ESC cultures (Evans et al., 2012). In another paper, they attributed 
this outcome to a different mechanism suggesting probably dystrophic mineral deposition, which 
can be caused when inorganic phosphates from locally high levels of ALP activity precipitate 
with calcium ions in cell culture media (Gentleman et al., 2009).  
 
 
8.6.2 Gene expression analysis of bone markers 
 
Gene expression analysis of important bone markers was performed on samples obtained from 
the last week of culture, day 21 and day 29, using qRT–PCR in order to evaluate osteogenic 
differentiation and to perform a comparison between Dex and Sim protocols and also among 3D 
static and dynamic culture platforms. Starting with the early stage bone markers, ALP, Runx2 
and OSX, they all indicated higher expression level in the bioreactor platform compared to static 
configuration, with higher induction after Dex treatment compared to Sim.  
Cells treated with Dex have been shown previously to exhibit enhanced expression of mRNA for 
ALPase (Wong et al., 1990; Yamanouchi et al., 2001). Increased ALP expression in the 
bioreactor and low in static culture has been noticed previously by other research groups 
(Bancroft et al., 2002; Barron et al., 2012; Cartmell et al., 2003; Datta et al., 2006; Gomes et al., 
2003; Sikavitsas et al., 2003) which supported the idea that the favorable culture conditions 
created by the perfusion bioreactor enhanced ALP gene expression. 
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The transcription factors Runx2 and the downstream OSX are considered master regulators of 
osteogenic differentiation. OSX exhibited a distinct time frame of expression based on the 
different substances, indicating an earlier induction after Sim treatment and a later induction 
after Dex treatment.  
Runx2 is characterised as an osteoblast-specific transcription factor. At the early stage of 
embryogenesis, it directs pluripotent mesenchymal stem cells to the osteoblast lineage and 
supports immature osteoblast to form immature bone (Ziros et al., 2008). The level of Runx2 
determines the maturational stage of the osteoblast and its expression has to be downregulated in 
order to proceed to terminal differentiation to mature osteoblasts. Runx2 also triggers the 
expression of major bone matrix protein genes (Komori, 2010a; Komori, 2010b). Forced 
expression of Runx2/Cbfa1 in non-osteoblastic cells induces the expression of the principal 
osteoblast-specific genes (Ducy et al., 1997).  
OSX is an important transcription factor required for bone formation (Nakashima et al., 2002). 
During bone development, osteoblast precursor cells, which express OSX, are the ones, which 
will generate mature osteolineage cells (Karsenty and Wagner, 2002; Maes et al., 2010). OSX-
expressing cells provide a transient source of osteoblasts (Park et al., 2012a), implying the 
presence of a more primitive source sustaining osteolineage cells throughout the lifetime. It has 
been shown recently that OSX expression is correlated with successive waves of progenitors 
with the capacity to generate mature osteolineage cells (Mizoguchi et al., 2014). 
The expression of another two early stage bone markers, Col I, the most abundant bone matrix 
protein and BMP2, the strongest osteoinductive agent, was also evaluated. Col I indicated 
significant upregulation after Dex treatment compared to Sim and higher level in static compared 
to dynamic configuration. Increased Col I expression in static platform has been indicated 
previously by other research groups (Chang and Hughes-Fulford, 2009; Cho et al., 2010; Dahlin 
et al., 2013; Wang et al., 2009). BMP2, as well, was also expressed after induction with Dex 
compared to Sim and the effect was more profound at an early time point for both tested 
platforms. The favorable environment created by the perfusion culture maintained the high 
expression of BMP2 for longer time compared to static.  
The above results suggested better support of early osteogenic differentiation in the perfusion 
bioreactor platform compared to static configuration, as indicated by the higher and timely 
ordered expression of the tested early bone markers starting with Col I, BMP2 and ALP by day 
21 followed by Runx2 and OSX by day 29. Moreover, treatment with Dex induced higher 
expression of early stage markers of osteogenic differentiation in comparison to Sim treatment. 
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In the next step, gene expression of late stage bone markers was also calculated. Bglap and BSP 
are two characteristic bone matrix proteins starting to be expressed when cells begin to acquire 
and achieve a more mature phenotype. BSP is considered a middle-to-late-stage marker of 
osteogenic differentiation (Hatakeyama et al., 2013), which is expressed in developing bones 
during endochondral ossification and during mineralisation (Holm et al., 2014) while Bglap is a 
marker of the more mature phenotype of osteoblastic cells. Analysis of osteoprogenitor 
development indicated that BSP is expressed at two distinct times: the first during the 
proliferative immature osteoprogenitor phase and the second during maturation from 
preosteoblasts to osteoblasts (Aubin, 2001). Both genes were highly upregulated after Sim 
treatment and the induction was more pronounced in the perfusion bioreactor configuration. 
Results suggested that Sim treatment significantly induced the expression of these important late 
stage bone markers compared to Dex treatment.  
The expression of two bone matrix proteins, OPN and ON, was then evaluated. OPN is 
expressed late after mineralization has been initiated (Sodek et al., 2000) whereas ON is early 
expressed and decreases when cells go towards mineralisation. Similar to this information, OPN 
indicated late expression whereas ON was earlier expressed at both culture configurations with 
higher expression in the bioreactor compared to static. Moreover, the expression of both genes 
was significantly induced after Dex treatment compared to Sim treatment. It has been also shown 
that immature osteoblasts express OPN and BSP whereas mature osteoblasts strongly express 
OCN (Maruyama et al., 2007).  
The above findings suggested a better support of late osteogenic differentiation by the perfusion 
bioreactor platform as indicated by the higher expression level of the tested markers, which also 
followed the expected time ordered expression profile starting with Bglap and followed by BSP 
expression. To further support that, ON was initially expressed followed by OPN during 
mineralisation. 
To summarize, treatment with Dex induced the expression of early bone markers while treatment 
with Sim increased significantly the expression of late bone markers. Gene expression was better 
supported by perfusion culture as indicated by the higher level achieved for both early and late 
stage bone markers tested and by the more appropriate differentiation pathway followed together 
with the expected time line profile of gene expression patterns, compared to static configuration, 
which exhibited low gene expression, suggesting not proper induction towards the osteoblastic 
phenotype. To further support this outcome, it has been previously indicated that Dex enhanced 
the differentiation and promoted the expression of osteoblastic phenotype in human osteoblastic 
cells in vitro through gene expression analysis (Yamanouchi et al., 2001). 
 208 
In conclusion, higher gene expression levels of bone markers in combination with higher 
calcium deposition and increased cell numbers suggested the superior capacity of perfusion 
bioreactor to properly support osteogenic differentiation.   
One important observation from the gene expression results is the low level achieved by the 
majority of bone markers. There is further literature support for this outcome. Evans and his 
colleagues observed in their experiments that important bone markers were all expressed, but 
their expression level was relatively low, something that was also observed in the obtained 
results from these experiments. They strongly supported however that it is possible to produce 
osteoblastic cells from ESCs without the characteristic upregulation of bone markers (Evans et 
al., 2012). Another group observed that ESCs treated with common osteogenic medium 
mineralised considerably, but their differentiation was incomplete and the ECM, which formed 
late during the experiment, didn’t exhibit the expression of characteristic bone markers. They 
supported that mineralisation observed was not conventional osteogenesis (Shimko et al., 2004).  
 
8.6.3 Evaluation of ossification and germ layer formation through gene expression 
 
For the first time to our knowledge, the ossification pathway followed was tested through the 
examination of a couple of chondrocyte and hypertrophic chondrocyte markers and also the 
progress in the gene expression of the three germ layers after treatment with Sim in order to get 
more insight information regarding the whole differentiation process.  
The transcription factor Sox9 has been shown to express in mesenchymal condensations and 
common progenitors of osteoblasts and chondroblasts have been indicated to derive from Sox9 
expressing precursors (Akiyama et al., 2005). Sox9 has been also proved to regulate the 
expression of major proteins of cartilage matrix, such as Aggrecan. It has been suggested that 
early mesenchymal progenitors cells with the capacity to differentiate to various cell types, for 
example osteoblasts or chondrocytes, contain promoter elements for the expression of Sox9, 
Aggrecan and Collagen 2 (Ono et al., 2014b). In these experiments, Sox9 and Aggrecan 
indicated similar expression profile with higher level achieved in the bioreactor culture 
compared to static after Sim treatment.  
The marker of hypertrophic chondrocytes, Collagen 10, was also evaluated and its expression 
pattern followed that of Aggrecan. Examination of these three markers supported the idea that 
endochondral ossification was followed after treatment of mESCs with Sim and once more, the 
perfusion bioreactor better supported this process, as indicated from the higher expression levels.  
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Finally, one more thing performed for the first time was extended gene expression analysis of 
markers from all the three germ layers.  
Evaluation started with two ectoderm markers, the transcription factor Pax6 and the Nestin 
protein. Pax6 has been shown to regulate neuroectoderm formation both in humans (Zhang et al., 
2010a) and in mice (Quinn et al., 2010; Suter et al., 2009) and Nestin is a well-known and 
widely tested marker of ectoderm that has been shown to express in ES-derived progenitor cells 
that have the potential to develop into neuroectodermal, endodermal and mesodermal lineages 
(Wiese et al., 2004). Both genes indicated high expression level in the bioreactor compared to 
the low level in static culture.  
Although Nestin is a marker of ectoderm, it has been shown recently that nestin-expressing cells 
are related with vasculature and contain early cells of the osteoblast and other lineages. In 
particular, it has been indicated that osteoblasts and bone lining cells expressed Nestin. Based on 
that, it has been suggested that Nestin acts downstream of Runx2 in the mesenchymal lineages 
and Runx2 is needed in order to direct mesenchymal precursors to become either cells of the 
osteoblast lineage positive for Nestin expression or preosteoblasts expressing OSX (Ono et al., 
2014a). For further confirmation, it has been indicated that nestin-expressing MSCS contribute 
normally to skeletal formation (Mendez-Ferrer et al., 2010). 
Next analysis involved the examination of two endoderm markers, the transcription factors Gata 
4 and Sox 17. These factors have been shown to express during the differentiation of ESCs into 
the extraembryonic endoderm (ExE) and to be essential for its development (Niakan et al., 
2010). ExE has been suggested to play crucial roles in mammalian development. Gata factors 
contribute to the early-stage differentiation of ESCs while Sox factors support and enhance the 
late-stage differentiation (Shimoda et al., 2007). Both endoderm markers indicated a better 
induction of their expression in static culture configuration.  
Finally, the expression of three markers of the germ layer of interest, mesoderm in this case, was 
evaluated. Tested genes included the transcription factors Hand1 and BMP4 and the Desmin 
protein. In general, all the three genes exhibited higher expression in the bioreactor platform 
compared to static, at both tested time points. Gene expression of the above markers suggested a 
better induction of mesoderm formation in the perfusion bioreactor compared to static culture, as 
indicated by the higher gene expression at crucial time points. Results will need to be repeated 
for further validation. 
To summarize, gene expression results from markers of the three germ layers suggested that the 
protocol used for osteogenic differentiation of mESCs employing AA, b-GP and Sim generated a 
cell population that retained in a very low level the expression of markers from all the three germ 
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layers suggesting the more progenitor status of the cells and the possibility of having also other 
cell types before committing to fully mature osteogenic phenotype. In particular, cells cultured 
within the perfusion bioreactor maintained a more progenitor like phenotype while cells in static 
seemed to acquire a more mature phenotype but without achieving the high gene expression 
level needed in order to properly support osteogenic differentiation. 
It is well established that, the process of osteogenesis from ESCs is usually triggered, by 
supplementing the medium with AA, b-GP and Dex. These factors, however, are not specifically 
osteoinductive and it has been previously indicated from several research groups that cells from 
other lineages can be also generated (Sato et al., 2006; Shin et al., 2004; Srivastava et al., 2006; 
Tsuneto et al., 2005). It has been shown specifically that such osteogenically treated cultures 
retain a potentially undifferentiated population of cells (Karner et al., 2009). Similar to that and 
based on the acquired results, it could be suggested that cultures treated with Sim preserved a 
cell population with the ability to generate cells from all three germ layers of the embryo. 
Last analysis was comparison of the metabolic profile between Sim and Dex in static 
configuration from samples obtained from day 29. Preliminary results indicated higher glucose 
and lower lactate in the Sim-containing media compared to the Dex-containing media suggesting 
better culture environment with less metabolic constraints in the Sim-containing media.  
 
8.7 Side experiment 
 
It has been observed that ECM protein components regulate not only cell adhesion but also 
differentiation (Reilly and Engler, 2010). Matrix composition has been proven to influence ESC 
differentiation (Battista et al., 2005). 
Following that idea, a recently published paper from the lab supported that fibronectin enhanced 
osteogenic differentiation of mESCS (Kang et al., 2015). Moreover, fibronectin has been 
previously identified (Kang et al., 2009b) as one of the main components secreted in HepG2-
CM. In order to obtain additional information, fibronectin coating was tested in combination 
with Sim treatment. Comparison was performed with gelatin coating as a control. ARS and ALP 
analysis suggested better performance with fibronectin, but more experiments would need to be 
performed for further validation. 
To further support that idea, the important role of adhesion molecules in osteogenic 
differentiation has been recognized. In particular, several studies from different groups suggested 
and proved the idea that fibronectin supports and regulates osteoblast differentiation (Moursi et 
al., 1996; Moursi et al., 1997; Weiss and Reddi, 1980; Weiss and Reddi, 1981a; Weiss and 
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Reddi, 1981b). It also has an essential role during the early stages of osteoblast differentiation 
before initiation of matrix formation and subsequent mineralisation (Cowles et al., 1998).  
Fibronectin has been shown to influence osteogenic differentiation both in 2D and 3D culture 
configurations (Martino et al., 2009). In particular, enhancement of osteoblast differentiation and 
mineralisation has been indicated on fibronectin treated plates (Mathews et al., 2012; Singh and 
Schwarzbauer, 2012) 
 
8.8 Outcome of the project 
 
The aim of this project was the creation of 3D mineralised cellular constructs made from mESCs 
encapsulated in alginate hydrogels after chemical induction with Sim and cultured in the custom 
made RWV perfusion bioreactor, which can support high cell numbers needed for potential use 
in cellular therapies. The obtained results suggested the generation of a progenitor cell type with 
the capacity to further differentiate into osteoblast cell.  
Previous results, by another group, implied the generation of greater amount of stem and 
progenitor cell types from the Synthecon bioreactor compared to the static system (Fridley et al., 
2010). It was not desired to obtain a fully mature cell phenotype. For in vivo applications, it is 
better to implant not a final and fully completed product, but something that will be in a stage 
that could activate mechanisms inside the body to participate more effectively in the healing 
process by incorporating body’s own regenerative capacity. 
The above suggestion can be further supported by recent findings, which demonstrated that 
progenitor cells derived from pluripotent stem cell sources and cultured within the dynamic 
environment of a bioreactor, may represent an interesting cell source for the fabrication of bone 
substitutes for the repair of large skeletal defects in humans, as indicated by their superior 
performance in ECM production and bone development, compared to MSCs derived from adult 
sources (de Peppo et al., 2013a; de Peppo et al., 2013b).  
Last but not least, it has been demonstrated recently the principle idea of using dynamic culture 
for ES cell differentiation into therapeutic cell lineages. Bioreactor platforms could provide 
clinically relevant numbers of homogenous cell populations in order to be applied for various 
therapeutic applications. It has been suggested that bioreactor type and culture parameters 
significantly influence the differentiation of ESCs and lead to the generation of unique 
population of progenitor cells from all three germ layers of embryonic development (Fridley et 
al., 2010). 
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8.9 Challenges of the study 
 
One more thing that should be taken into account for the development of an efficient protocol for 
osteogenic differentiation is the ability to supply the necessary factors at the appropriate time 
point in order to induce different functions. To be more specific, cells initially need to proliferate 
and expand their numbers; they will then gradually start producing the ECM that will support the 
final stage of mineralisation.  
Challenges associated with the scaling up of TE constructs to clinically relevant dimensions, 
such as limited oxygen and nutrient supply may begin to look for novel approaches that seek to 
mimic developmental processes. The possibility to combine developmental and engineering 
processes together with molecular, biochemical and clinical techniques for skeletal TE can help 
in the improvement in healthcare costs and quality of life of the increasing aging population 
(Dawson and Oreffo, 2008). 
 
 
8.10 Accomplishments of the study 
 
One significant feature of this study was the employment of a novel custom-made bioreactor that 
combined the advantages of two widely employed platforms: the RWV and the flow perfusion. 
Experiments with this system provided novel information regarding osteogenic differentiation 
that could also contribute to the development of protocols that would potentially improve the 
process of cell differentiation towards the osteoblast lineage. 
As mentioned previously, the generation of novel, reproducible and efficient protocols is an 
urgent requirement for osteodifferentiation. These protocols should be based on the 
developmental growth of the desired tissue to be formed. In this project, the employment of Sim, 
a widely used molecule as a drug to lower cholesterol, was tested. The evaluation of a small 
molecule, previously used as a drug, indicates great safety and faster approval time with less in 
vivo validation in order to be tested in humans. It also indicates potentially less side effects from 
its application. Moreover, as mentioned before, the need for low cost therapeutic solutions is 
urgent. One of the problems with the use of growth factors for osteogenic differentiation is their 
high cost due to the recombinant technology utilized for their production.  
To summarize, it is important to consider that this study provided information regarding the use 
of a bioreactor platform combined with a small molecule osteoinductive agent in order to 
achieve the generation of cellular mineralised constructs that could be applied for treatment of 
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critical-size bone defects in humans. The positive element of this study was the fact that 
differentiation was performed without the use of any expensive growth factors, something that 
can contribute to the reduction of the cost for cell culture in the future.  
 This study also reinforced a recent idea, supported by other groups as well, that the generation 
of high number of osteoprogenitor cells is required by a bioreactor platform in order to achieve 
proper regeneration by exploiting also the advantages provided by the body’s own regenerative 
capacity. Mature cells will be effective but probably with limited lifetime and without the ability 
to interact with the local niche and integrate with the environment to fully restore tissue function.  
One significant outcome from this study was the necessity to analyze and examine various 
aspects of the desired tissue and employ different methods and various techniques for analysis of 
the final derived product when the aim is to form new strategy for clinical applications. Obtained 
results indicated that many times, relying only on biochemical or only on genetic tests could 
have some false-positive or false-negative results. In order to have the complete image and be 
able to make the right decisions, it is necessary to analyse several different aspects and be 
confident after that to reach a safe conclusion.  
 
8.11 Important observations and implications of the study 
 
The tissue of interest in this project was bone and based on that, genetic analysis usually focus 
on the valuation of the expression of various bone markers in order to confirm the phenotype of 
the end product. One additional thing observed from this project was the fact that evaluation of 
the whole followed pathway, from the initial undifferentiated cell to the mature osteoblast should 
be performed in order to elucidate the precise differentiation process. It is important to 
understand all the different stages the cell goes through in order to achieve the final desired cell 
type. In the case of pluripotent stem cells, it has been shown that they first need to commit to a 
specific germ layer before proceeding to the differentiation to the desired cell type (Sui et al., 
2013). Osteogenic differentiation is enhanced and better supported by the RWV perfusion 
culture configuration compared to the 3D static culture in tissue culture flasks. High cell 
numbers of good quality differentiated cells needed for cellular therapies can be also obtained 
from culture in the favourable environment generated by continuous supply of fresh media and 
removal of metabolic by-products in that platform configuration. The importance of 3D cultures, 
as a valuable tool for the development of novel strategies for clinical applications, was 
highlighted through this study. 3D cultures can bridge the gap between 2D cultures and animal 
models, thus providing significant information regarding both in vitro and in vivo experiments.  
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8.12 Contribution 
To summarize, this study contributed to the acquisition of significant and novel information 
regarding 3D culture and osteogenic differentiation of pluripotent stem cells in a bioreactor 
platform. Details of the performed analysis were provided together with their significance and 
the respective outcome. All these elements could be employed by people in future studies on 
bone formation, regeneration and osteogenic differentiation. They would provide a useful 
guideline for the experiments they need to perform and details on the parts they need to be aware 
of. The significant cost reduction of the generated cellular constructs, by using small molecules 
instead of growth factors for the osteogenic differentiation, was also highlighted.  
 
 
To summarize, the conclusions analyzed and presented on this chapter are the following ones: 
 
- 3D bioprocess of mESCs using the favourable environment created by the perfusion bioreactor 
generated and supported high cell numbers 
- Treatment with Dex induced osteogenic differentiation as indicated by high gene expression of 
important bone markers 
- Sim supplementation in the culture media should be performed in the appropriate time point to 
avoid cell cycle inhibition 
- Treatment with Sim in 3D culture dynamic configuration can support the generation of high 
cell number of osteoprogenitor cells 
- Superior capacity of perfusion bioreactor to properly support osteogenic differentiation as 
indicated by the high gene expression of bone markers and increased calcium deposition 
 
8.13 Future directions         
 
The results obtained from this PhD project indicated and suggested an important advantage and 
potential use of the custom made RWV perfusion bioreactor in generating clinically relevant 
cells numbers of good quality for therapeutic applications related with bone defects and 
osteogenic malformations. In vitro studies should be further extended with the analysis not only 
of the gene expression but also of the protein expression profile. Moreover, metabolic analysis 
should be performed in a more detailed and high-throughput way to investigate the effects of 
metabolic stress on gene expression and other significant culture parameters. Finally, it is crucial 
to evaluate the osteogenic capacity of the cells generated from the bioreactor configuration and 
to proceed for in vivo confirmation through animal experiments. 
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The necessity for in vivo evaluation of osteogenesis through appropriate animal experiments has 
been recognized from the beginning of this project. Based on this idea, set up of the future 
animal experiment, in order to optimize the created fracture, identify and solve all the possible 
problems that could appear during surgery, has been already performed by my other supervisor, 
Mr Eleftherios Tsiridis, who is an expert Orthopaedic Surgeon. Rabbits were used as a good 
animal model being closer to the human status and mimicking in a higher lever human critical 
size bone defects compared to the widely used nowadays mice models. 
mESCS were the first group of pluripotent stem cells widely employed and tested for various 
research purposes, mainly related with regenerative applications. These cells are easy to obtain, 
culture in vitro and expand their numbers compared to hESCs. These features rendered them a 
good cell source for TE applications. They also don’t have problems regarding ethical issues, as 
it is the case with human cells. Fundamental research has been performed for years, by many 
groups around the world, employing these cells and significant conclusions have been draw 
(Duplomb et al., 2007; Garreta et al., 2006; Kirkham et al., 2012). ESCs from other animals have 
been isolated but there are limited information regarding their use and restricted in vitro capacity 
for proliferation and differentiation and rapid decline in pluripotency after several passages 
compared to mouse cells (Honda et al., 2008).  
For these reasons, mESCS were used and tested in this PhD research project as a good and 
previously tested source with the capacity to provide high cell numbers needed for potential 
application in future cell therapies. Moreover, culture protocols developed in mouse cells have 
been employed successfully in human cells indicating their transferable capacity (Bielby et al., 
2004). The existence of similar signaling pathways for the regulation of both mouse and human 
ESCs has been indicated (Keller, 2005) (Murry and Keller, 2008). 
In vitro investigation needs to be followed and validated by in vivo experiment in the appropriate 
animal model. Mouse models are widely used. However, in view of developing cell therapies for 
humans, the necessity to employ a better animal model to perform experiments is urgent. Bigger 
animals, such as rabbits, constitute a better animal model being closer to the human status and 
mimicking in a higher lever human critical size bone defects compared to the widely used 
nowadays mice models. Rabbit is one of the most commonly used animals for musculoskeletal 
research studies (Pearce et al., 2007) and for this reason, it was used in this PhD research project 
for in vivo validation of the generated construct.   
Three, 16-week-old male, New Zealand white rabbits with a mean weight of 3.6kg were used in 
this study to be tested for a metaphyseal fracture healing capacity. All sterility precautions were 
followed as per human surgery. Anaesthesia was performed using different injections of 
 antibiotics in concentrations calculated according to each animal’s weight. 
process, the creation of a non-critical size defect was performed at this stage. There were two 
groups of animals. The experimental group was filled with 2.5 ml of alginate beads
at this point while the control group was left unfilled. In F
from various stages during the process of the animal prepa
          
 
                                 
 
                      
 
Figure 8.2: Animal experiment set
created defect wrapped around with 
(c) and (d). The animal incubator where experimental animals were placed under control 
environmental conditions (e) and (f).
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(Figure 8.3), which were both manufactured in the School of Engineering at the Nat
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 The experiment was running for 3 months. After this period, the animal was sacrificed and it 
could be observed that the defect has been completed repaired. The obtained results indicated 
and strongly suggested that a period of less than three months would 
in order to test and evaluate the regenerative capacity of the implanted hydrogels in comparison 
to the negative control. Three months was a long time and even the control group defect has been 
completely repaired, thus there was
the experimental group. X-ray photos were also acquired in order to better observe a
the final outcome (Figure 8.4). 
                                              
                       
                    
 
Figure 8.4: Animal experiment 
bone from the negative control 
obtained on the beginning of the experiment
were provided by Mr Tsiridis in
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APPENDIX 
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3. Mechanical strength analysis of bone-like construct 
 
3.1. Results obtained from Dr Yushik Hwang thesis (Hwang, 2007) 
Particle Calculated Young's 
modulus (kPa) 
Alginate 35.2 
Alginate + Cell 29.3 
Bone Construct 666.2 
 
Alginate: pure alginate bead without cells. 
Alginate + Cells: Alginate bead encapsulating undifferentiated 
mESCs with same cell density as Bone construct 
 
3.2. Results obtained from Dr Jae Min Cha thesis (Cha, 2010) 
Young’s Modulus (kPa) 
Alginate bead 35.23 
Control 13.32 
BSEL 572.1 
HARV 219.2 
STATIC 93.05 
 
Alginate bead: alginate hydrogel without cells 
                 Control: hydrogel composed of undifferentiated ESCs with a similar cell density as 
 the bone-tissue like construct (about 3.5 - 4 x 105 cells/bead) 
 
4. Live-dead results in static culture obtained from Dr Wesley Liam Randle thesis (Randle, 2006) 
 
 
 
 
Live / Dead staining images of 3D static cultured for 29 days.  
Image dimensions = 12367 x 845 μm. x10 objective.  
Green fluorescence indicates viable cells 
 220 
5. Real time PCR data from Dr Jae Min Cha examining the expression of plurirotent 
markers Nanog and Rex1 and primitive ectoderm Fgf5  
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